﻿Micormedex NeoFax Essentials 2014 Table of Contents
Title Acetaminophen 
===Dose===  ==Intravenous== Preterm infants 32 weeks postmenstrual age or older: 10 mg/kg/dose IV every 6 hours as needed or around-the-clock. 1
May consider a 20 mg/kg loading dose . 0
==Oral== Preterm infants less than 32 weeks Postmenstrual Age: 20 to 25 mg/kg orally; then 12 to 15 mg/kg/dose every 12 hours as needed or around-the-clock. 1
Preterm infants greater than or equal to 32 weeks Postmenstrual Age: 20 to 25 mg/kg orally; then 12 to 15 mg/kg/dose every 8 hours as needed or around-the-clock. 1
Term infants: 20 to 25 mg/kg orally; then 12 to 15 mg/kg/dose every 6 hours as needed or around-the-clock. 1
==Rectal== Preterm infants less than 32 weeks Postmenstrual Age: 30 mg/kg rectally; then 12 to 18 mg/kg/dose every 12 hours as needed or around-the-clock. 1
Preterm infants greater than or equal to 32 weeks Postmenstrual Age: 30 mg/kg rectally; then 12 to 18 mg/kg/dose every 8 hours as needed or around-the-clock. 1
Term infants: 30 mg/kg rectally; then 12 to 18 mg/kg/dose every 6 hours as needed or around-the-clock. 1
==Administration== Intravenous: Administer IV over 15 minutes. 1
Withdraw appropriate dose and administer in bottle, bag, or IV syringe; dose should be administered within 6 hours . 1
The administered volume in a neonate should always be 7.5 mL or less . 0
Use with caution in patients with hepatocellular insufficiency, severe renal insufficiency, glucose 6 phosphate dehydrogenase deficiency, chronic malnutrition, or dehydration/hypovolemia . 0
for the risk of wheezing and acetaminophen use in the previous year of life . 0
for eczema symptoms and acetaminophen exposure in the previous 12 months in adolescents ==Pharmacology== Nonnarcotic analgesic and antipyretic. 0
Peak serum concentration occurs approximately 60 minutes after an oral dose. 1
Elimination half-life is approximately 3 hours in term neonates, 5 hours in preterm neonates greater than 32 weeks gestation, and up to 11 hours in more immature neonates. 1
included in the PARANEO study. 0
An effect compartment concentration of 10 mg/L was associated with a pain score reduction of 3.4 units . 0
occur with IV acetaminophen . 0
administered IV acetaminophen . 0
of therapeutic dosesin a retrospective analysis . 0
==Special Considerations/Preparation== Available orally in various liquid formulations containing 32, 80, and 100 mg/mL. 0
Suppositories contain 80,120, 325, and 650 mg.. 0
Vial is for single use only and should be used within 6 hours of opening. 0
, followed by 50 mg/kg in 5% dextrose or 1/2 NS over 4 hours, then 100 mg/kg in 5% dextrose or 1/2 NS over 16 hours. 1
NAC solution concentrations of 40 mg/mL have been used to avoid fluid overload and hyponatremia in the neonate. 0
==Solution Compatibility== D5W; NS. 0
, methylprednisolone 125 mg/mL, metoclopramide 5 mg/mL, midazolam 5 mg/mL, morphine 15 mg/mL, nalbuphine 20 mg/mL, ondansetron 2 mg/mL, potassium chloride 0.1 mEq/mL. 0
Compatibility information refers to physical compatibility and is derived from Trissel’s™ 2 Clinical Pharmaceutics Database. 0
The user is referred to Trissel’s™ 2 for more complete details. 0
Trissel’s™ 2 Clinical Pharmaceutics Database, version updated on 06/15/2013. 0
Title Acetaminophen 
===Dose===  ==Intravenous== Preterm infants 32 weeks postmenstrual age or older: 10 mg/kg/dose IV every 6 hours as needed or around-the-clock. 1
Term infants: 20 to 25 mg/kg orally; then 12 to 15 mg/kg/dose every 6 hours as needed or around-the-clock. 1
Preterm infants greater than or equal to 32 weeks Postmenstrual Age: 30 mg/kg rectally; then 12 to 18 mg/kg/dose every 8 hours as needed or around-the-clock. 1
for the risk of wheezing and acetaminophen use in the previous year of life . 0
for eczema symptoms and acetaminophen exposure in the previous 12 months in adolescents ==Pharmacology== Nonnarcotic analgesic and antipyretic. 0
, in a retrospective analysis . 0
Trissel’s™ 2 Clinical Pharmaceutics Database, version updated on 06/15/2013. 0
Title Acyclovir 
===Dose===  Herpes Simplex Virus Infection, Treatment and Preemptive Therapy: 20 mg/kg/dose IV every 8 hours; infuse over 1 hour . 1
Treat localized herpes simplex disease for 14 days and disseminated or CNS disease for 21 days . 1
is positive after approximately 21 days of acyclovir therapy. 1
The duration for preemptive therapy without proven disease is 10 days . 1
Herpes Simplex Virus Infection, Chronic suppression: 300 mg/m2/dose orally 3 times a day. 1
Begin suppressive therapy immediately after completion of IV treatment and continue for 6 months . 1
Varicella-Zoster Virus Infection:10 to 15 mg/kg/dose IV every 8 hours for 5 to 10 days . 1
==
===Dose===  Adjustments== Preterm infant less than 33 weeks gestational age:give usual IV dose every 12 hours . 1
0.8 to 1.1 mg/dL: give usual IV dose every 12 hours . 1
or SCr 1.2 to 1.5 mg/dL with decreasing urine output: give usual IV dose every 24 hours . 1
or SCr greater than 1.5 mg/dL or urine output less than 1 mL/kg/hour: decrease IV dose by 50% and give every 24 hours . 1
==Administration== Intravenous route: Administer as IV infusion over 1 hour at a concentration of 7 mg/mL or less in D5W or NS . 0
started immediately after IV treatment for CNS HSV disease was associated with better neurological outcomes when compared with placebo. 1
. 0
In patients with SEM disease receiving 6 months of suppressive oral acyclovir therapy started immediately after IV treatment, the time to 2 recurrences of skin lesions was 1.7 months longer in the treatment group compared with placebo. 1
Of the 15 infants with SEM disease assessed at 12 months, there were no differences in Bayley scores between acyclovir and placebo. 1
An absolute neutrophil count of 500 cells/mm3 or less was reported in 20% to 25% of patients receiving acyclovir compared with 5% to 7% receiving placebo; no patient had complications associated with neutropenia . 0
, infants treated for CNS or disseminated HSV disease received oral acyclovir suppressive therapy for 2 years. 1
Starting doses were 1200 to 1600 mg/m2 every 12 hours to achieve an acyclovir peak serum concentration greater than 2 mcg/mL . 1
who received oral acyclovir suppressive therapy, initial oral acyclovir doses were 600 to 1400 mg/m2 every 8 to 12 hours. 1
The mean acyclovir dose required to achieve the target peak concentration of 2 mcg/mL or greater was 1340 mg/m2/dose given every 12 hours. 1
Long-term neurological development was normal in 7 of the 9 children; the 2 children who developed neurological impairment experienced a delay in oral therapy following completion of parenteral acyclovir therapy . 1
CSF concentrations are 30% to 50% of serum concentrations. 0
Oral absorption is 15% to 30%. 1
Serum half-life is 3 to 4 hours in patients with normal renal and hepatic function. 1
==Adverse Effects== Neutropenia occurs in approximately 20% of patients; decrease dose or treat with GCSF if ANC remains less than 500/mm3. 0
Phlebitis may occur at IV site due to alkaline pH of 10. 0
Risk of transient renal dysfunction and crystalluria is minimized by slow infusion rates and adequate patient hydration. 0
or as powder for solution in 500-mg and 1-g vials. 0
Prepare powder for solution by dissolving contents of 500-mg vial in 10 mL sterile water for injection. 0
Reconstituted solution is stable at room temperature for 12 hours. 1
Infusion solution concentration should be no greater than 7 mg/mL . 0
A 5-mg/mL dilution may be made by adding 1 mL of 50 mg/mL concentration to 9 mL of preservative-free normal saline. 0
Dilution should be used within 24 hours. 1
Oral suspension available in 200-mg/5 mL concentration. 0
==Solution Compatibility== D5W and NS. 0
Title Acyclovir 
===Dose===  Herpes Simplex Virus Infection, Treatment and Preemptive Therapy: 20 mg/kg/dose IV every 8 hours; infuse over 1 hour . 1
or SCr 1.2 to 1.5 mg/dL with decreasing urine output: give usual IV dose every 24 hours . 1
or SCr greater than 1.5 mg/dL or urine output less than 1 mL/kg/hour: decrease IV dose by 50% and give every 24 hours . 1
The mean acyclovir dose required to achieve the target peak concentration of 2 mcg/mL or greater was 1340 mg/m2/dose given every 12 hours. 1
Long-term neurological development was normal in 7 of the 9 children; the 2 children who developed neurological impairment experienced a delay in oral therapy following completion of parenteral acyclovir therapy . 1
Title Adenosine . 0
Increase dose in 50 mcg/kg increments every 2 minutes until return of sinus rhythm. 1
Usual maximum dose: 250 mcg/kg. 0
Response should occur within 2 minutes of the dose. 1
Estimated serum half-life is 10 seconds. 1
==Adverse Effects== Flushing, dyspnea, and irritability occur frequently, but usually resolve within 1 minute. 0
arrhythmias may occur between termination of SVT and onset of normal sinus rhythm. 0
Recurrence of SVT occurs in approximately 30% of treated patients. 0
==Special Considerations/Preparation== Supplied in 2-mL vials containing 6 mg adenosine dissolved in NS. 0
. 0
with 9-mL NS to make a solution with a final concentration of 300 mcg/mL. 0
Title Adenosine . 0
Title Albuterol 
===Dose===  Bronchodilation: 0.1 to 0.5 mg/kg/dose every 2 to 6 hours via nebulizer. 1
every 2 to 6 hours via MDI with spacer device placed in the inspiratory limb of the ventilator circuit. 1
Oral: 0.1 to 0.3 mg/kg/dose orally every 6 to 8 hours. 1
. 0
Consider alternative potassium-lowering therapies for potassium levels greater than 7.5 mmol/L. 0
. 0
. 0
==Pharmacology== Specific β2-adrenergic agonist. 0
Studies in vitro indicate that approximately 5% of a MDI dose administered using an in-line holding chamber/spacer device, versus less than 1% of a nebulizer dose, is delivered to the lung. 0
Onset of action is 30 minutes; duration is 4 to 8 hours. 1
. 0
Time to peak serum concentration is 3 to 4 hours. 1
Consider not administering when heart rate is greater than 180 beats per minute. 1
==Special Considerations/Preparation== Oral dosage form: Syrup, 2 mg/5 mL. 0
Inhalation solution: Available as either 5 mg/mL, 0.83 mg/mL, 0.42 mg/mL, or 0.21 mg/mL. 0
A 0.1 mg/mL dilution for inhalation may be made by adding 3 mL of 0.83 mg/mL albuterol concentration to 22 mL of preservative-free normal saline. 0
Stable for 7 days refrigerated. 1
Proventil® HFA and Ventolin® HFA 90 mcg albuterol base per actuation. 0
Title Albuterol 
===Dose===  Bronchodilation: 0.1 to 0.5 mg/kg/dose every 2 to 6 hours via nebulizer. 1
Title Alprostadil 
===Dose===  Initial dose: 0.05 to 0.1 mcg/kg per minute by continuous IV infusion. 1
Maintenance dose: May be as low as 0.01 mcg/kg per minute. 0
yielding a concentration of 10 mcg/mL. 0
Infuse at a rate of 0.6 mL/kg per hour to provide a dose of 0.1 mcg/kg per minute. 1
Black Box Warning According to the manufacturer's black box warning, apnea has been reported in 10% to 12% of neonates with congenital heart defects treated with alprostadil. 0
Apnea is seen most often in neonates weighing less than 2 kg at birth, and usually appears during the first hour of drug infusion. 1
Maximal drug effect usually seen within 30 minutes in cyanotic lesion; may take several hours in acyanotic lesions. 1
, hypotension, fever, leukocytosis, cutaneous flushing, and bradycardia. 0
, especially with doses greater than 0.05 mcg/kg/minute. 0
. 0
: Seizures, hypoventilation, tachycardia, cardiac arrest, edema, sepsis, diarrhea, and disseminated intravascular coagulation. 0
: Urticaria, bronchospasm, hemorrhage, hypoglycemia, and hypocalcemia. 0
Musculoskeletal changes: Widened fontanels, pretibial and soft tissue swelling, and swelling of the extremities may occur after 9 days of therapy. 0
therapy. 1
ampules that must be refrigerated. 0
Dilute before administration to a concentration of 20 mcg/mL or less. 0
Prepare fresh infusion solutions every 24 hours. 1
is 23,250 mOsm/kg. 0
Title Alprostadil 
===Dose===  Initial dose: 0.05 to 0.1 mcg/kg per minute by continuous IV infusion. 1
: Seizures, hypoventilation, tachycardia, cardiac arrest, edema, sepsis, diarrhea, and disseminated intravascular coagulation. 0
therapy. 1
Title Alteplase 
===Dose===  Restoration of function to central venous catheter: Instill into dysfunctional catheter at a concentration of 1 mg/mL. 0
Use 110% of the internal lumen volume of the catheter, not to exceed 2 mg in 2 mL. 0
If catheter function is not restored in 120 minutes after 1 dose, a second dose may be instilled. 0
. 0
. 0
Duration of therapy is 6 to 48 hours. 1
If administering directly into the thrombus, dose may be increased after 6 hours to a maximum of 500 mcg/kg per hour. 0
If localized bleeding occurs, stop infusion for 1 hour and restart using 100 mcg/kg per hour. 1
Infused doses ranged from 20 to 500 mcg/kg per hour. 0
Call 1-800-NOCLOTS for case reporting and treatment guidance. 0
Severe uncontrolled hypertension ==Pharmacology== Alteplase binds strongly and specifically to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. 0
The risk of complications increases at doses above 450 mcg/kg per hour. 1
. 0
==Special Considerations/Preparation== Activase® is supplied as lyophilized powder in 50 mg and 100 mg vials. 0
respectively, for a concentration of 1 mg/mL. 0
Can be further diluted with NS or D5W to a concentration of 0.5 mg/mL if necessary. 0
Use reconstituted solution within 8 hours of mixing when stored refrigerated or at room temperature. 1
Cathflo® Activase® is supplied as lyophilized powder in 2-mg vials. 0
Reconstitute by adding 2.2 mL sterile water for injection to a final concentration of 1 mg/mL. 0
Use reconstituted solution within 8 hours of mixing. 0
==Solution Compatibility== NS and D5W. 0
Title Alteplase 
===Dose===  Restoration of function to central venous catheter: Instill into dysfunctional catheter at a concentration of 1 mg/mL. 0
Severe uncontrolled hypertension ==Pharmacology== Alteplase binds strongly and specifically to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. 0
There may be less toxicity with less frequent dosing, due to less renal drug accumulation. 0
==Monitoring== Measure serum concentrations when treating for more than 48 hours. 1
Obtain peak concentration 30 minutes after end of infusion, and trough concentration just prior to the next dose. 1
When treating patients with serious infections or significantly changing fluid or renal status consider measuring the serum concentration 24 hours after a dose, and use the chart below for the suggested dosing interval. 0
(Draw 30 minutes after end of infusion, 1 hour after IM injection. 1
Trough: 2 to 5 mcg/mL ==Special Considerations/Preparation== Available in concentrations of 50 mg/mL and 250 mg/mL. 0
For IV use, dilute with a compatible solution to a concentration of 2.5 to 5 mg/mL. 0
After dilution, solutions are stable for 24 hours at room temperature. 1
==Solution Compatibility== D5W, D10W, D20W, and NS. 0
, hydrocortisone succinate, hyaluronidase, linezolid, lorazepam, magnesium sulfate, metronidazole, midazolam, milrinone, morphine, nicardipine, penicillin g, pentobarbital, phenobarbital, potassium chloride, ranitidine, remifentanil, sodium bicarbonate, vancomycin, vitamin K1, and zidovudine. 0
, imipenem/cilastatin, mezlocillin, nafcillin, oxacillin, phenytoin, propofol, thiopental, and ticarcillin/clavulanate. 0
(Draw 30 minutes after end of infusion, 1 hour after IM injection. 1
Trough: 2 to 5 mcg/mL ==Special Considerations/Preparation== Available in concentrations of 50 mg/mL and 250 mg/mL. 0
, hydrocortisone succinate, hyaluronidase, linezolid, lorazepam, magnesium sulfate, metronidazole, midazolam, milrinone, morphine, nicardipine, penicillin g, pentobarbital, phenobarbital, potassium chloride, ranitidine, remifentanil, sodium bicarbonate, vancomycin, vitamin K1, and zidovudine. 0
Title Aminophylline 
===Dose===  Loading dose: 8 mg/kg IV infusion over 30 minutes, or orally. 1
. 0
==Uses== Treatment of neonatal apnea, including post-extubation, post-anesthesia, and prostaglandin E1-induced. 0
. 0
Theophylline metabolism and clearance mature to adult values by 55 weeks postmenstrual age. 1
Aminophylline salt is 78.9% theophylline. 1
Theophylline administered orally is approximately 80% bioavailable; therefore, no dosage adjustment is necessary when changing from IV aminophylline to oral theophylline. 0
Treatment of Serious Theophylline Toxicity: Activated charcoal, 1 g/kg as a slurry by gavage tube every 2 to 4 hours. 1
Consider withholding next dose if heart rate is greater than 180 beats per minute. 1
Apnea of prematurity: 7 to 12 mcg/mL. 0
. 0
in 10- and 20-mL vials. 0
with 4 mL NS or D5W to yield a final concentration of 5 mg/mL. 0
Stable for 4 days refrigerated. 1
and contains 20% alcohol. 0
==Solution Compatibility== D5W, D10W, and NS. 0
solutions. 0
Acyclovir, ampicillin, amikacin, aztreonam, caffeine citrate, calcium gluconate, ceftazidime, chloramphenicol, cimetidine, dexamethasone, dopamine, enalaprilat, erythromycin lactobionate, esmolol, famotidine, fluconazole, flumazenil, furosemide, heparin, hydrocortisone succinate, lidocaine, linezolid, meropenem, metoclopramide, midazolam, morphine, nafcillin, nicardipine, nitroglycerin, pancuronium bromide, pentobarbital, phenobarbital, piperacillin, piperacillin/tazobactam, potassium chloride, propofol, prostaglandin E1, ranitidine, remifentanil, sodium bicarbonate, vancomycin, and vecuronium. 0
Title Aminophylline 
===Dose===  Loading dose: 8 mg/kg IV infusion over 30 minutes, or orally. 1
Title Amiodarone 
===Dose===  IV Loading 
===Dose=== : 5 mg/kg IV infusion given over 30 to 60 minutes, preferably in a central vein. 1
. 0
Begin at 7 mcg/kg/minute and titrate by monitoring effects. 0
For infusions lasting longer than 1 hour, amiodarone IV concentrations should not exceed 2 mg/mL unless using a central line. 0
Consider switching to oral therapy within 24 to 48 hours. 1
Oral: 5 to 10 mg/kg/dose every 12 hours. 1
in adults. 0
. 0
Drug-drug interaction potentially occur when given in combination with drugs that inhibit cytochrome CYP3A4: phenytoin, fosphenytoin, clarithromycin, erythromycin, azole antifungals (e.
 Half-life reported to be 26 to 107 days in adults. 1
Contains 37.3% iodine by weight. 0
Oral absorption is variable with approximately 50% bioavailability. 0
Hypotension may be due, in part, to the co-solvents, polysorbate 80 and benzyl alcohol, which are components of the original amiodarone product . 0
, ages 30 days to 15 years, hypotension and bradycardia were reported in 36% and 20% of patients, respectively. 0
AV block was reported in 15% of patients. 0
. 0
. 0
. 0
have been reported with prolonged oral use in adults. 0
Monitor T3, T4, and TSH. 0
concentrations in premix bags. 0
Nexterone®does not contain benzyl alcohol or polysorbate 80, and therefore does not carry a warning regarding benzyl alcohol and fatal gasping syndrome in neonates. 0
Generic amiodarone is also available as 50 mg/mL concentration in 5, 10, and 20 mL vials. 0
80 as a preservative. 0
Oral: Supplied in 100-mg, 200-mg, 300-mg, and 400-mg tablets. 0
An oral suspension with a final concentration of 5 mg/mL may be made as follows: crush a 200-mg tablet, slowly mix in 20 mL of 1% methylcellulose, and then add in 20 mL of simple syrup to make a total volume of 40 mL. 0
==Solution Compatibility== D5W, and NS at concentrations of 1 to 6 mg/mL. 0
Title Amiodarone 
===Dose===  IV Loading 
===Dose=== : 5 mg/kg IV infusion given over 30 to 60 minutes, preferably in a central vein. 1
For infusions lasting longer than 1 hour, amiodarone IV concentrations should not exceed 2 mg/mL unless using a central line. 0
. 0
Title Amphotericin B 
===Dose===  1 to 1.5 mg/kg every 24 hours IV infusion over 2 to 6 hours. 1
Dosage modification for renal dysfunction is only necessary if serum creatinine increases greater than 0.4 mg/dL from baseline during therapy - hold dose for 2 to 5 days. 1
Black Box Warning According to the manufacturer's black box warning, it is recommended that the product name and dosage are verified if the prescribed dose exceeds 1.5 mg/kg. 0
. 0
Elimination half-life is approximately 15 days. 1
and/or a transient increase in serum creatinine occurs in approximately 16% of treated patients. 1
Renal blood flow and GFR may be decreased by 20% to 60%. 0
Sodium intake greater than 4 mEq/kg per day may prevent or decrease nephrotoxicity. 0
Cardiac arrest has occurred in patients who received 10 times the recommended dose. 0
==Special Considerations/Preparation== Available as powder for injection in 50-mg vials. 0
Reconstitute with 10 mL of D5W or preservative free sterile water to a concentration of 5 mg/mL, then dilute further using D5W to a concentration no greater than 0.1 mg/mL for infusion. 0
Reconstituted solution stable for 24 hours at room temperature or 7 days in refrigerator. 1
May filter if necessary; mean pore diameter should not be less than 1 micron. 0
==Solution Compatibility== D5W, D10W, D15W, and D20W. 0
Title Amphotericin B 
===Dose===  1 to 1.5 mg/kg every 24 hours IV infusion over 2 to 6 hours. 1
==Solution Compatibility== D5W, D10W, D15W, and D20W. 0
Title Amphotericin B Lipid Complex 
===Dose===  5 mg/kg/dose IV infusion every 24 hours. 1
at a concentration of 1 to 2 mg/mL. 0
If infusion lasts longer than 2 hours, shake the bag to mix the contents every 2 hours. 1
Flush existing IV line with D5W prior to infusion or administer in a separate IV line. 1
==Pharmacology== Amphotericin B lipid complex consists of amphotericin B complexed with two phospholipids in a 1:1 drug-to-lipid ratio. 0
Mean serum half-life in adults 24 to 38 hours. 1
. 0
Withdraw the appropriate dose into a syringe using an 18 gauge needle. 0
Remove the needle and replace with the supplied 5 micron filter needle. 0
Dilute the drug with D5W so that the final infusion concentration is 1 to 2 mg/mL. 0
The diluted admixture is stable for 48 hours refrigerated and an additional 6 hours at room temperature . 1
==Solution Compatibility== D5W at 1 to 2 mg/mL dilution. 0
Title Amphotericin B Lipid Complex 
===Dose===  5 mg/kg/dose IV infusion every 24 hours. 1
Title Amphotericin B Liposome 
===Dose===  5 to 7 mg/kg per dose every 24 hours IV infusion by syringe pump over 2 hours. 1
==Special Considerations/Preparation== Available as powder for injection in 50 mg vials. 0
Reconstitute by adding 12 mL of sterile water for injection to a yield a concentration of 4 mg/mL. 0
Immediately shake vial vigorously for 30 seconds. 0
Reconstituted suspension stable for 24 hours refrigerated. 1
Before administration, AmBisome® must be diluted with D5W to a final concentration less than 2 mg/mL. 0
1 mL of reconstituted solution into 3 mL of D5W. 0
Use solution within 6 hours of dilution. 1
==Solution Compatibility== D5W, D10W, D20W, D25W. 0
Title Amphotericin B Liposome 
===Dose===  5 to 7 mg/kg per dose every 24 hours IV infusion by syringe pump over 2 hours. 1
Title Ampicillin 
===Dose===  25 to 50 mg/kg/dose by IV slow push, or IM. 0
Therapy should be discontinued at 48 hours if the probability of sepsis is low . 1
Serum half-life in term infants younger than 7 days is approximately 4 hours. 1
has been reported after the third or fourth dose in neonates 33 to 41 weeks GA receiving 50 to 100 mg/kg every 12 hours . 1
has also been reported after at least 10 doses in preterm very low birth-weight neonates 23 to 30 weeks GA receiving 50 to 100 mg/kg every 12 hours . 1
==Special Considerations/Preparation== Available as powder for injection in 125-, 250-, 500-mg, 1-g, 2-g, and 10-g vials. 0
Maximum concentration for IV infusion is 100 mg/mL. 0
Mix to a final concentration of 250 mg/mL for IM administration. 0
Reconstituted solution must be used within 1 hour of mixing because of loss of potency. 0
Solution Incompatibility Dex/AA and D10W Terminal Injection Site Compatibility Fat emulsion. 0
Title Ampicillin 
===Dose===  25 to 50 mg/kg/dose by IV slow push, or IM. 0
Title Anidulafungin 
===Dose===  Candidiasis Full term infants when intolerant to or resistant to fluconazole or amphotericin B Loading dose: 3 mg/kg IV for 1 dose . 1
Maintenance dose: 1.5 mg/kg IV once daily . 0
Duration of therapy for proven infection, without systemic complications, is at least 2 weeks after documented clearance of Candida from the bloodstream and resolution of symptoms . 1
==Administration== Administer by IV Infusion over 60 minutes ; not to exceed 1.1 mg/minute . 1
Candida species are the most common cause of invasive fungal infection in humans; mortality in neonates and children from invasive candidiasis is 10% to 15%. 0
Antifungal therapy should be started on all candidemic patients within 24 hours of a blood culture positive for yeast; delays are associated with increased mortality . 1
. 0
pharmacokinetic data applied to an animal model of the disease . 0
FDA Approved Indications Treatment of candidemia, esophageal candidiasis, and intra-abdominal abscess and peritonitis due to Candida in patients older than 16 years . 0
have been reported; to reduce occurrence, do not exceed an infusion rate of 1.1 mg/minute . 0
-glucan, an essential fungal cell wall component . 0
The minimum effective concentration 90 against Aspergillus fumigatus is 0.008 mcg/mL . 0
In a single-dose study, less than 1% was recovered in urine and approximately 30% was recovered in the feces over 9 days, of which less than 10% was intact anidulafungin. 0
, a process which may alter volume of distribution and/or clearance, and therefore drug exposure. 0
in a safety study of 8 neonates . 0
==Special Considerations/Preparation== Available as 50-mg and 100-mg single-use vials of anidulafungin lyophilized powder for solution. 0
are permitted for 96 hours; then, vial may be returned to refrigerator . 0
or less. 0
For infusion, dilute appropriate dose in sufficient volume of D5W or NS to final concentration of 0.8 mg/mL. 0
, for up to 48 hours or frozen for at least 72 hours prior to administration . 1
==Solution Compatibility== D5W, NS. 0
Trissel’s™ 2 Clinical Pharmaceutics Database, version updated on 06/15/2012. 0
Title Anidulafungin 
===Dose===  Candidiasis Full term infants when intolerant to or resistant to fluconazole or amphotericin B Loading dose: 3 mg/kg IV for 1 dose . 1
==Administration== Administer by IV Infusion over 60 minutes ; not to exceed 1.1 mg/minute . 1
Candida species are the most common cause of invasive fungal infection in humans; mortality in neonates and children from invasive candidiasis is 10% to 15%. 0
In a single-dose study, less than 1% was recovered in urine and approximately 30% was recovered in the feces over 9 days, of which less than 10% was intact anidulafungin. 0
==Solution Compatibility== D5W, NS. 0
. 0
Trissel’s™ 2 Clinical Pharmaceutics Database, version updated on 06/15/2012. 0
Title AquADEKsâ„¢  orally every 24 hours . 1
listed in the table below are for healthy infants 0 to 6 months of age. 1
Title AquADEKsâ„¢  orally every 24 hours . 1
Title Arginine 
===Dose===  Acute Hyperammonemia - Urea Cycle Disorders Pending Definitive Diagnosis of Urea Cycle Enzyme Deficiency: Loading dose: Arginine hydrochloride 600 mg/kg in combination with sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg as an IV infusion over 90 to 120 minutes . 0
Maintenance dose: Arginine hydrochloride 600 mg/kg in combination with sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg as an IV infusion over 24 hours . 0
Known CPS, OTC, or NAGS Deficiency: Loading dose: Arginine hydrochloride 200 mg/kg in combination with sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg as an IV infusion over 90 to 120 minutes . 0
Maintenance dose: Arginine hydrochloride 200 mg/kg in combination with sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg as an IV infusion over 24 hours . 0
Known ASS or ASL Deficiency: Loading dose: Arginine hydrochloride 600 mg/kg in combination with sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg as an IV infusion over 90 to 120 minutes . 0
Maintenance dose: Arginine hydrochloride 600 mg/kg in combination with sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg as an IV infusion over 24 hours . 0
Repeating the loading dose within 24 hours of the initial loading dose should be considered only for patients with a severe disorder receiving dialysis . 1
For loading and maintenance doses, dilute arginine and sodium phenylacetate/sodium benzoate in 25 to 35 mL/kg of D10W prior to administration . 0
==Contraindications/Precautions== Arginine hydrochloride contains 47.5 mEq of chloride in 100 mL. 0
Hyperchloremic metabolic acidosis has been reported in 2 pediatric patients receiving excessive arginine. 0
==Monitoring== Plasma ammonia levels every hour during dialysis until levels stabilize to less than 200 to 300 micromoles/L. 1
==Special Considerations/Preparation== Arginine hydrochloride is supplied as a 10% solution. 0
, and contains 47.5 mEq of chloride in 100 mL. 0
==Solution Compatibility== D10W and sodium phenylacetate/sodium benzoate 10%. 0
Repeating the loading dose within 24 hours of the initial loading dose should be considered only for patients with a severe disorder receiving dialysis . 1
==Special Considerations/Preparation== Arginine hydrochloride is supplied as a 10% solution. 0
Title Aspirin , Recurrent: 1 to 5 mg/kg orally once daily . 0
Thrombosis; Prophylaxis 1 to 5 mg/kg orally once daily . 0
have been used in neonates undergoing heart surgery . 0
, rather than lower doses used for antiplatelet effects . 0
Aspirin is a more specific inhibitor against COX-1 over COX-2 . 1
This enzyme inhibition blocks the formation of thromboxane A2 from arachidonic acid which would reduce platelet shape change, aggregation, and the release reaction . 0
Rapidly absorbed following oral administration with peak concentration achieved in 2 hours. 1
; less than 10% is excreted unchanged in the urine. 0
At higher doses, when saturation of metabolic pathways occurs, renal excretion dominates with greater than 50% of unchanged salicylic acid eliminated in the urine. 0
Elimination half-life is approximately 2 to 3 hours at low dose and 12 hours at anti-inflammatory doses . 1
==Special Considerations/Preparation== Available as 81-mg chewable tablets. 0
Also available as 300- and 600-mg rectal suppositories. 0
Title Aspirin , Recurrent: 1 to 5 mg/kg orally once daily . 0
Title Atropine 
===Dose===  Bradycardia IV: 0.01 to 0.03 mg/kg/dose IV over 1 minute, or IM. 1
===Dose===  can be repeated every 10 to 15 minutes to achieve desired effect, with a maximum total dose of 0.04 mg/kg. 1
ET: 0.01 to 0.03 mg/kg/dose immediately followed by 1 mL NS. 0
Oral: Begin with 0.02 mg/kg/dose given every 4 to 6 hours. 1
May increase gradually to 0.09 mg/kg/dose. 0
Premedication for Intubation 0.01 to 0.02 mg/kg IV over 1 minute immediately prior to other premedications . 1
Peak tachycardia is 12 to 16 minutes after dose is given. 1
Relaxes bronchial smooth muscle, thus reducing airway resistance and increasing dead space by 30%. 0
Duration of action is 6 hours. 1
==Adverse Effects== Cardiac arrhythmias can occur, particularly during the first 2 minutes following IV administration; usually a simple A-V dissociation, more often caused by smaller rather than larger doses. 1
for injection. 0
Title Atropine 
===Dose===  Bradycardia IV: 0.01 to 0.03 mg/kg/dose IV over 1 minute, or IM. 1
==Adverse Effects== Cardiac arrhythmias can occur, particularly during the first 2 minutes following IV administration; usually a simple A-V dissociation, more often caused by smaller rather than larger doses. 1
for injection. 0
Title Azithromycin 
===Dose===  Treatment and Prophylaxis of Pertussis Infections: 10 mg/kg/dose orally once daily for 5 days. 1
Suggested IV dose: 5 mg/kg/dose once daily. 1
: 1 to 2 drops of the 1% ophthalmic solution instilled in each conjunctival sac. 0
Oral bioavailability is 38% in adults and children and is not affected by food. 0
is thought to be due to extensive uptake and subsequent release of drug from tissues. 0
Diarrhea and/or vomiting occur in 5% to 12% of patients. 0
There is one new case report of pyloric stenosis in 2 of 3 triplets treated with azithromycin for pertussis. 0
==Special Considerations/Preparation== Oral suspension is available in 300, 600, 900, and 1,200 mg bottles. 0
. 0
Use within 10 days once bottle has been opened. 1
Azithromycin for intravenous injection is supplied in single use vials containing 500 mg lyophilized powder. 0
Reconstitute by adding 4.8 mL Sterile Water for Injection, then shake the vial until all the drug is dissolved. 0
The concentration of the reconstituted solution is 100 mg/mL. 0
It is stable at room temperature for 24 hours. 1
Dilute prior to administration using a compatible solution to a final concentration of 1 to 2 mg/mL. 0
Diluted solution stable for 24 hours at room temperature or 7 days in refrigerator. 1
Infuse over at least 60 minutes. 1
==Solution Compatibility== D5W, NS, 5% Dextrose in 0.45% NaCl with 20 mEq/L KCl, and Lactated Ringer's. 0
Title Azithromycin 
===Dose===  Treatment and Prophylaxis of Pertussis Infections: 10 mg/kg/dose orally once daily for 5 days. 1
The concentration of the reconstituted solution is 100 mg/mL. 0
Title Aztreonam 
===Dose===  30 mg/kg/dose IV slow push over 5 to 10 minutes, or IM. 1
Good tissue and fluid penetration has been demonstrated in adults, along with protein-binding of 50 to 65%. 0
Serum half-life in neonates is 3 to 9 hours. 1
==Special Considerations/Preparation== Available as powder for injection in 500-mg, 1-g, and 2-g vials. 0
Reconstituted solution stable for 48 hours at room temperature, 7 days refrigerated. 1
Title Aztreonam 
===Dose===  30 mg/kg/dose IV slow push over 5 to 10 minutes, or IM. 1
==Special Considerations/Preparation== Available as powder for injection in 500-mg, 1-g, and 2-g vials. 0
Title Beractant 
===Dose===  4 mL/kg/dose intratracheally, divided into 4 aliquots . 0
Prophylaxis: First dose is given as soon as possible after birth, with up to three additional doses in the first 48 hours of life, if indicated . 1
Rescue treatment of RDS: Up to four doses in first 48 hours of life, no more frequently than every 6 hours . 1
==Administration== Before administration, allow to stand at room temperature for 20 minutes, or warm in the hand for at least 8 minutes. 1
Shorten a 5F end-hole catheter so tip of catheter will protrude just beyond end of ET tube above infant's carina. 0
needle . 0
After administration of each quarter-dose, the dosing catheter is removed from the ET tube and the infant is ventilated for at least 30 seconds until stable . 0
, 0.5 to 1.75 mg/mL triglyceridesSpecial Considerations/Preparation Available in 4- and 8-mL single-use vials. 0
and protect from light. 0
Unopened vials that have been warmed to room temperature one time may be refrigerated within 24 hours and stored for future use. 0
Rescue treatment of RDS: Up to four doses in first 48 hours of life, no more frequently than every 6 hours . 1
Shorten a 5F end-hole catheter so tip of catheter will protrude just beyond end of ET tube above infant's carina. 0
Title Bumetanide 
===Dose===  0.005 to 0.05 mg/kg/dose IV slow push, IM, or orally. 0
===Dose===  up to 0.1 mg/kg have been used in neonates; however, there are no pharmacodynamic data showing doses greater than 0.05 mg/kg provide additional benefit . 0
Preterm infants less than 34 weeks gestation in the first 2 months of life: every 24 hours. 1
Afterward: every 12 hours. 1
Preterm infants 34 weeks or more gestation and term infants in the first month of life: every 24 hours. 1
were given over 1 to 2 minutes. 1
All doses were associated with at least a 2-fold increase in urine output and electrolyte excretion rates. 0
The dose range corresponding to the maximal effect was 0.035 to 0.04 mg/kg. 0
to doses greater than 0.05 mg/kg . 1
Although doses of 0.05 and 0.1 mg/kg have been studied in neonates, only pharmacokinetic endpoints were determined, and no pharmacodynamic endpoints were reported . 0
In a retrospective study in preterm infants with oliguric renal failure and inadequate response to furosemide, bumetanide was effective in significantly increasing urine output in 29 of 35 infants. 0
The mean bumetanide dose and duration of therapy were 0.03 +/- 0.016 mg/kg every 12 to 24 hours and 5.9 days, respectively. 1
Urine output increased from 0.6 +/- 0.6 mL/kg/hour to 3 +/- 2.1 mL/kg/hour . 0
==Administration== Intravenous: Give undiluted over 1 to 2 minutes . 1
via the cytochrome CYP pathway. 0
Serum half-life varies from 4 to 19 hours in neonates, determined by gestational age, postnatal age, and disease state. 1
benzyl alcohol; pH adjusted to 7. 0
A 0.125-mg/mL dilution may be made by adding 3 mL of 0.25-mg/mL injectable solution to 3 mL preservative-free normal saline for injection. 0
Refrigerated dilution is stable for 24 hours. 1
Title Bumetanide 
===Dose===  0.005 to 0.05 mg/kg/dose IV slow push, IM, or orally. 0
to doses greater than 0.05 mg/kg . 1
Administer slowly in 3- to 5-mL incremental doses with sufficient time between doses to detect signs/symptoms of unintentional intravascular or intrathecal injection. 0
, and 0.2 mg/kg/hr up to a maximum of 0.25 mg/kg/hr for continuous epidural infusion for a maximum duration of 24 to 36 hours . 1
than lidocaine 0.5% or 1.5% when administered caudally . 0
Efficacy data are lacking in neonates; however, in 2 pharmacokinetic studies bupivacaine nerve blocks were used in neonates without associated toxic concentrations or observed adverse events . 0
===Dose===  range is 0.5 to 1 mg/kg with usual doses of 0.6 mg/kg of 0.75% hyperbaric bupivacaine in 8.25% dextrose and 0.8 mg/kg of 0.5% isobaric bupivacaine . 0
who received 0.75% bupivacaine 0.6 mg/kg in 8.25% dextrose solution with 0.02 mL of 1:1000 epinephrine . 0
Use is not recommended in pediatric patients younger than 12 years . 0
Use in patients younger than 18 years is not recommended . 0
Glenohumeral chondrolysis has been reported in pediatric patients following intra- articular 48- to 72-hour infusions of local anesthetics with and without epinephrine. 0
The 0.75% concentration is not approved for local infiltration or any other peripheral nerve block, except the retrobulbar block. 0
In most cases, this has followed use of the 0.75% concentration. 0
The 0.75% concentration should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary . 0
Protein binding: 95%. 0
After regional block, time to peak is 30 to 45 minutes, followed by a decline to insignificant levels during the next 3 to 6 hours. 1
Mainly excreted through kidney; 6% excreted unchanged in the urine. 0
Half-life is 2.7 hours and 8.1 hours in adults and neonates, respectively . 1
The bupivacaine concentrations considered toxic are 2 to 4 mg/mL . 0
. 0
, respectively . 0
administered spinal anesthesia with 0.5% isobaric bupivacaine 1 mg/kg with or without epinephrine 1:200,000. 0
Total and free bupivacaine concentrations were 0.31+/-0.17 mcg/mL and 0.047+/-0.032 mcg/mL, respectively, for the without epinephrine group and 0.25+/-0.09 mcg/mL and 0.062+/-0.025 mcg/mL, respectively, for the with epinephrine group . 0
after interpleural nerve block with bupivacaine 2 mg/kg . 0
administered intercostal block with 1.5 mg/kg bupivacaine 0.25% , the values were 2.56 L/kg, 132 minutes, 16.93 mL/kg/min, and 0.82 mcg/mL, respectively . 0
administered spinal anesthesia with bupivacaine . 0
Consider monitoring concentrations when a local anesthesia is administered by continuous infusion at doses greater than 0.5 mg/kg/hr . 0
containing methylparaben as a preservative. 0
for 15 minutes . 1
of bupivacaine in 3-mL single-dose ampules, 10-mL and 30-mL single-dose vials, and a 50-mL multidose vial. 0
Each mL also contains 0.0091 mg of epinephrine and 0.5 mg of sodium metabisulfite. 0
Marcaine™ Spinal: Available as 2-mL single-dose ampules containing 15 mg of bupivacaine and 165 mg of dextrose. 0
for 15 minutes. 1
Sensorcaine®: Available as 0.25% and 0.5% of bupivacaine in 50-mL multidose vials. 0
. 0
: Available as 0.25%, 0.5%, and 0.75% of preservative-free bupivacaine in 10-mL and 30-mL single-dose vials and 30-mL ampules. 0
Sensorcaine® with epinephrine 1:200,000: Available as 0.25% and 0.5% of bupivacaine in 50-mL multidose vials. 0
. 0
of preservative-free bupivacaine. 0
Each mL contains 0.005 mg epinephrine and 0.5 mg sodium metabisulfite. 0
Compatibility information refers to physical compatibility and is derived from Trissel’s™ 2 Clinical Pharmaceutics Database. 0
Trissel’s™ 2 Clinical Pharmaceutics Database, version updated on 06/15/2012. 0
Title Bupivacaine 
===Dose===  The dose varies with anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. 0
administered spinal anesthesia with 0.5% isobaric bupivacaine 1 mg/kg with or without epinephrine 1:200,000. 0
Total and free bupivacaine concentrations were 0.31+/-0.17 mcg/mL and 0.047+/-0.032 mcg/mL, respectively, for the without epinephrine group and 0.25+/-0.09 mcg/mL and 0.062+/-0.025 mcg/mL, respectively, for the with epinephrine group . 0
Consider monitoring concentrations when a local anesthesia is administered by continuous infusion at doses greater than 0.5 mg/kg/hr . 0
Sensorcaine® with epinephrine 1:200,000: Available as 0.25% and 0.5% of bupivacaine in 50-mL multidose vials. 0
Trissel’s™ 2 Clinical Pharmaceutics Database, version updated on 06/15/2012. 0
Title Caffeine Citrate 
===Dose===  Loading dose: 20 to 25 mg/kg of caffeine citrate IV over 30 minutes or orally. 1
. 0
Maintenance dose: 5 to 10 mg/kg per dose of caffeine citrate IV slow push or orally every 24 hours. 1
. 0
Maintenance dose should be started 24 hours after the loading dose. 1
Caffeine increases the respiratory center output, chemoreceptor sensitivity to CO2, smooth muscle relaxation, and cardiac output. 0
In neonates, approximately 86% is excreted unchanged in the urine, with the remainder metabolized via the CYP1A2 enzyme system. 0
The serum half-life of caffeine ranges from 40 to 230 hours, decreasing with advancing postmenstrual age until 60 weeks PMA. 1
have been reported to decrease cerebral and intestinal blood flow velocity. 0
Monitoring of serum drug concentration should be based on a trough level determined on approximately day 5 of therapy. 1
Therapeutic trough serum concentration is 5 to 25 mcg/mL. 0
Concentrations greater than 40 to 50 mcg/mL are toxic. 0
Monitor heart rate; consider withholding dose if greater than 180 beats per minute. 1
==Special Considerations/Preparation== Both Cafcit® Oral Solution and Cafcit® Injection for intravenous administration are preservative free and available in 3-mL single use vials. 0
. 0
Alternatively, an oral solution may be prepared by dissolving 2.5 g of caffeine anhydrous powder in 250 mL of water, yielding a final concentration of 10 mg/mL. 0
Solution is stable for 4 weeks refrigerated. 1
==Solution Compatibility== D5W and D50W. 0
, isoproterenol, lidocaine, metoclopramide, morphine, nitroprusside, pancuronium, penicillin G, phenobarbital, sodium bicarbonate, and vancomycin. 0
Title Caffeine Citrate 
===Dose===  Loading dose: 20 to 25 mg/kg of caffeine citrate IV over 30 minutes or orally. 1
In neonates, approximately 86% is excreted unchanged in the urine, with the remainder metabolized via the CYP1A2 enzyme system. 0
Title Calcium - Oral 
===Dose===  20 to 80 mg/kg elemental calcium per day orally in divided doses scheduled around oral feedings. 0
: 2 to 8 mL/kg per day. 0
: 0.2 to 0.8 mL/kg per day. 0
: 1 to 3.5 mL/kg per day. 0
==Pharmacology== Absorption of calcium administered orally is approximately 50%. 0
Absorption takes place throughout the small intestine, and is primarily regulated by 1,25-dihydroxy Vitamin D.
 The osmolarity of calcium glubionate syrup is 2500 mOsm/L, and of calcium gluconate is 700 mOsm/L. 0
in 5-mL unit dose cups. 0
and is available in 473 mL bottles. 0
Osmolarity is 2500 mOsm/L. 1
Title Calcium - Oral 
===Dose===  20 to 80 mg/kg elemental calcium per day orally in divided doses scheduled around oral feedings. 0
: 2 to 8 mL/kg per day. 0
: 0.2 to 0.8 mL/kg per day. 0
Title Calcium chloride 10%  slow IV push/IO; repeat dose as necessary for clinical effect . 0
Maximum single dose 2 g . 0
. 0
Dilute in appropriate fluid, then infuse in IV over 10 to 30 minutes while monitoring for bradycardia . 1
Stop infusion if heart rate is less than 100 beats per minute. 1
. 0
Treat for 3 to 5 days . 1
. 0
Infuse IV over 10 to 30 minutes. 1
==Administration== Administer by slow IV push for cardiac arrest ; infuse over 30 to 60 minutes for other indications . 1
. 0
. 0
Ionized calcium is the physiologically active fraction, accounting for approximately 50% of total blood calcium. 0
with citrate, phosphate, and bicarbonate. 0
Clinical signs suggestive of hypocalcemia in neonates include muscle twitching, jitteriness, generalized seizures, and QTc above 0.4 second. 0
. 0
Osmolarity is 2040 mOsm/L. 1
Amikacin, amiodarone, chloramphenicol, dobutamine, dopamine, epinephrine, esmolol, hydrocortisone, isoproterenol, lidocaine, micafungin, milrinone, morphine, penicillin G, pentobarbital, phenobarbital, prostaglandin E1, and sodium nitroprusside. 0
Title Calcium chloride 10%  slow IV push/IO; repeat dose as necessary for clinical effect . 0
. 0
with citrate, phosphate, and bicarbonate. 0
Amikacin, amiodarone, chloramphenicol, dobutamine, dopamine, epinephrine, esmolol, hydrocortisone, isoproterenol, lidocaine, micafungin, milrinone, morphine, penicillin G, pentobarbital, phenobarbital, prostaglandin E1, and sodium nitroprusside. 0
Title Calcium gluconate 10%  . 0
. 0
. 0
Infuse IV over 10 minutes. 1
==Administration== Administer by slow IV push for cardiac arrest; infuse over 30 to 60 minutes for other indications . 1
Administer slowly as bolus, about 1.5 mL over 1 minute, do not exceed 200 mg/min as an intermittent infusion or continuous infusion . 1
Studies showed that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. 0
==Pharmacology== Ionized calcium is the physiologically active fraction, accounting for approximately 50% of total blood calcium. 0
. 0
Osmolarity is 700 mOsm/L. 1
Title Calcium gluconate 10%  . 0
==Administration== Administer by slow IV push for cardiac arrest; infuse over 30 to 60 minutes for other indications . 1
Title Calfactant 
===Dose===  Initial dose: 3 mL/kg intratracheally; may be repeated if needed every 12 hours up to a total of 3 doses. 1
For prophylactic therapy in premature infants less than 29 weeks of gestational age at significant risk for respiratory distress syndrome, Infasurf® should be given as soon as possible, preferably within 30 minutes after birth . 1
In the Infasurf® versus Survanta® treatment trial, repeat doses were administered as early as 6 hours after the previous dose for a total of up to 4 doses if the infant was still intubated and required at least 30% inspired oxygen to maintain a PaO2 of 80 torr or less . 0
Administration by instilling the suspension through a side-port adapter into the endotracheal tube. 0
should be administered in 2 aliquots of 1.5 mL/kg each. 0
Administration is made while ventilation is continued over 20 to 30 breaths for each aliquot, with small bursts timed only during the inspiratory cycles. 1
Administration by instilling the suspension through a 5 French feeding tube inserted into the endotracheal tube. 0
The total dose is instilled in 4 equal aliquots with the catheter removed between each instillation and mechanical ventilation resumed for 0.5 to 2 minutes. 1
For even distribution of calfactant, each of the aliquots should be administered with the neonate in 1 of 4 positions; prone, supine, right, and left lateral. 0
in premature infants less than 29 weeks of gestational age at significant risk for RDS. 1
Treatment should be given as soon as possible, preferably within 30 minutes after birth . 1
and requiring endotracheal intubation . 0
and 0.65 mg of proteins including 0.26 mg of SP-B . 0
. 0
==Special Considerations/Preparation== Available in 3-mL and 6-mL single-use vials. 0
The 3 mL vial must be stored upright. 0
==Special Considerations/Preparation== Available in 3-mL and 6-mL single-use vials. 0
Title Captopril 
===Dose===  Initial dose: 0.01 to 0.05 mg/kg/dose orally every 8 to 12 hours. 1
==Administration== Administer 1 hour before feeding; food decreases absorption. 1
Onset of action is 15 minutes after a dose, with peak effects seen in 30 to 90 minutes. 1
. 0
than those recommended above. 0
==Special Considerations/Preparation== Available in 12.5-mg, 25-mg, 50-mg, and 100-mg tablets. 0
. 0
to decrease oxidation, then adding sufficient water to make a final volume of 200 mL. 0
The final concentration is 0.03 mg/mL captopril and 5 mg/mL sodium ascorbate. 0
Solution is stable for 14 days at room temperature, 56 days refrigerated. 1
Title Captopril 
===Dose===  Initial dose: 0.01 to 0.05 mg/kg/dose orally every 8 to 12 hours. 1
Title Carglumic Acid  deficiency; Adjunct: Initial, 100 to 250 mg/kg/day divided into 2 to 4 doses per day concomitantly with other ammonia lowering agents. 0
Normal plasma ammonia levels usually attained by day 3. 0
Therapy is continuous and life-long . 1
, maintenance doses were typically less than 100 mg/kg/day . 0
tube administration. 0
For oral administration, measure dose using an oral syringe, discard the unused portion, administer immediately, then refill the oral syringe with 1 to 2 mL of water and administer immediately to ensure complete delivery of dose. 0
===Dose===  used in these cases ranged from 70 to 200 mg/kg/day, administered as a single dose or over a 48-hour period . 0
During initial treatment, complete protein restriction is recommended for 24 to 48 hours; supplement calories to avoid catabolism and nitrogen turnover . 1
, which is the first enzyme in the urea cycle. 0
Carglumic acid acts as a replacement for NAG in patients with NAGS deficiency, thereby activating CPS 1. 0
Following administration, plasma ammonia levels are reduced within 24 hours. 1
Tmax occurs in 2 to 4 hours. 1
. 0
Mean terminal half-life is 5.6 hours . 1
==Adverse Effects== Adverse reaction which occurred in 13% or more patients from a retrospective case series include abdominal pain, anemia, diarrhea, ear infection, headache, infection, nasopharyngitis, pyrexia, tonsillitis, and vomiting . 0
==Special Considerations/Preparation== Available as a 200-mg tablet. 0
Discard product 1 month after first opening . 1
==Adverse Effects== Adverse reaction which occurred in 13% or more patients from a retrospective case series include abdominal pain, anemia, diarrhea, ear infection, headache, infection, nasopharyngitis, pyrexia, tonsillitis, and vomiting . 0
==Special Considerations/Preparation== Available as a 200-mg tablet. 0
Title Caspofungin  per dose every 24 hours. 1
==Administration== Administer by slow IV infusion over approximately 1 hour at a concentration not to exceed 0.5 mg/mL. 1
-D-glucan, an integral component of the fungal cell wall. 0
==Special Considerations/Preparation== Cancidas® is supplied as a white to off-white powder cake in single-use vials, containing either 50 or 70 mg. Equilibrate the refrigerated vial to room temperature. 0
Aseptically add 10.8 mL Normal Saline or Sterile Water for Injection to the vial. 0
to a final concentration not to exceed 0.5 mg/mL. 0
The infusion solution can be stored for up to 24 hours at room temperature or up to 48 hours refrigerated. 1
Title Caspofungin  per dose every 24 hours. 1
Title CeFAZolin 
===Dose===  25 mg/kg/dose IV or IM. 0
Half-life in neonates is 3 to 5 hours. 1
==Special Considerations/Preparation== Available as powder for injection in 500-mg and 1000-mg vials. 0
Reconstitute 500-mg vial using 2 mL of sterile water for injection to a concentration of 225 mg/mL. 0
Reconstitute 1000-mg vial using 3 mL of sterile water for injection to a concentration of 330 mg/mL. 0
Reconstituted solution stable for 24 hours at room temperature or 10 days in refrigerator. 1
For bolus injection, further dilute reconstituted vial with approximately 5 mL of sterile water. 0
For intermittent or continuous infusion, further dilute reconstituted drug to a concentration of 5 to 20 mg/mL in compatible solution. 0
==Solution Compatibility== D5W, D10W, and NS. 0
Acyclovir, alprostadil, amikacin, aztreonam, calcium gluconate, clindamycin, enalaprilat, esmolol, famotidine, fluconazole, heparin, insulin, lidocaine, linezolid, magnesium sulfate, midazolam, milrinone, morphine, metronidazole, multivitamins, nicardipine, pancuronium bromide, propofol, prostaglandin E1, ranitidine, remifentanil, and vecuronium. 0
Title CeFAZolin 
===Dose===  25 mg/kg/dose IV or IM. 0
Title CefOXitin 
===Dose===  90 to 100 mg/kg/day IV divided every 8 hours . 1
==Administration== Give as an intermittent IV infusion at a concentration of 10 to 40 mg/mL over 15 to 60 minutes ; . 1
. 0
. 0
Transient eosinophilia and elevation of hepatic transaminases have been reported in less than 3% of treated patients. 0
==Special Considerations/Preparation== Available as powder for injection in 1-g and 2-g vials. 0
IV administration: Reconstitute 1-g vial with 9.5 mL sterile water for injection to a concentration of 100 mg/mL. 0
A 40 mg/mL dilution may be made by adding 4 mL of reconstituted solution to 6 mL sterile water for injection, or D5W. 0
Stable for 18 hours at room temperature or 7 days refrigerated. 1
Title CefOXitin 
===Dose===  90 to 100 mg/kg/day IV divided every 8 hours . 1
Title CefTAZidime 
===Dose===  30 mg/kg/dose IV infusion by syringe pump over 30 minutes, or IM. 1
To reduce pain at IM injection site, ceftazidime may be mixed with 1% lidocaine without epinephrine. 0
Serum half-life in neonates is 3 to 12 hours. 1
==Special Considerations/Preparation== Available as powder for injection in 500-mg and 1-g, 2-g, and 6-g vials. 0
Intravenous solution: Reconstitute 500-mg vial with 10 mL of sterile water for injection to make a concentration of 50 mg/mL. 0
Reconstituted solution stable for 12 hours at room temperature, 3 days refrigerated. 1
Intramuscular solution: Prepared by reconstituting 500-mg vial with 2.2 mL of 1% lidocaine without epinephrine or Sterile Water to a concentration of 200 mg/mL. 0
Solution is stable for 12 hours at room temperature, 3 days refrigerated. 1
Title CefTAZidime 
===Dose===  30 mg/kg/dose IV infusion by syringe pump over 30 minutes, or IM. 1
Title CefTRIAXone 
===Dose===  Sepsis: 50 mg/kg IV every 24 hours. 1
Meningitis: 100 mg/kg IV loading dose, then 80 mg/kg IV every 24 hours. 1
Gonococcal Infections Disseminated Gonococcal Infections: 25 to 50 mg/kg/day IV/IM in a single daily dose for 7 days, with a duration of 10 to 14 days if meningitis is documented. 0
IV/IM as a single dose. 0
IV/IM as a single dose. 0
==Administration== Intravenous: Infusion by syringe pump over 30 minutes. 1
Avoid administration of calcium-containing solutions or products within 48 hours of the last administration of ceftriaxone. 0
Intramuscular: To reduce pain at the injection site, reconstitute with 1% lidocaine without epinephrine to a final concentration of 250 mg/mL or 350 mg/mL. 0
There have been 7 reported cases of cardiorespiratory arrest in young infants, with 6 deaths, associated with concurrent administration of ceftriaxone and calcium-containing intravenous solutions. 0
significantly exceeded the FDA recommended dose and/or was administered IV push. 0
in 4 of the 5 infants for which results were available. 0
and renal mechanisms. 0
Serum half-life in premature infants is 5 to 16 hours. 1
==Special Considerations/Preparation== Intravenous solution: Available as a powder for injection in 250-mg, 500-mg, 1-g, and 2-g vials. 0
to a concentration of 100 mg/mL. 0
Reconstituted solution is stable for 2 days at room temperature, 10 days refrigerated. 1
To make 40-mg/mL solution add 6.2 mL to the 250-mg vial. 0
Intramuscular solution: Prepared by reconstituting 250-mg vial with 0.9 mL of 1% lidocaine without epinephrine to a concentration of 250 mg/mL. 0
Solution is stable for 24 hours at room temperature, 3 days refrigerated. 1
Title CefTRIAXone 
===Dose===  Sepsis: 50 mg/kg IV every 24 hours. 1
IV/IM as a single dose. 0
significantly exceeded the FDA recommended dose and/or was administered IV push. 0
Title Cefepime 
===Dose===  Term and preterm infants greater than 28 days of age: 50 mg/kg/dose IV every 12 hours. 1
Term and preterm infants 28 days of age and younger: 30 mg/kg/dose IV every 12 hours. 1
Meningitis and severe infections due to Pseudomonas aeruginosa or Enterobacter spp: 50 mg/kg/dose IV every 12 hours. 1
==Administration== Administer via IV infusion by syringe pump over 30 minutes, or IM. 1
To reduce pain at IM injection site, cefepime may be mixed with 1% lidocaine without epinephrine. 0
, especially Pseudomonas aeruginosathat are resistant to 3rd generation cephalosporins. 0
, and it is primarily excreted unchanged in the urine. 0
Serum half-life in infants older than 2 months of age is approximately 2 hours. 1
==Special Considerations/Preparation== Available as powder for injection in 500-mg and 1-g, and 2-g vials. 0
Reconstitute 500- mg vial with 5 mL of sterile water for injection to a concentration of 100 mg/mL. 0
Maximum concentration for IV administration is 160 mg/mL, and for IM administration 280 mg/mL. 0
Reconstituted solution stable for 24 hours at room temperature, 7 days refrigerated. 1
==Solution Compatibility== D5W, D10W, D5LR, D5NS, and NS. 0
Title Cefepime 
===Dose===  Term and preterm infants greater than 28 days of age: 50 mg/kg/dose IV every 12 hours. 1
==Administration== Administer via IV infusion by syringe pump over 30 minutes, or IM. 1
, especially Pseudomonas aeruginosathat are resistant to 3rd generation cephalosporins. 0
Title Cefotaxime 
===Dose===  50 mg/kg/dose IV or IM. 0
, empiric or therapeutic use of cefotaxime should be limited to infants having gram-negative meningitis. 0
Serum half-life in the premature infant is approximately 3 to 6 hours. 1
==Special Considerations/Preparation== Available as powder for injection in 500-mg, 1-g, and 2-g vials. 0
The 500-mg vial is reconstituted with 10 mL sterile water for injection to yield a concentration of 50 mg/mL. 0
Title Cefotaxime 
===Dose===  50 mg/kg/dose IV or IM. 0
==Special Considerations/Preparation== Available as powder for injection in 500-mg, 1-g, and 2-g vials. 0
Title Chloral hydrate 
===Dose===  25 to 75 mg/kg per dose orally or rectally. 0
==Pharmacology== Well absorbed from the oral route, with the onset of action in 10 to 15 minutes. 0
have long serum half-lives in neonates and accumulate with repeated doses. 1
==Adverse Effects== Episodes of bradycardia are more frequent for up to 24 hours after a single dose in former premature infants. 1
==Special Considerations/Preparation== Chloral hydrate is available in syrup as 100-mg/mL concentration. 0
Osmolality is 3285 mOsm/kg of water. 0
Title Chloral hydrate 
===Dose===  25 to 75 mg/kg per dose orally or rectally. 0
==Pharmacology== Well absorbed from the oral route, with the onset of action in 10 to 15 minutes. 0
Title Chloramphenicol 
===Dose===  Loading dose: 20 mg/kg IV infusion by syringe pump over 30 minutes. 1
Maintenance dose: (Begin 12 hours after loading dose. 1
Premature infants under 1 month of age: 2.5 mg/kg/dose every 6 hours. 1
Full-term infants under 1 week of age and premature infants over 1 month of age: 5 mg/kg/dose every 6 hours. 1
Full-term infants over 1 week of age: 12.5 mg/kg/dose every 6 hours. 1
. 0
Therapeutic peak serum concentration: 10 to 25 mcg/mL. 0
==Special Considerations/Preparation== Chloramphenicol succinate is available as powder for injection in a 1-g vial. 0
of sodium per gram. 0
Reconstitute with 10 mL sterile water for injection or D5W to a concentration of 100 mg/mL. 0
For IV intermittent infusion, further dilute to a concentration of 20 to 25 mg/mL in compatible solution. 0
Acyclovir, amikacin, aminophylline, ampicillin, calcium chloride, calcium gluconate, dopamine, enalaprilat, esmolol, heparin, hydrocortisone succinate, lidocaine, magnesium sulfate, metronidazole, morphine, nafcillin, nicardipine, oxacillin, penicillin G, pentobarbital, potassium chloride, ranitidine, sodium bicarbonate, and vitamin K1. 0
==Terminal Injection Site Incompatibility== Erythromycin lactobionate, fluconazole, metoclopramide, phenytoin, and vancomycin. 0
Title Chloramphenicol 
===Dose===  Loading dose: 20 mg/kg IV infusion by syringe pump over 30 minutes. 1
Acyclovir, amikacin, aminophylline, ampicillin, calcium chloride, calcium gluconate, dopamine, enalaprilat, esmolol, heparin, hydrocortisone succinate, lidocaine, magnesium sulfate, metronidazole, morphine, nafcillin, nicardipine, oxacillin, penicillin G, pentobarbital, potassium chloride, ranitidine, sodium bicarbonate, and vitamin K1. 0
==Terminal Injection Site Incompatibility== Erythromycin lactobionate, fluconazole, metoclopramide, phenytoin, and vancomycin. 0
Title Chlorothiazide 
===Dose===  Diuresis: 10 to 20 mg/kg/dose orally every 12 hours. 1
Adjuvant treatment of central diabetes insipidus: 5 mg/kg/dose orally every 12 hours. 1
Onset of action within 1 hour. 1
Elimination half-life depends on GFR, and is approximately 5 hours. 1
==Special Considerations/Preparation== Available as a 250 mg/5mL suspension for oral use. 0
Injectable formulation available in 500-mg vial as lyophilized powder for reconstitution. 0
of sterile water for injection to make a concentration of 28 mg/mL. 0
. 0
Solution Compatibility D5W and NS. 0
Title Chlorothiazide 
===Dose===  Diuresis: 10 to 20 mg/kg/dose orally every 12 hours. 1
Title Cimetidine 
===Dose===  2.5 to 5 mg/kg/dose every 6 to 12 hours orally or IV infusion over 15 to 30 minutes. 1
==Pharmacology== Inhibits gastric acid secretion by histamine H2-receptor antagonism. 0
Peak inhibition occurs in 15 to 60 minutes after both oral and IV administration. 1
Metabolized in the liver via sulfation and hydroxylation to inactive compounds that are 90% renally eliminated. 0
Half-life in neonates is 1.1 to 3.4 hours, and is prolonged in patients with renal or hepatic insufficiency. 1
==Special Considerations/Preparation== Available as a 150-mg/mL injectable solution in 2-mL single-use vials and 8-mL multidose vials. 0
A 15-mg/mL dilution may be made by adding 1 mL of 150 mg/mL concentration to 9 mL of preservative-free normal saline. 0
Dilution stable for 48 hours. 1
contains 2.8% alcohol. 0
of manufacturer's oral solution to 24 mL of sterile water. 0
Stable for 14 days refrigerated. 1
Also available in 200-, 300-, 400-, and 800-mg tablets. 0
Acetazolamide, acyclovir, amikacin, aminophylline, ampicillin, atropine, aztreonam, caffeine citrate, cefotaxime, cefoxitin, ceftazidime, clindamycin, dexamethasone, diazepam, digoxin, enalaprilat, epinephrine, erythromycin lactobionate, esmolol, fentanyl, fluconazole, flumazenil, furosemide, gentamicin, glycopyrrolate, heparin, insulin, isoproterenol, lidocaine, linezolid, lorazepam, meperidine, meropenem, metoclopramide, midazolam, milrinone, morphine, nafcillin, nicardipine, nitroprusside, pancuronium, penicillin G, piperacillin/tazobactam, potassium chloride, propofol, prostaglandin E1 , protamine, remifentanil, sodium bicarbonate, vancomycin, vecuronium, vitamin K1, and zidovudine. 0
Title Cimetidine 
===Dose===  2.5 to 5 mg/kg/dose every 6 to 12 hours orally or IV infusion over 15 to 30 minutes. 1
==Special Considerations/Preparation== Available as a 150-mg/mL injectable solution in 2-mL single-use vials and 8-mL multidose vials. 0
==Solution Compatibility== D5W, D10W, and NS. 0
Title Clindamycin 
===Dose===  5 to 7.5 mg/kg/dose IV infusion by syringe pump over 30 minutes, or orally. 1
. 0
is reconstituted with sterile water for injection, yielding a 75 mg per 5 mL solution. 0
Stable at room temperature for 2 weeks. 1
is available as a 150 mg/mL solution in 2-mL, 4-mL, and 6-mL vials containing 9.45 mg/mL benzyl alcohol. 0
It should be diluted using D5W, NS, or LR to a maximum concentration of 18 mg/mL, and infused at a rate no greater than 30 mg/min. 0
without benzyl alcohol containing 300 mg, 600 mg or 900 mg of clindamycin. 0
Acyclovir, amikacin, amiodarone, ampicillin, aztreonam, caffeine citrate, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, cimetidine, enalaprilat, esmolol, gentamicin, heparin, hydrocortisone succinate, linezolid, magnesium sulfate, metoclopramide, metronidazole, midazolam, milrinone, morphine, netilmicin, nicardipine, penicillin G, piperacillin, piperacillin/tazobactam, potassium chloride, propofol, prostaglandin E1, ranitidine, remifentanil, sodium bicarbonate, tobramycin, and zidovudine. 0
Title Clindamycin 
===Dose===  5 to 7.5 mg/kg/dose IV infusion by syringe pump over 30 minutes, or orally. 1
Title CloNIDine 
===Dose===  Neonatal Abstinence Syndrome; Adjunct 35 weeks GA and older:0.5 to 1 mcg/kg orally every 4 to 6 hours . 1
was diluted in NS to a concentration of 5 mcg/mL and used orally in a randomized controlled trial . 0
In a prospective, randomized, double-blind, placebo-controlled trial, infants 35 weeks GA and older receiving DTO with oral clonidine experienced fewer treatment failures, a shorter duration of treatment and observation, and required less DTO than infants receiving DTO with placebo. 1
Epidural administration above the C4 dermatome is also contraindicated . 0
==Pharmacology== Clonidine is a centrally acting alpha-2-adrenergic agonist. 1
After oral administration, onset of action of hypotension occurs within 30 to 60 minutes with a peak effect within 2 to 4 hours. 1
Peak concentrations occur 3 to 5 hours after dosing of immediate-release formulation. 0
Approximately 50% of a dose is metabolized in the liver and approximately 40% to 60% of a dose is eliminated in the urine as unchanged drug. 1
Elimination half-life in neonates is 44 to 72 hours and is prolonged in patients with renal impairment . 1
Pharmacokinetic modelling showed that by the age of 1 month, neonates had achieved 70% of adult clearance . 1
==Monitoring== Monitor heart rate and blood pressure every 4 hours the first 2 days of therapy and every 12 hours thereafter; monitor blood pressure closely for 48 hours after discontinuing clonidine to access for rebound hypertension. 1
or the Lipsitz tool . 0
==Special Considerations/Preparation== Oral formulations available as 0.1-, 0.2- and 0.3-mg immediate-release tablets. 0
0.2 mg- clonidine tablets, adding 2 mL of Purified Water, USP, to make a fine paste, and adding enough Simple Syrup, NF, for a final volume of 60 mL. 0
. 0
Clonidine for epidural injection is available in concentrations of 100 mcg/mL and 500 mcg/mL in 10-mL single-dose vials. 0
The 500 mcg/mL- strength must be diluted with NS to a final concentration not exceeding 100 mcg/mL prior to use. 0
==Pharmacology== Clonidine is a centrally acting alpha-2-adrenergic agonist. 1
or the Lipsitz tool . 0
Title Clopidogrel 
===Dose===  Thrombosis; Prophylaxis 35 weeks of gestation or greater:initial, 0.2 mg/kg orally once daily . 1
as a 75 mg/day regimen in adults. 0
. 0
Discontinuation Clopidogrel should be discontinued 5 days prior to elective surgery if an antiplatelet effect is not desired . 0
when clopidogrel was used concomitantly with aspirin . 0
, 1 case each of severe epistaxis and gastrointestinal bleeding was reported in the 2 children receiving concomitant warfarin and clopidogrel therapy . 0
. 0
Concomitant use with the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided as platelet activity may be reduced . 0
. 0
The combination group consisted of 4 patients taking omeprazole and 1 patient taking lansoprazole . 0
Black Box Warning Clopidogrel efficacy is dependent on its activation to an active metabolite by CYP2C19. 0
In patients who are CYP2C19 poor metabolizers, clopidogrel at recommended doses forms less of that metabolite and has a smaller effect on platelet function. 0
Tests are available to identify a patient's CYP2C19 genotype; these tests can help determine therapeutic strategy. 0
Consider alternative treatment or treatment strategies in CYP2C19 poor metabolizers . 0
P2Y12 receptor on platelets. 0
. 0
===Dose=== -dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses. 1
Platelet inhibition reaches steady state at days 3 to 7 after therapy initiation. 1
Platelet aggregation and bleeding time gradually return to baseline values after treatment is discontinued, generally in about 5 days. 1
Bioavailability is at least 50%; food does not affect absorption. 0
Peak concentration achieved 30 to 60 minutes after administration. 1
. 0
Approximately 50% and 46% is eliminated in the urine and feces, respectively. 0
. 0
The half-life of the active metabolite is about 30 minutes . 1
==Monitoring== Measure bleeding time prior to therapy initiation and 3 to 7 days after therapy initiation to assess drug efficacy. 1
Monitor hematological parameters closely during the first few months of therapy and every 2 to 3 months in patients on long-term therapy . 1
==Special Considerations/Preparation== Available as 75-mg and 300-mg tablets . 0
An extemporaneous clopidogrel oral suspension can be compounded by triturating four 75-mg tablets in a mortar and mixing with 30 mL of Ora-Plus and 30 mL of Ora-Sweet for a final concentration of 5 mg/mL. 0
Suspension is stable for 60 days at room temperature or refrigerated. 1
. 0
. 0
Monitor hematological parameters closely during the first few months of therapy and every 2 to 3 months in patients on long-term therapy . 1
===Dose===  1 or 2 drops instilled in the eye 10 to 30 minutes prior to funduscopy. 1
Use solutions containing concentrations of 0.5% or less in neonates. 0
May be used in conjunction with 1 drop of phenylephrine 2.5% ophthalmic solution. 0
Apply pressure to the lacrimal sac during and for 2 minutes after instillation to minimize systemic absorption. 1
Maximal mydriasis occurs 30 to 60 minutes following administration. 1
Recovery of accommodation occurs in 6 to 24 hours. 1
Without lacrimal sac occlusion, approximately 80% of each drop may pass through the nasolacrimal system and be available for rapid systemic absorption by the nasal mucosa. 0
==Adverse Effects== Feedings should be withheld for 4 hours following procedure. 1
The use of solutions with concentrations of 1% or greater have caused systemic toxicity in infants. 0
==Special Considerations/Preparation== Supplied as ophthalmic solution 0.5% in 15-mL Drop-tainers, and 1% and 2% concentrations in 2-, 5- and 15-mL Drop-tainers. 0
is commercially available in 2- and 5-mL Drop-tainers. 0
may be prepared in a 15-mL bottle with 3.75 mL of cyclopentolate 2%, 7.5 mL of tropicamide 1%, and 3.75 mL of phenylephrine 10%. 0
The final solution contains cyclopentolate 0.5%, tropicamide 0.5%, and phenylephrine 2.5%. 0
===Dose===  1 or 2 drops instilled in the eye 10 to 30 minutes prior to funduscopy. 1
Apply pressure to the lacrimal sac during and for 2 minutes after instillation to minimize systemic absorption. 1
may be prepared in a 15-mL bottle with 3.75 mL of cyclopentolate 2%, 7.5 mL of tropicamide 1%, and 3.75 mL of phenylephrine 10%. 0
Title DOBUTamine 
===Dose===  2 to 25 mcg/kg per minute continuous IV infusion. 1
:Mix 30 mL of 800 mcg/mL solution using dobutamine concentration of 12.5 mg/mL. 0
to yield 30 mL of infusion solution with a concentration of 800 mcg/mL. 0
==Pharmacology== Synthetic catecholamine with primarily β1-adrenergic activity. 0
Onset of action is 1 to 2 minutes after IV administration, with peak effect in 10 minutes. 1
and premixed bags in concentrations of 1, 2, and 4 mg/mL. 0
Diluted solutions for infusion should be used within 24 hours. 1
Dobutamine is most stable in solutions with a pH at or below 5. 1
In alkaline solutions, the catechol moieties are oxidized, cyclized, and polymerized to colored materials. 0
All fat emulsions have pH ranges from 6 to 9. 0
Caution is urged when co-infusing dobutamine and fat emulsion together; dobutamine may degrade over time in this alkaline pH resulting in lower than expected clinical effects. 0
==Solution Compatibility== D5W, D5NS, D10W, LR, and NS. 0
Title DOBUTamine 
===Dose===  2 to 25 mcg/kg per minute continuous IV infusion. 1
Title DOPamine 
===Dose===  2 to 20 mcg/kg per minute continuous IV infusion. 1
:Mix 30 mL of 800 mcg/mL solution using dopamine concentration of 40 mg/mL. 0
to yield 30 mL of infusion solution with a concentration of 800 mcg/mL. 0
Suggested treatment for extravasation: Inject a 0.5 mg/mL solution of phentolamine into the affected area. 0
The usual amount needed is 1 to 5 mL, depending on the size of the infiltrate. 0
Serum half-life is 2 to 5 minutes, but clearance is quite variable. 1
Selective renal vasodilation associated with increases in urine output has been noted in preterm neonates at doses of 2 to 5 mcg/kg/minute. 0
the ability of the neonatal heart to increase stroke volume. 0
==Special Considerations/Preparation== Available in 40-mg/mL, 80-mg/mL, and 160-mg/mL vials for injection and premixed bags in concentrations of 800, 1600, and 3200 mcg/mL. 0
Diluted solutions stable for 24 hours. 1
Dopamine is most stable in solutions with a pH at or below 5. 1
In alkaline solutions, the catechol moieties are oxidized, cyclized, and polymerized to colored materials. 0
All fat emulsions have pH ranges from 6 to 9. 0
Caution is urged when co-infusing dopamine and fat emulsion together; dopamine may degrade over time in this alkaline pH resulting in lower than expected clinical effects. 0
Aminophylline, amiodarone, aztreonam, caffeine citrate, calcium chloride, caspofungin, cefotaxime, cefoxitin, ceftazidime, chloramphenicol, dobutamine, enalaprilat, epinephrine, esmolol, famotidine, fentanyl, fluconazole, flumazenil, gentamicin, heparin, hydrocortisone succinate, ibuprofen lysine, lidocaine, linezolid, lorazepam, meropenem, metronidazole, micafungin, midazolam, milrinone, morphine, nicardipine, nitroglycerin, nitroprusside, oxacillin, pancuronium bromide, piperacillin/tazobactam, potassium chloride, propofol, prostaglandin E1, ranitidine, tobramycin, vecuronium, and zidovudine. 0
Title DOPamine 
===Dose===  2 to 20 mcg/kg per minute continuous IV infusion. 1
Title DT/Td Vaccine 
===Dose===  0.5 mL IM . 0
of diphtheria toxoid and 5 Lf of tetanus toxoid . 0
. 0
is available as 0.5-mL single-dose vials. 0
. 0
Title DTaP Vaccine 
===Dose===  0.5 mL IM in the anterolateral thigh. 0
. 0
Contraindications to further DTaP vaccination: in children who develop encephalopathy within 7 days following any DTP vaccination, DT vaccine should be substituted for the remaining doses; in children who develop an immediate anaphylactic reaction, further immunization with any of the three antigens should be deferred; and in children with a progressive neurologic disorder, it is prudent to delay the initial dose of DTaP vaccine until further observation and study have clarified their neurologic status and the effect of treatment . 1
occurring within 48 hours  Convulsions with or without fever occurring within 3 days ==Pharmacology== DTaP vaccines are aluminum-salt-adsorbed preparations. 1
Each dose of Daptacel®contains 15 Lf diphtheria toxoid, 5 Lf tetanus toxoid, 5 mcg fimbriae types 2 and 3, 5 mcg FHA, and 3 mcg pertactin, with 3.3 mg 2-phenoxyethanol as a preservative. 0
Each dose of Infanrix® contains 25 Lf diphtheria toxoid, 10 Lf tetanus toxoid, 25 mcg inactivated toxin, 25 mcg FHA, and 8 mcg pertactin, with 2.5 mg 2-phenoxyethanol as a preservative. 0
Each dose of Tripedia® contains 6.7 Lf diphtheria toxoid, 5 Lf tetanus toxoid, 23.4 mcg inactivated toxin, and 23.4 mcg FHA . 0
. 0
occurring within 48 hours  Convulsions with or without fever occurring within 3 days ==Pharmacology== DTaP vaccines are aluminum-salt-adsorbed preparations. 1
Title DTaP-HepB-IPV Combination Vaccine 
===Dose===  0.5 mL IM in the anterolateral thigh. 0
Pediarix® should not be administered to any infant before the age of 6 weeks. 1
Contraindications to further DTaP vaccination: in children who develop encephalopathy within 7 days following any DTP vaccination, DT vaccine should be substituted for the remaining doses; in children who develop an immediate anaphylactic reaction, further immunization with any of the three antigens should be deferred; and in children with a progressive neurologic disorder, it is prudent to delay the initial dose of DTaP vaccine until further observation and study have clarified their neurologic status and the effect of treatment . 1
occurring within 48 hours  Convulsions with or without fever occurring within 3 days ==Pharmacology== Each dose of Pediarix® contains the type and amount of diphtheria and tetanus toxoids and pertussis antigens as Infanrix®, and hepatitis B virus antigens as Engerix-B ®. 1
. 0
The immunologic responses following 3 doses of DTaP-HepB-IPV were generally similar to those following 3 doses of the individual vaccines administered separately . 0
after Pediarix® than with the individual component vaccines administered separately . 0
Apnea, bradycardia, and desaturation events are common in premature infants for 48 hours after vaccination . 1
, and in disposable prefilled Tip-Lock® syringes, which contain latex. 0
Contraindications to further DTaP vaccination: in children who develop encephalopathy within 7 days following any DTP vaccination, DT vaccine should be substituted for the remaining doses; in children who develop an immediate anaphylactic reaction, further immunization with any of the three antigens should be deferred; and in children with a progressive neurologic disorder, it is prudent to delay the initial dose of DTaP vaccine until further observation and study have clarified their neurologic status and the effect of treatment . 1
Title Dexamethasone 
===Dose===  DART Trial Protocol: 0.075 mg/kg/dose every 12 hours for 3 days, 0.05 mg/kg/dose every 12 hours for 3 days, 0.025 mg/kg/dose every 12 hours for 2 days, and 0.01 mg/kg/dose every 12 hours for 2 days. 1
at 36 weeks . 1
Biologic half-life is 36 to 54 hours. 1
==Adverse Effects== The February 2002 AAP and CPS statement strongly discourages routine use of dexamethasone. 0
Use preservative-free drug wherever possible. 0
Gastrointestinal perforation and GI hemorrhage occur more frequently in patients treated beginning on Day 1 and in those also being treated concurrently with indomethacin. 0
Cardiac effects noted by Day 14 of therapy include increased left ventricular wall thickness with outflow tract obstruction and transient impairment of left ventricular filling, systolic anterior motion of the mitral valve, and ST-segment depression. 0
Echocardiogram if treating longer than 7 days. 1
. 0
Stable for 30 days under refrigeration at dilutions of 0.2 mg/mL and 0.4 mg/mL in NS in PVC minibags . 0
Stable for 22 days at room temperature at dilutions of 0.1 mg/mL and 1 mg/mL in NS in polypropylene syringes . 0
Stable for 28 days under refrigeration and at room temperature at a dilution of 1 mg/mL in bacteriostatic NS in glass vials . 0
Stable for up to 14 days at room temperature at dilutions of 0.08 mg/mL and 0.6 mg/mL in D5W in polyvinyl chloride bags . 0
concentrations. 0
Intensol™ concentrate contains alcohol 30%. 0
Discard opened bottle of Intensol™ after 90 days. 1
Tablets are available in the following strengths: 0.5, 0.75, 1, 1.5, 2, 4, and 6 mg . 0
A 0.5 mg/mL oral suspension can be made by diluting 1 mL of the 4 mg/mL IV solution up to a total volume of 8 mL with a 1:1 mixture of Ora-Sweet® and Ora-Plus®. 0
The oral suspension is physically and chemically stable for up to 91 days with or without refrigeration . 1
Title Dexamethasone 
===Dose===  DART Trial Protocol: 0.075 mg/kg/dose every 12 hours for 3 days, 0.05 mg/kg/dose every 12 hours for 3 days, 0.025 mg/kg/dose every 12 hours for 2 days, and 0.01 mg/kg/dose every 12 hours for 2 days. 1
at 36 weeks . 1
. 0
Title Dextrose 
===Dose===  Hypoglycemia Initial  as D10W . 0
Maintenance 
===Dose=== : Continuous infusion of a 5% to 10% dextrose IV solution with appropriate maintenance electrolytes at an initial glucose infusion rate of 5 to 8 mg/kg/minute. 0
to maintain acceptable blood glucose levels, particularly in patients with persistent hyperinsulinemic hypoglycemia. 0
Hyperkalemia Initial, continuous IV infusion of 0.5 g/kg/hour dextrose and 0.1 to 0.2 units/kg/hour regular insulin. 1
Parenteral Nutrition Recommendations An initial dextrose infusion rate of 6 to 8 mg/kg/minute, advanced as tolerated to a goal rate of 10 to 12 mg/kg/minute, is recommended in neonates. 1
An initial rate of 4 to 8 mg/kg/minute should be considered in preterm neonates. 1
==Administration== Generally, glucose concentrations greater than 15% should be administered via a central vein to minimize risk of phlebitis and thrombosis. 0
, peripheral infusion of a 20% glucose solution did not cause a higher rate or severity of phlebitis compared with peripheral infusion of a 15% glucose solution. 0
are hypertonic and may cause phlebitis and thrombosis at injection site. 0
Intravenous dextrose provides 3.4 kcal/g . 0
==Monitoring== Frequent monitoring of blood glucose is recommended; reasonable goal is blood glucose between 40 and 50 mg/dL. 0
==Special Considerations/Preparation== Available as 50% concentrated solution in 50-mL single-dose vials and syringes, and 25% concentrated solution in single-use 10-mL syringes. 0
Title Dextrose 
===Dose===  Hypoglycemia Initial  as D10W . 0
==Administration== Generally, glucose concentrations greater than 15% should be administered via a central vein to minimize risk of phlebitis and thrombosis. 0
, peripheral infusion of a 20% glucose solution did not cause a higher rate or severity of phlebitis compared with peripheral infusion of a 15% glucose solution. 0
Title Diazoxide 
===Dose===  2 to 5 mg/kg/dose orally given every 8 hours. 1
Positive responses are usually seen within 48 to 72 hours, and occur in less than 50% of neonates. 0
The serum half-life is 10 to 24 hours in infants. 1
Protein binding is more than 90% in adults, and it is primarily excreted unchanged by the kidneys. 0
==Special Considerations/Preparation== Proglycem® is available as an oral suspension, 50 mg/mL concentration. 0
Alcohol content is 7.25%. 0
Title Diazoxide 
===Dose===  2 to 5 mg/kg/dose orally given every 8 hours. 1
Title Didanosine 
===Dose===  HIV Infection 14 days or older: The manufacturer recommends 100 mg/m2 orally twice daily ; however, guidelines for the treatment of HIV-infected children recommend that a dose of 50 mg/m2 twice daily may be more appropriate for neonates . 0
; however, to improve adherence, may be given with a feeding . 0
==Uses== Treatment of HIV-1 infection, in combination with other antiretroviral agents. 0
If an infant is definitively diagnosed with HIV infection while receiving prophylactic treatment for prevention of mother-to-child transmission of HIV, prophylactic antiretrovirals should be discontinued immediately and treatment initiated with a 3-drug combination regimen. 0
. 0
Pediatric FDA Approved Indications Treatment of HIV-1 infection, in combination with other antiretroviral agents, in children 2 weeks or older . 0
==Pharmacology== Didanosine is a nucleoside reverse transcriptase inhibitor active against HIV type 1. 1
The AUC is equivalent for buffered or enteric-coated formulations. 0
Mean bioavailability is approximately 25% in children. 0
Cmax occurs from 0.25 to 1.5 hours following oral administration of the pediatric powder for solution. 0
Protein binding is less than 5%. 0
. 0
showed that body weight is the primary factor associated with oral clearance. 0
is 0.8 hours . 1
/day . 0
and CD4 cell counts, as well as CBC with differential, serum chemistries, and liver and renal function tests at baseline, at 4 to 8 weeks after initiating or changing therapy, and at least every 3 to 4 months thereafter. 1
Screen for clinical adverse effects and assess regimen adherence within 1 to 2 weeks of initiating therapy, at 4 to 8 weeks after initiating or changing therapy, and at least every 3 to 4 months thereafter. 1
Lipid panel and urinalysis are recommended at baseline and every 6 to 12 months during therapy . 1
==Special Considerations/Preparation== Available in pediatric powder for oral solution in 4- and 8-ounce glass bottles containing 2 g and 4 g of didanosine, respectively. 0
Reconstitute each 2-g or 4-g bottle with 100 mL or 200 mL of purified water, USP, respectively, for an initial concentration of 20 mg/mL. 0
This solution should be immediately mixed with one part Maximum Strength Mylanta® Liquid, resulting in a final concentration of didanosine 10 mg/mL. 0
for up to 30 days, and discard any unused portion after this time . 1
Title Didanosine 
===Dose===  HIV Infection 14 days or older: The manufacturer recommends 100 mg/m2 orally twice daily ; however, guidelines for the treatment of HIV-infected children recommend that a dose of 50 mg/m2 twice daily may be more appropriate for neonates . 0
==Pharmacology== Didanosine is a nucleoside reverse transcriptase inhibitor active against HIV type 1. 1
The AUC is equivalent for buffered or enteric-coated formulations. 0
Reconstitute each 2-g or 4-g bottle with 100 mL or 200 mL of purified water, USP, respectively, for an initial concentration of 20 mg/mL. 0
Give over 24 hours as 3 divided doses. 1
Oral doses should be 25% greater than IV doses. 1
==Administration== Intravenous: Administer IV slow push over 5 to 10 minutes. 1
May be given undiluted or diluted at least 4-fold in compatible diluents or precipitation may occur. 0
For small dose volumes, a 1:10 dilution of the 100 mcg/mL concentration to provide a final concentration of 10 mcg/mL may be required. 0
May induce ventricular arrhythmias in patients undergoing electrical cardioversion; consider reducing dose or discontinuing use 1 to 2 days prior to procedure. 0
Serum concentration peaks 30 to 90 minutes after an oral dose, with myocardial peak occurring in 4 to 6 hours. 1
20% protein bound. 0
Treatment of Life-Threatening Digoxin Toxicity: Digibind® Digoxin Immune Fab, IV over 30 minutes through 0.22-micron filter. 1
. 0
Therapeutic serum concentration is 1 to 2 nanograms/mL. 0
. 0
Draw up digoxin into syringe. 0
Inject desired amount of drug into second syringe containing a 4-fold or greater volume of solution-compatible diluent. 0
: D5W, D10W, NS, and sterile water for injection. 0
Total Loading 
===Dose=== Administration Intravenous: Administer IV slow push over 5 to 10 minutes. 1
Treatment of Life-Threatening Digoxin Toxicity: Digibind® Digoxin Immune Fab, IV over 30 minutes through 0.22-micron filter. 1
Inject desired amount of drug into second syringe containing a 4-fold or greater volume of solution-compatible diluent. 0
will bind approximately 0.5 mg of digoxin or digitoxin . 0
Acute Ingestion of Known Amount . 0
IV initially . 0
/100 . 0
. 0
may be given undiluted via a tuberculin syringe or the reconstituted solution may be further diluted with 36 mL of NS to achieve a 1 mg/mL concentration. 0
Administer by slow IV infusion over 30 minutes; if cardiac arrest is imminent, the solution can be given by bolus injection . 1
or more, or amounts leading to serum concentrations of 10 ng/mL or greater; chronic ingestions leading to levels greater than 4 ng/mL; and in the presence of severe ventricular arrhythmias, bradycardia, second/third degree heart block that is unresponsive to atropine, or potassium levels greater than 6 mEq/L with rapidly progressive signs of toxicity . 0
ECG abnormalities and hyperkalemia typically resolve within 4 hours after digoxin immune Fab administration . 1
The elimination half-life in patients with normal renal function is approximately 15 hours. 1
In patients with renal impairment, the half-life may be increased by up to 10-fold . 0
. 0
==Special Considerations/Preparation== Available as a vial containing 40 mg of digoxin immune Fab protein. 0
Reconstitute the vial with 4 mL of Sterile Water for Injection and mix gently; the final concentration will be approximately 10 mg/mL. 0
May dilute the reconstituted solution with NS to a concentration of 1 mg/mL for small doses or to an appropriate volume of NS for administration. 0
Use reconstituted product immediately; if not used immediately, refrigerate and use within 4 hours . 0
will bind approximately 0.5 mg of digoxin or digitoxin . 0
may be given undiluted via a tuberculin syringe or the reconstituted solution may be further diluted with 36 mL of NS to achieve a 1 mg/mL concentration. 0
Title Dornase alfa 
===Dose===  1.25 mL to 2.5 mL via nebulizer, or 0.2 mL/kg instilled directly into the endotracheal tube. 0
Clinical improvements in the thickness of secretions and ventilation usually occur within 3 hours of administration. 0
with no preservative. 0
and protected from strong light. 0
Title Dornase alfa 
===Dose===  1.25 mL to 2.5 mL via nebulizer, or 0.2 mL/kg instilled directly into the endotracheal tube. 0
Title EMLAÂ® 
===Dose===  Apply 1 to 2 g to distal half of the penis, then wrap with occlusive dressing. 1
Allow dressing to remain intact for 60 to 90 minutes, remove and clean treated area completely prior to circumcision to avoid systemic absorption. 0
==Pharmacology== EMLA cream, containing 2.5% lidocaine and 2.5% prilocaine, attenuates the pain response to circumcision when applied 60 to 90 minutes before the procedure. 0
Neonates are deficient in methemoglobin NADH cytochrome b5 reductase. 0
When measured, blood levels of methemoglobin in neonates after the application of 1 g of EMLA cream have been well below toxic levels. 0
Two cases of methemoglobinemia in infants occurred after greater than 3 g of EMLA cream was applied; in 1 of these cases, the infant also was receiving sulfamethoxazole. 0
==Special Considerations/Preparation== Available in 5-g and 30-g tubes with Tegaderm dressing. 0
Each gram of EMLA contains lidocaine 25 mg and prilocaine 25 mg in a eutectic mixture. 0
pH of the product is 9. 0
Contains no preservatives. 0
Title EMLAÂ® 
===Dose===  Apply 1 to 2 g to distal half of the penis, then wrap with occlusive dressing. 1
. 0
Follow IV administration with 0.5 to 1 mL flush of normal saline . 0
IV continuous infusion: Start at 0.1 mcg/kg per minute and adjust to desired response, to a maximum of 1 mcg/kg per minute. 1
. 0
==Administration== Intravenous: When giving IV push, follow administration with 0.5 to 1 mL flush of normal saline. 0
concentration to prepare continuous infusion solution. 0
For continuous infusion, dilute in compatible diluent to a concentration of 10 to 60 mcg/mL. 0
:Mix 50 mL of 20 mcg/mL solution using epinephrine concentration of 1 mg/mL. 0
to yield 50 mL of infusion solution with a concentration of 20 mcg/mL. 0
Maximum concentration 60 mcg/mL. 0
Nonetheless, it is reasonable to continue to use epinephrine when adequate ventilation and chest compressions have failed to increase the heart rate to greater than 60 beats per minute . 1
Suggested treatment: Inject a 1 mg/mL solution of phentolamine into the affected area. 0
concentration. 0
concentration to prepare continuous infusion solution. 0
Amikacin, amiodarone, caffeine citrate, calcium chloride, calcium gluconate, ceftazidime, cimetidine, dobutamine, dopamine, famotidine, fentanyl, furosemide, heparin, hydrocortisone succinate, ibuprofen lysine, lorazepam, midazolam, milrinone, morphine, nicardipine, nitroglycerin, nitroprusside, pancuronium bromide, potassium chloride, propofol, ranitidine, remifentanil, vecuronium, and vitamin K1. 0
==Terminal Injection Site Incompatibility== Aminophylline, ampicillin, hyaluronidase, micafungin, and sodium bicarbonate. 0
. 0
For continuous infusion, dilute in compatible diluent to a concentration of 10 to 60 mcg/mL. 0
to yield 50 mL of infusion solution with a concentration of 20 mcg/mL. 0
concentration to prepare continuous infusion solution. 0
Amikacin, amiodarone, caffeine citrate, calcium chloride, calcium gluconate, ceftazidime, cimetidine, dobutamine, dopamine, famotidine, fentanyl, furosemide, heparin, hydrocortisone succinate, ibuprofen lysine, lorazepam, midazolam, milrinone, morphine, nicardipine, nitroglycerin, nitroprusside, pancuronium bromide, potassium chloride, propofol, ranitidine, remifentanil, vecuronium, and vitamin K1. 0
==Terminal Injection Site Incompatibility== Aminophylline, ampicillin, hyaluronidase, micafungin, and sodium bicarbonate. 0
Title Emtricitabine 
===Dose===  HIV Infection 3 mg/kg orally once daily . 0
every 24 hours. 1
every 24 hours. 1
every 24 hours; give dose after hemodialysis on hemodialysis days. 1
==Uses== Treatment of HIV-1 infection, in combination with other antiretroviral agents: If an infant is definitively diagnosed with HIV infection while receiving prophylactic treatment for prevention of mother-to-child transmission of HIV, prophylactic antiretrovirals should be discontinued immediately and treatment initiated with a 3-drug combination regimen. 0
. 0
Pediatric FDA Approved Indications Treatment of HIV-1 infection, in combination with other antiretroviral agents, in children starting at birth . 0
==Pharmacology== Emtricitabine a synthetic nucleoside analog with activity against HIV-1 reverse transcriptase and HBV DNA polymerase, and is consistently 4 to 10 times more potent than lamivudine, the other NRTI with similar activity. 0
Mean absolute bioavailability of emtricitabine is 93% and 75% for the capsules and the oral solution, respectively, and the relative bioavailability of the oral solution is approximately 80% of the capsules . 0
during the first 3 months of life, emtricitabine exposure was similar to the exposures achieved in patients 3 months to 17 years of age with a 6 mg/kg-dose and adults with a 200-mg dose. 1
Emtricitabine AUC decreased with increasing age over the first 3 months of life, correlating with an increase in total body clearance of the drug . 1
Rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose. 1
Protein binding is less than 4%. 0
Following emtricitabine administration, approximately 86% and 14% of the dose was recovered in the urine and feces, respectively. 0
Half-life is approximately 12 hours in neonates . 1
, no safety issues were noted . 0
of patients. 0
. 0
. 0
. 0
==Monitoring== KEY: AST = aspartate aminotransferase; ALT = alanine aminotransferase; BUN = blood urea nitrogen CBC = complete blood count * Baseline may not be necessary if pre-therapy monitoring was performed within 30 to 45 days. 1
. 0
# For nevirapine, obtain serum transaminase concentrations every 2 weeks for the first 4 weeks of therapy, then monthly for 3 months, and every 3 to 4 months thereafter. 1
# # May be too early to detect immunological response in the CD4 count/percentage Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, 2012; AIDSinfo ==Special Considerations/Preparation== Available in an oral solution with a concentration of 10 mg/mL. 0
. 0
If stored at room temperature, the oral solution is stable for up to 90 days, and any unused portion must be discarded after this time . 1
Mean absolute bioavailability of emtricitabine is 93% and 75% for the capsules and the oral solution, respectively, and the relative bioavailability of the oral solution is approximately 80% of the capsules . 0
of patients. 0
==Monitoring== KEY: AST = aspartate aminotransferase; ALT = alanine aminotransferase; BUN = blood urea nitrogen CBC = complete blood count * Baseline may not be necessary if pre-therapy monitoring was performed within 30 to 45 days. 1
Title Enalapril maleate  given orally every 24 hours. 1
, as frequently as every 6 hours. 1
Bioavailability of oral dosage form is uncertain in neonates, but is significantly less than the 60% reported in adults. 0
Onset of action after oral dose is 1 to 2 hours. 1
Duration of action is quite variable in neonates, ranging from 8 to 24 hours. 1
==Special Considerations/Preparation== Supplied in 2.5-mg, 5-mg, 10-mg, and 20-mg tablets. 0
. 0
Mixture should be placed in a bottle and shaken for at least 2 minutes, left to stand for 60 minutes, and then shaken for an additional minute. 1
Add 150 mL of Ora-Sweet SF®, yielding a final concentration of 1 mg/mL. 0
Suspension is stable for 30 days refrigerated. 1
Title Enalapril maleate  given orally every 24 hours. 1
1.62 Enalaprilat 
Title Enalaprilat  IV over 5 minutes every 24 hours. 1
==Special Considerations/Preparation== Enalaprilat is supplied as a 1.25-mg/mL solution for injection in 1-mL and 2-mL vials. 0
Benzyl alcohol content is 9 mg/mL. 0
. 0
Dilution stable for 24 hours. 1
==Solution Compatibility== D5W, D5NS, NS, and D5LR. 0
Title Enalaprilat  IV over 5 minutes every 24 hours. 1
Title Enoxaparin 
===Dose===  Treatment of Thrombosis: Term infants: initial, 1.7 mg/kg per dose subQ every 12 hours. 1
Preterm infants: initial, 2 mg/kg per dose subQ every 12 hours. 1
Adjust dosage to maintain anti-factor Xa level between 0.5 and 1.0 unit/mL. 0
Dosage requirements to maintain target anti-factor Xa levels in preterm infants are quite variable, ranging from 0.8 to 3 mg/kg every 12 hours. 1
Infants 2 months of age and older: initial, 1 mg/kg per dose subQ every 12 hours. 1
Adjust dosage to maintain anti-factor Xa level between 0.5 and 1 unit/mL. 0
A suggested dosage adjustment is 0.125 mg/kg/dose until therapeutic anti-Xa level is achieved. 0
achieved more rapid therapeutic anti- factor Xa levels resulting in fewer venipunctures, without an increase in adverse events, compared with standard doses. 0
The authors concluded a higher starting dose of 1.8 mg/kg every 12 hours for infants less than 3 months of age and 1.5 mg/kg every 12 hours for children 3 to 12 months of age may be considered . 1
found that only 41% of patients attained therapeutic anti- Xa levels with initial dosing consistent with current standard treatment guidelines. 0
: less than one month of age, 1.8 mg/kg; one month to 1 year, 1.64 mg/kg . 0
also revealed that less than half of the population achieved therapeutic anti-Xa levels following the initial dose with the current standard treatment guidelines. 1
: less than 2 months of age, 1.6 mg/kg; 2 months to 1 year, 1.5 mg/kg . 1
was associated with therapeutic anti-Xa levels and no reported dose measurement errors. 0
. 0
had a supra-therapeutic initial anti-Xa level without hemorrhagic consequences. 0
Low-risk prophylaxis: 0.75 mg/kg per dose subQ every 12 hours. 1
Infants 2 months of age and older: 0.5 mg/kg per dose subQ every 12 hours. 1
Adjust dosage to maintain anti-factor Xa level between 0.1 and 0.4 units/mL. 0
Less frequent bleeding complications. 0
Call 1-800-NOCLOTS for case reporting and treatment guidance. 0
The overall incidence is approximately 4%. 1
Bioavailability is almost 100% after subcutaneous administration, with peak activity 2.5 to 4 hours later. 1
The apparent half-life of anti-Xaactivity is 4 to 5 hours. 1
. 0
If measured 2 to 6 hours after a dose, target therapeutic range is 0.5 to 0.8 units/mL. 0
Obtain anti-factor Xa levels initially, weekly during hospitalization, and then every 3 to 4 weeks in stable patients. 1
==Special Considerations/Preparation== Available as 100-mg/mL concentration as 30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/mL in preservative-free prefilled syringes. 0
Multidose vial available in 100-mg/mL concentration with 15 mg benzyl alcohol per 1 mL as a preservative. 0
transferred to tuberculin syringes and stored under refrigeration retained anti-Xa activity for 10 days. 0
was stable for 4 weeks in glass vials stored at room temperature. 0
for 2 weeks stored at room temperature or under refrigeration. 1
for 31 days. 1
was diluted with sterile water and stored under the same conditions. 0
Stability of enoxaparin in commercially available 5% glucose solution was not tested in this study; however, the authors suggest that an increase in glucose concentration would not affect the stability of the dilution . 0
. 0
At least 90% of the baseline anti-Xa activity was retained under these conditions . 0
in polyvinyl chloride containers was stable for up to 48 hours at room temperature; greater than 94% of the baseline anti-Xa activity was retained during the time period . 1
==Solution Compatibility== NS, D5W, and sterile water. 0
Title Enoxaparin 
===Dose===  Treatment of Thrombosis: Term infants: initial, 1.7 mg/kg per dose subQ every 12 hours. 1
The authors concluded a higher starting dose of 1.8 mg/kg every 12 hours for infants less than 3 months of age and 1.5 mg/kg every 12 hours for children 3 to 12 months of age may be considered . 1
Bioavailability is almost 100% after subcutaneous administration, with peak activity 2.5 to 4 hours later. 1
transferred to tuberculin syringes and stored under refrigeration retained anti-Xa activity for 10 days. 0
in polyvinyl chloride containers was stable for up to 48 hours at room temperature; greater than 94% of the baseline anti-Xa activity was retained during the time period . 1
Title Epoetin alfa 
===Dose===  200 to 400 units/kg/dose, 3 to 5 times per week, for 2 to 6 weeks. 1
Total dose per week is 600 to 1400 units per kg. 1
Short course: 300 units/kg/dose daily for 10 days. 1
. 0
Those most likely to benefit are infants with birth weights less than 800 g and phlebotomy losses greater than 30 mL/kg. 1
. 0
==Pharmacology== Epoetin alfa is a 165-amino acid glycoprotein manufactured by recombinant DNA technology that has the same biological effects as endogenous erythropoietin. 0
Noticeable effects on hematocrit and reticulocyte counts occur within 2 weeks. 1
Subcutaneously administered drug appears to be pharmacodynamically as effective as IV, despite only 40% bioavailability. 0
Half-life of r-HuEPO in preterm infants is approximately 12 hours. 1
, but no differences were observed in the randomized trial by Maier et al. 0
==Special Considerations/Preparation== Available in preservative-free, single-use, 1-mL vials containing 2000, 3000, 4000, 10,000, or 40,000 units formulated in an isotonic, sodium chloride/sodium citrate buffered solution with 2.5 mg human albumin. 0
Undiluted epoetin is stable in plastic syringes for 2 weeks. 1
For IV infusion, dilute epoetin in 2 mL of solutions containing at least 0.05% protein and infuse over 4 hours. 1
These dilutions are stable for 24 hours. 1
benzyl alcohol solution with 2.5-mg albumin per mL. 0
Discard multidose vials 21 days after initial entry. 1
Title Epoetin alfa 
===Dose===  200 to 400 units/kg/dose, 3 to 5 times per week, for 2 to 6 weeks. 1
==Special Considerations/Preparation== Available in preservative-free, single-use, 1-mL vials containing 2000, 3000, 4000, 10,000, or 40,000 units formulated in an isotonic, sodium chloride/sodium citrate buffered solution with 2.5 mg human albumin. 0
Title Erythromycin 
===Dose===  ==Oral== Treatment of pneumonitis and conjunctivitis due to Chlamydia trachomatis: 12.5 mg/kg per dose orally every 6 hours for 14 days. 1
Treatment and prophylaxis of pertussis: 12.5 mg/kg per dose orally every 6 hours for 14 days. 1
The drug of choice in infants younger than 1 month of age is azithromycin. 1
Treatment of feeding intolerance due to dysmotility: 10 mg/kg per dose orally every 6 hours for 2 days, followed by 4 mg/kg per dose orally every 6 hours for 5 days. 1
Other infections and prophylaxis: 10 mg/kg per dose orally every 6 hours. 1
==Intravenous== Severe infections when oral route unavailable: 5 to 10 mg/kg per dose IV infusion by syringe pump over at least 60 minutes every 6 hours. 1
Ophthalmic Prophylaxis of ophthalmia neonatorum: Ribbon of 0.5% ointment instilled in each conjunctival sac. 0
==Administration== Intravenous: Give as intermittent infusion over at least 60 minutes at a concentration of 1 to 5 mg/mL. 1
Infantile hypertropic pyloric stenosis occurred in 5% of infants receiving erythromycin for pertussis prophylaxis. 0
lactobionate to preterm infants, using doses of 6.25 to 10 mg/kg, yielded peak serum concentrations of 1.9 to 3.7 mcg/mL and a half-life of 2 hours. 1
Plasma clearance of midazolam is reduced by 50%. 0
. 0
==Special Considerations/Preparation== Erythromycin ethylsuccinate oral suspension is available in concentrations of 200 mg- and 400 mg per 5 mL. 0
up to a final volume of 10 mL with sterile water. 0
Erythromycin ethylsuccinate suspension made from powder for suspension, at usual concentrations of 40 mg/mL and 80 mg/mL, is stable for 35 days at room temperature. 0
Available as powder for injection in 500-mg and 1-g vials. 0
Reconstitute 500-mg vial with 10 mL of sterile water for injection to concentration of 50 mg/mL. 0
Reconstituted solution stable for 24 hours at room temperature or 2 weeks in refrigerator. 1
After reconstitution, dilute to a concentration of 1 to 5 mg/mL for infusion. 0
To make a 5- mg/mL dilution, add 1 mL of reconstituted solution to 9 mL sterile water for injection. 0
Use diluted drug within 8 hours . 1
Erythromycin ophthalmic is available as a 0.5% ointment. 0
In the event of a shortage, the CDC recommends azithromycin ophthalmic solution 1%. 0
. 0
Title Erythromycin 
===Dose===  ==Oral== Treatment of pneumonitis and conjunctivitis due to Chlamydia trachomatis: 12.5 mg/kg per dose orally every 6 hours for 14 days. 1
Ophthalmic Prophylaxis of ophthalmia neonatorum: Ribbon of 0.5% ointment instilled in each conjunctival sac. 0
. 0
To make a 5- mg/mL dilution, add 1 mL of reconstituted solution to 9 mL sterile water for injection. 0
Title Esmolol : 100 mcg/kg per minute continuous infusion. 1
Increase in increments of 50 to 100 mcg/kg per minute every 5 minutes until control of the ventricular rate is achieved. 1
Acute management of postoperative hypertension: 50 mcg/kg per minute continuous infusion. 0
Increase in increments of 25 to 50 mcg/kg per minute every 5 minutes until desired blood pressure is achieved. 1
Usual maximum dosage: 200 mcg/kg per minute. 0
===Dose===  greater than 300 mcg/kg per minute are likely to cause hypotension. 1
duration of action. 1
. 0
vials, and 2500 mg/250 mL and 2000 mg/100 mL ready-to-use premixed bags. 0
The pH is approximately 4.5 to 5.5. 0
Osmolarity is 312 mOsm/L. 1
Stable for at least 24 hours at room temperature or refrigeration when diluted in compatible solutions to a concentration of 10 mg/mL. 1
==Solution Compatibility== D5W, LR, D5LR, NS, ½ NS, D5 ½ NS, and D5NS. 0
==Terminal Injection Site Incompatibility== Amphotericin B, diazepam, furosemide, procainamide, and sodium bicarbonate 5% injection. 0
Title Esmolol : 100 mcg/kg per minute continuous infusion. 1
==Solution Compatibility== D5W, LR, D5LR, NS, ½ NS, D5 ½ NS, and D5NS. 0
Title Famotidine 
===Dose===  IV: 0.25 to 0.5 mg/kg/dose IV slow push every 24 hours. 1
Oral: 0.5 to 1 mg/kg/dose orally every 24 hours. 1
==Administration== IV push: Dilute to concentration of 2 to 4 mg/mL with 0.9% NS; give over a period of at least 2 minutes. 0
Oral: Shake oral suspension vigorously for 5 to 10 seconds prior to each use. 0
by 3 months of age. 1
Oral bioavailability is 42 to 50%. 0
==Adverse Effects== The use of H2 blockers in preterm infants has been associated with an increased risk for late-onset bacterial and fungal sepsis. 0
adverse effects noted in adults were headache, dizziness, constipation, and diarrhea. 0
. 0
benzyl alcohol as a preservative. 0
A 1-mg/mL dilution may be made by adding 1 mL of the 10 mg/mL concentrated solution to 9 mL of sterile water for injection. 0
Dilution stable for 7 days at room temperature. 1
Although diluted Pepcid® Injection has been shown to be physically and chemically stable for 7 days at room temperature, there are no data on the maintenance of sterility after dilution. 1
Therefore, it is recommended that if not used immediately after preparation, diluted solutions of Pepcid® Injection should be refrigerated and used within 48 hours. 1
Pepcid® for oral suspension is supplied as a powder containing 400 mg famotidine. 0
Constitute by slowly adding 46 mL Purified Water and shaking vigorously for 5-10 seconds. 0
. 0
Stable at room temperature for 30 days. 1
==Solution Compatibility== D5W, D10W, NS, and Dex/AA solutions. 0
Terminal Injection Site Compatibility Acyclovir, aminophylline, amiodarone, ampicillin, atropine, aztreonam, calcium gluconate, caspofungin, cefazolin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, dexamethasone, digoxin, dobutamine, dopamine, enalaprilat, epinephrine, erythromycin lactobionate, esmolol, fluconazole, flumazenil, furosemide, gentamicin, heparin, hydrocortisone succinate, imipenem/cilastatin, insulin, isoproterenol, lidocaine, linezolid, lorazepam, magnesium sulfate, metoclopramide, mezlocillin, midazolam, morphine, nafcillin, nicardipine, nitroglycerin, oxacillin, phenytoin, piperacillin, potassium chloride, procainamide, propofol, remifentanil, sodium bicarbonate, sodium nitroprusside, ticarcillin/clavulanate, vancomycin, and vitamin K1. 0
==Terminal Injection Site Incompatibility== Azithromycin, cefepime and piperacillin/tazobactam. 0
Title Famotidine 
===Dose===  IV: 0.25 to 0.5 mg/kg/dose IV slow push every 24 hours. 1
==Pharmacology== Inhibits gastric acid secretion by histamine H2-receptor antagonism. 0
Terminal Injection Site Compatibility Acyclovir, aminophylline, amiodarone, ampicillin, atropine, aztreonam, calcium gluconate, caspofungin, cefazolin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, dexamethasone, digoxin, dobutamine, dopamine, enalaprilat, epinephrine, erythromycin lactobionate, esmolol, fluconazole, flumazenil, furosemide, gentamicin, heparin, hydrocortisone succinate, imipenem/cilastatin, insulin, isoproterenol, lidocaine, linezolid, lorazepam, magnesium sulfate, metoclopramide, mezlocillin, midazolam, morphine, nafcillin, nicardipine, nitroglycerin, oxacillin, phenytoin, piperacillin, potassium chloride, procainamide, propofol, remifentanil, sodium bicarbonate, sodium nitroprusside, ticarcillin/clavulanate, vancomycin, and vitamin K1. 0
==Terminal Injection Site Incompatibility== Azithromycin, cefepime and piperacillin/tazobactam. 0
Title Fat Emulsion 
===Dose===  Begin at 0.5 g/kg per day IV increasing by 0.5 g/kg per day to a maximum of 3 g/kg per day. 1
Infusion rate should not exceed 0.15 g/kg per hour. 1
24 hour infusion times are preferred. 1
Essential fatty acid deficiency may be prevented with 0.5 to 1 g/kg per day. 0
Infusion rates should not exceed 1 g/kg in four hours. 1
isotonic emulsions of either soybean or safflower oil. 0
Fat particle size is between 0.4 and 0.5 microns in diameter, similar to endogenous chylomicrons. 0
and infected infants. 1
of heparin. 0
adding a multivitamin preparation to the Dex/AA solution. 0
==Monitoring== Monitor serum triglyceridesSpecial Considerations/Preparation Liposyn® and Intralipid® are available in 10% and 20% concentrations in 50-, 100-, 250-, and 500-mL bottles. 0
Use within 24 hours when dispensed in syringes. 1
Dobutamine and dopamine are most stable in solutions with a pH at or below 5. 0
In alkaline solutions, the catechol moieties are oxidized, cyclized, and polymerized to colored materials. 0
All fat emulsions have pH ranges from 6 to 9. 0
Caution is urged when co-infusing dobutamine or dopamine and fat emulsion together; dobutamine or dopamine may degrade over time in this alkaline pH resulting in lower than expected clinical effects. 0
, isoproterenol, lidocaine, meropenem, netilmicin, norepinephrine, oxacillin, penicillin G, piperacillin/tazobactam, potassium chloride, sulfamethoxazole/trimethoprim, ticarcillin, and tobramycin. 0
Title Fat Emulsion 
===Dose===  Begin at 0.5 g/kg per day IV increasing by 0.5 g/kg per day to a maximum of 3 g/kg per day. 1
isotonic emulsions of either soybean or safflower oil. 0
==Monitoring== Monitor serum triglyceridesSpecial Considerations/Preparation Liposyn® and Intralipid® are available in 10% and 20% concentrations in 50-, 100-, 250-, and 500-mL bottles. 0
Title FentaNYL 
===Dose===  Sedation and Analgesia: 0.5 to 4 mcg/kg per dose IV slow push. 1
. 0
Infusion rate: 1 to 5 mcg/kg per hour. 1
Anesthesia: 5 to 50 mcg/kg per dose. 0
==Pharmacology== Synthetic opioid narcotic analgesic that is 50 to 100 times more potent than morphine on a weight basis. 0
Metabolized extensively in the liver by CYP 3A4 enzyme system and then excreted by the kidney. 0
. 0
are used and may also occur unexpectedly because of redistribution. 0
Chest wall rigidity has occurred in 4% of neonates who received 2.2 to 6.5 mcg/kg per dose, occasionally associated with laryngospasm. 1
Significant withdrawal symptoms have been reported in patients treated with continuous infusion for 5 days or longer. 0
Available in 2-, 5-, 10-, and 20-mL ampules in a concentration of 50 mcg/mL. 0
A 10- mcg/mL dilution may be made by adding 1 mL of the 50-mcg/mL concentration to 4 mL preservative-free normal saline. 0
Stable for 24 hours refrigerated. 1
Title FentaNYL 
===Dose===  Sedation and Analgesia: 0.5 to 4 mcg/kg per dose IV slow push. 1
are used and may also occur unexpectedly because of redistribution. 0
Title Ferrous sulfate 
===Dose===  2 mg/kg/day of elemental iron for growing premature infants. 1
. 0
Begin therapy after 2 weeks of age. 1
Infants with birthweights less than 1000 grams may need 4 mg/kg/day. 0
6 mg/kg/day of elemental iron for patients receiving erythropoietin. 0
Administer orally in 1 or 2 divided doses, preferably diluted in formula. 0
. 0
. 0
Title Ferrous sulfate 
===Dose===  2 mg/kg/day of elemental iron for growing premature infants. 1
Title Flecainide 
===Dose===  Begin at 2 mg/kg per dose every 12 hours orally. 1
Adjust dose based on response and serum concentrations to a maximum of 4 mg/kg per dose every 12 hours. 1
Optimal effect may take 2 to 3 days of therapy to achieve, and steady-state plasma levels may not be reached until 3 to 5 days at a given dosage in patients with normal renal and hepatic function. 0
Therefore, do not increase dosage more frequently than approximately once every 4 days. 1
Peak serum concentrations occur 2 to 3 hours after an oral dose. 1
Plasma protein binding is about 40% in adults and is independent of plasma drug level. 0
Children under 1 year of age have elimination half- life values of 11 to 12 hours. 1
Elimination half-life in newborns after maternal administration is as long as 29 hours. 1
Follow trough serum concentrations closely at initiation, 3 to 5 days after any dose change, and with any significant change in clinical status or diet. 1
Therapeutic trough levels are 200 to 800 nanograms/mL. 0
==Special Considerations/Preparation== Supplied in 50-mg, 100-mg, and 150-mg tablets. 0
to form a uniform paste, then add to this mixture enough vehicle to make a final volume of 120 mL. 0
Stable for 45 days refrigerated and at room temperature when stored in amber glass or plastic . 0
An oral suspension with a final concentration of 20 mg/mL may also be compounded. 0
and placed in a 120-mL amber polyethylene terephthalate bottle is stable, retaining a mean of at least 92% of the initial drug concentration, for up to 60 days when stored without light at 5 and 25 degrees C . 0
Title Flecainide 
===Dose===  Begin at 2 mg/kg per dose every 12 hours orally. 1
Title Fluconazole 
===Dose===  Invasive Candidiasis: 12 to 25 mg/kg loading dose, then 6 to 12 mg/kg per dose IV, or orally. 1
. 0
. 0
Inhibits cytochrome P-450-dependent ergosterol synthesis. 0
Well absorbed after oral administration, with peak serum concentrations reached within 1 to 2 hours. 1
Less than 12% protein binding. 0
Serum half-life is 30 to 180 hours in severely ill VLBW infants in the first 2 weeks of life and approximately 17 hours in children. 1
Reversible elevations of transaminases have occurred in 12% of children. 0
A retrospective study using historical controls reports direct hyperbilirubinemia in the absence of elevated transaminases in some infants treated prophylactically for 6 weeks. 0
. 0
Oral dosage form is available as a powder for suspension in concentrations of 10 mg/mL and 40 mg/mL. 0
Prepare both concentrations by adding 24 mL distilled water to bottle of powder and shaking vigorously. 0
Each bottle will deliver 35 mL of suspension. 0
Suspension is stable at room temperature for 2 weeks. 1
==Solution Compatibility== D5W and D10W. 0
Title Fluconazole 
===Dose===  Invasive Candidiasis: 12 to 25 mg/kg loading dose, then 6 to 12 mg/kg per dose IV, or orally. 1
. 0
Title Flucytosine 
===Dose===  12.5 to 37.5 mg/kg per dose every 6 hours orally. 1
90% renal elimination of unchanged drug, proportional to GFR. 1
Serum half-life in adults is 3 to 5 hours if renal function is normal, but 30 to 250 hours if renal impairment is present. 1
==Adverse Effects== Toxicities are related to serum concentration above 100 mcg/mL, and are usually reversible if the drug is stopped or the dose is reduced. 0
==Monitoring== Desired peak serum concentration ranges from 50 to 80 mcg/mL. 0
==Special Considerations/Preparation== Flucytosine is available as 250- and 500-mg capsules. 0
to make a final volume of 100 mL. 0
Suspension is stable for 60 days at room temperature or under refrigeration. 1
to make a final volume of 60 mL. 0
Suspension is stable for at least 90 days when stored at room temperature or under refrigeration. 1
Title Flucytosine 
===Dose===  12.5 to 37.5 mg/kg per dose every 6 hours orally. 1
90% renal elimination of unchanged drug, proportional to GFR. 1
Title Flumazenil 
===Dose===  IV: 5 to 10 mcg/kg/dose IV over 15 seconds. 1
May repeat every 45 seconds until the patient is awake. 0
. 0
Intranasal: 40 mcg/kg/dose divided equally between both nostrils. 0
Rectal:15 to 30 mcg/kg/dose, may repeat if sedation not reversed within 15 to 20 minutes. 0
Elimination half-life in children 20 to 75 minutes. 1
. 0
Resedation has been reported in 10% of treated pediatric patients, occurring 19 to 50 minutes after initial dosing. 0
==Special Considerations/Preparation== Available in an injectable form as a 0.1 mg/mL concentration in 5- and 10-mL multidose vials. 0
If drawn into a syringe or mixed with D5W, LR, or NS, discard solution after 24 hours. 0
Discard opened vials within 24 hours. 1
==Solution Compatibility== D5W, Lactated Ringer's, and NS. 0
Title Flumazenil 
===Dose===  IV: 5 to 10 mcg/kg/dose IV over 15 seconds. 1
. 0
Loading dose: 15 to 20 mg PE/kg IM or IV infusion over at least 10 minutes. 1
Maintenance dose: 4 to 8 mg PE/kg every 24 hours IM or IV slow push. 1
Begin maintenance 24 hours after loading dose. 1
Term infants older than 1 week of age may require up to 8 mg PE/kg per dose every 8 to 12 hours. 1
at a concentration of 1.5 to 25 mg PE/mL. 0
Dilute in 5% dextrose or normal saline. 0
. 0
per minute because of the risk of severe hypotension and cardiac arrhythmias. 0
Each 1.5 mg of fosphenytoin is metabolically converted to 1 mg phenytoin. 0
After IM administration, peak is reached in approximately 20 to 30 minutes. 1
Conversion half-life of fosphenytoin administered intravenously to infants and children is approximately 8 minutes. 1
; only free fraction can cross blood-brain barrier. 0
Potent inducer of cytochrome P450 enzyme systems resulting in a reduction of serum levels of drugs metabolized by this system. 0
due to rapid conversion. 0
. 0
Onset of symptoms is typically within 28 days, but can occur later. 1
allele, HLA-B*1502, found in patients of Asian ancestry may be a risk factor for the development of SJS/TEN in patients taking phenytoin. 0
Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502 . 0
==Monitoring== Monitor electrocardiogram, blood pressure, and respiratory function continuously during infusion and for 10 to 20 minutes after end of infusion . 1
concentration 2 hours after IV dose and 4 hours after IM dose. 1
Therapeutic serum phenytoin concentration is 10 to 20 mg/L for total phenytoin and 1 to 2 mg/L for unbound phenytoin. 0
==Special Considerations/Preparation== Available as an injectable solution in a concentration equivalent to 50 mg PE/mL, in 2- and 10-mL vials. 0
Administer IV after diluting in NS or D5W to a concentration of 1.5 to 25 mg PE/mL. 0
The pH is 8.6 to 9 . 0
Stable for 48 hours at room temperature. 1
Phosphate load: Provides 0.0037 mmol phosphate/mg PE . 0
==Solution Compatibility== D5W, D10W and NS. 0
==Monitoring== Monitor electrocardiogram, blood pressure, and respiratory function continuously during infusion and for 10 to 20 minutes after end of infusion . 1
Title Furosemide 
===Dose===  Initial 
===Dose=== : 1 mg/kg IV slow push, IM, or orally. 0
May increase to a maximum of 2 mg/kg/dose IV or 6 mg/kg/dose orally. 0
Initial Intervals: Premature infant: every 24 hours. 1
Full-term infant: every 12 hours. 1
Full-term infant older than 1 month: every 6 to 8 hours. 1
, furosemide was associated with no or inconsistent effects on lung function in preterm infants less than 3 weeks of age. 1
improvement in lung compliance and airway resistance. 0
Time to peak effect when given IV is 1 to 3 hours; duration of effect is approximately 6 hours, although half-life may be as long as 67 hours in the most immature neonates. 1
This has been reported mainly in premature infants and a cumulative dose of 10 mg/kg or greater was associated with an increased risk . 0
==Special Considerations/Preparation== Furosemide oral solution is available in 8-mg/mL and 10-mg/mL concentrations. 0
Protect from light and discard open bottle after 90 days. 1
Furosemide for injection is available as a 10-mg/mL concentration in 2-, 4-, and 10-mL single use vials. 0
A 2-mg/mL dilution may be made by adding 2 mL of the 10-mg/mL injectable solution to 8-mL preservative-free normal saline for injection. 0
==Solution Compatibility== NS, D5W, D10W, and sterile water for injection. 0
Amikacin, aminophylline, amiodarone, ampicillin, atropine, aztreonam, bumetanide, calcium gluconate, cefepime, ceftazidime, cimetidine, dexamethasone, digoxin, epinephrine, famotidine, fentanyl, heparin, hydrocortisone succinate, ibuprofen lysine, indomethacin, lidocaine, lorazepam, linezolid, meropenem, micafungin, morphine, nitroglycerin, penicillin G, piperacillin/tazobactam, potassium chloride, propofol, prostaglandin E1, ranitidine, remifentanil, sodium bicarbonate, sodium nitroprusside, and tobramycin. 0
Title Furosemide 
===Dose===  Initial 
===Dose=== : 1 mg/kg IV slow push, IM, or orally. 0
Title Ganciclovir 
===Dose===  6 mg/kg/dose IV every 12 hours. 1
Treat for a minimum of 6 weeks if possible. 1
. 0
Chronic Oral Suppression: 30 to 40 mg/kg/dose orally every 8 hours. 1
Intravenous: Infuse over a period of 1 hour in compatible solution at a concentration not to exceed 10 mg/mL. 0
of solution; infuse into veins with adequate blood flow, permitting rapid dilution and distribution. 0
Mean half-life in infants less than 49 days postnatal age is 2.4 hours. 1
==Monitoring== CBC every 2 to 3 days during first 3 weeks of therapy, weekly thereafter if stable. 1
==Special Considerations/Preparation== Cytovene® is supplied as lyophilized powder for injection, 500 mg per vial. 0
Reconstitute by injecting 10 mL of sterile water for injection into the vial. 0
Reconstituted solution in the vial is stable at room temperature for 12 hours. 1
The pH is approximately 11; use caution when handling. 0
Osmolarity is 320 mOsm/kg. 1
from the vial and add to a compatible diluent fluid to make a final infusion concentration less than 10 mg/mL. 0
Although stable for 14 days, the infusion solution must be used within 24 hours of dilution to reduce the risk of bacterial contamination. 1
Available as 250-mg and 500-mg capsules. 0
250-mg capsules into a glass mortar wetted and triturated with Oral-Sweet® to a smooth paste. 0
Add 50-mL of Oral-Sweet® to the paste, mix, and transfer contents to an amber polyethylene terephthalate bottle. 0
Rinse the mortar with another 50 mL of Oral-Sweet® and transfer contents to the bottle. 0
Add enough Oral-Sweet® to make a final volume of 200 mL. 0
Stable for 123 days when stored at 23 to 25 degrees C.
 ==Solution Compatibility== NS, D5W, and LR. 0
Title Ganciclovir 
===Dose===  6 mg/kg/dose IV every 12 hours. 1
Trough: 0.5 to 1 mcg/mL ==Special Considerations/Preparation== Pediatric injectable solution available in a concentration of 10 mg/mL. 0
, insulin, linezolid, lorazepam, magnesium sulfate, meropenem, metronidazole, midazolam, milrinone, morphine, nicardipine, pancuronium bromide, penicillin g, prostaglandin E1, ranitidine, remifentanil, vecuronium, and zidovudine. 0
, indomethacin, mezlocillin, nafcillin, oxacillin, propofol, and ticarcillin/clavulanate. 0
Trough: 0.5 to 1 mcg/mL Suggested Dosing IntervalsSpecial Considerations/Preparation Pediatric injectable solution available in a concentration of 10 mg/mL. 0
Title Glucagon  IV push, IM, or subQ. 0
Maximum dose: 1 mg. 0
Continuous infusion: Begin with 10 to 20 mcg/kg/hour; doses of 0.5 to 1 mg per day regardless of age or weight have been used, given as a continuous infusion. 0
Should not be used at concentrations greater than 1 mg/mL; use 1 mL of diluent provided or Sterile Water for Injection. 0
For continuous infusion, glucagon in 10% dextrose has been used successfully in infants with persistent hypoglycemia. 1
There are no stability data available for glucagon in 10% dextrose. 0
Rise in blood glucose will last approximately 2 hours. 1
==Special Considerations/Preparation== Supplied in 1-mg single-dose vials. 0
Should not be used at concentrations greater than 1 mg/mL. 0
One unit of glucagon and 1 mg of glucagon are equivalent. 0
Title Glucagon  IV push, IM, or subQ. 0
Conjugate Vaccine 
===Dose===  0.5 mL IM in the anterolateral thigh or deltoid x 4 doses. 0
Give at 2, 4, and 6 months of age and a booster dose at 12 to 15 months of age . 1
is given at 2 and 4 months of age, a dose at 6 months is not necessary; the third dose is given at 12 to 15 months of age . 1
Also contraindicated in infants less than 6 weeks of age. 1
==Pharmacology== Three conjugate vaccines are currently approved for use in infants older than 2 months of age. 1
. 0
Reconstitute using only the 0.4% saline diluent provided in single-use 0.6-mL vials and use immediately. 0
Conjugate Vaccine 
===Dose===  0.5 mL IM in the anterolateral thigh or deltoid x 4 doses. 0
Title Heparin 
===Dose===  Maintaining patency of central vascular catheters: 0.5 units/kg/hour . 1
Maintaining patency of peripheral vascular catheters: 0.5 to 1 unit/mL of IV fluid. 0
Treatment of thrombosis: 75 units/kg bolus over 10 minutes, followed by 28 units/kg per hour continuous infusion. 1
. 0
Treatment should be limited to 10 to 14 days. 1
Some experts recommend switching to low molecular weight heparin after 3 to 5 days. 1
For renal vein thrombosis requiring treatment, 6 weeks to 3 months of heparin/low molecular weight heparin therapy is recommended . 1
==Administration== Intravenous: Administer loading doses as IV bolus over 10 minutes. 1
reference standard and test method has resulted in an approximately 10% reduction in heparin potency per USP unit. 0
. 0
has been reported to occur in approximately 1% of newborns exposed to heparin. 0
Renal excretion should occur within 6 hours, but may be delayed. 1
Half-life is dose-dependent, but averages 1 to 3 hours. 1
==Monitoring== Follow platelet counts every 2 to 3 days. 1
. 0
; 5000 units/mL, 10,000 units/mL, and 20,000 units/mL. 0
Also available in premixed infusion bags in D5W, NS, and ½ NS in various concentrations. 0
==Solution Compatibility== D5W, D10W, NS, and ½ NS. 0
Title Heparin 
===Dose===  Maintaining patency of central vascular catheters: 0.5 units/kg/hour . 1
===Dose===  0.5 mL IM in the anterolateral thigh. 0
Term and preterm newborns born to HBsAg-positive mother: Give within 12 hours of birth. 1
Term and preterm newborns born to HBsAg status unknown mother with BW greater than or equal to 2000 g: Give as soon as it is determined that the mother is HBsAg-positive, within 7 days of birth. 1
Preterm newborns born to HBsAg status unknown mother with BW less than 2000 g: If mother's status unavailable, give within 12 hours of birth. 1
Supplied in 1-mL and 5-mL single-dose vials and 0.5-mL and 1-mL unit- dose syringes. 0
Approximate potency of Nabi-HB® and HepaGam® is 312 international units/mL. 0
Use within 6 hours after vial has been entered . 1
===Dose===  0.5 mL IM in the anterolateral thigh. 0
Term and preterm newborns born to HBsAg status unknown mother with BW greater than or equal to 2000 g: Give as soon as it is determined that the mother is HBsAg-positive, within 7 days of birth. 1
IM . 0
Maternal HBsAg-Positive: Administer first dose before 12 hours of age regardless of birth weight. 1
Administer in combination with 0.5 mL of hepatitis B immune globulin. 0
These infants should be tested for HBsAg and HBsAg antibodies 1 to 2 months after receiving the last dose of the hepatitis B vaccine series . 1
Maternal HBsAg Unknown: Administer first dose before 12 hours of age. 1
If birthweight less than 2000 g, administer in combination with hepatitis B immune globulin if mother's HBsAg result is not available within 12 hours of age. 1
If birthweight 2000 g of greater and mother subsequently tests HBsAg positive, administer hepatitis B immune globulin to infant within 7 days of birth . 1
If birthweight less than 2000 g and medically stable, administer first dose at 30 days of chronologic age or at time of hospital discharge if before 30 days of chronologic age . 1
, second dose 1 to 2 months later, and third dose 6 months after first dose. 1
Monovalent or a combination vaccine containing HepB may be used to complete the series; 4 doses may be given if combination vaccine is used. 0
Monovalent HepB vaccine should be used for doses administered before 6 weeks of age . 1
A minimum of 4 weeks should elapse between the first and second doses, and 8 weeks between the second and third doses. 1
should be administered no earlier than 6 months of age and at least 4 months after the first dose . 1
Infants who did not receive a birth dose should be started on a 3-dose series of HepB- containing vaccine as soon as it is feasible . 1
A 22- to 25-gauge needle should be used. 0
The appropriate needle length is 7/8” to 1” for infants . 1
Fever greater than 37.7 degrees C occurs in 1% to 6%. 0
==Monitoring== Testing for immunity 3 months after completion of the vaccination series is recommended for infants born to HBsAg-positive mothers and, perhaps, for premature infants who received an early first dose. 1
==Special Considerations/Preparation== Recombivax HB® for infant use is supplied in 0.5-mL single-dose vials and single-dose prefilled syringes containing 5 mcg. 0
Engerix-B® is supplied in 0.5-mL single-dose vials and 0.5-mL single-dose prefilled disposable syringes containing 10 mcg per 0.5 mL. 0
. 0
A minimum of 4 weeks should elapse between the first and second doses, and 8 weeks between the second and third doses. 1
should be administered no earlier than 6 months of age and at least 4 months after the first dose . 1
Title Hib Conjugate/Hepatitis B Combination Vaccine 
===Dose===  0.5 mL IM in the anterolateral thigh . 0
==Uses== Comvax® is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age born to HBsAg-negative mothers. 1
Comvax® should not be used in infants younger than 6 weeks of age . 1
. 0
. 0
==Special Considerations/Preparation== Supplied in 0.5-mL single-dose vial. 0
Title Hyaluronidase  as 5 separate 0.2-mL subcutaneous injections around the periphery of the extravasation site. 0
Use 25- or 26-gauge needle and change after each injection. 0
Covering with a hydrogel dressing for 48 hours. 1
Amphadase®, Hydase™, and Hylenex® are supplied as 150 USP units/mL in 2 mL glass vials. 0
Title Hyaluronidase  as 5 separate 0.2-mL subcutaneous injections around the periphery of the extravasation site. 0
Title HydrALAZINE 
===Dose===  Parenteral: Begin with 0.1 to 0.5 mg/kg/dose every 6 to 8 hours. 1
===Dose===  may be gradually increased as required for blood pressure control to a maximum of 2 mg/kg/dose every 6 hours. 1
Oral: 0.25 to 1 mg/kg/dose every 6 to 8 hours, or approximately twice the required IV dose. 1
This is expected to reduce hydralazine IV dosage requirements to less than 0.15 mg/kg per dose. 1
Tachycardia, postural hypotension, headache, nausea, and a lupus-like syndrome occur in 10% to 20% of adults. 0
is available in 1-mL vial. 0
A 1-mg/mL dilution may be made by diluting 0.5 mL of the 20-mg/mL concentrate with 9.5 mL of preservative-free normal saline for injection. 0
Dilution is stable for 24 hours. 1
Oral tablet strengths include 10-, 25-, 50-, and 100-mg.
 To prepare an oral suspension, crush a 50 mg tablet and dissolve in 4 mL of 5% mannitol, then add 46 mL of sterile water to make a final concentration of 1 mg/mL. 0
Title HydrALAZINE 
===Dose===  Parenteral: Begin with 0.1 to 0.5 mg/kg/dose every 6 to 8 hours. 1
Title Hydrochlorothiazide 
===Dose===  1 to 2 mg/kg/dose orally every 12 hours. 1
Onset of action is within 1 hour. 1
==Special Considerations/Preparation== Supplied as 12.5-mg capsule and 25-, 50-, and 100-mg tablets. 0
. 0
Crush tablets to a fine powder, add 25 mL of vehicle, and mix to create a uniform paste. 0
Add vehicle to almost volume, transfer to amber bottle and add vehicle to final volume of 120 mL. 0
Label “shake well” and “protect from light”, with expiration date of 60 days. 1
In the stability study, at least 91% of the initial hydrochlorothiazide and spironolactone concentration was retained for up to 60 days when stored without light at 5 and 25 degrees C . 0
Title Hydrochlorothiazide 
===Dose===  1 to 2 mg/kg/dose orally every 12 hours. 1
Title Hydrocortisone 
===Dose===  Physiologic replacement: 7 to 9 mg/m2 per day IV or orally, in 2 or 3 doses. 0
: 20 to 30 mg/m2 per day IV, in 2 or 3 doses, or approximately 1 mg/kg per dose every 8 hours. 1
Body Surface AreaTreatment of chorioamnionitis-exposed ELBW infants to decrease risk of CLD: Initial dose: 0.5 mg/kg/dose IV every 12 hours for 12 days, followed by 0.25 mg/kg IV every 12 hours for 3 days . 1
. 0
For intravenous infusion, may dilute to 1 mg/mL in D5W or NS for infusion . 0
. 0
. 0
. 0
Low-dose hydrocortisone for the first 2 weeks of life should be considered for infants with evidence of fetal inflammation; however, there are insufficient data to support its use in all babies at risk for BPD . 0
are most likely to respond, and blood pressure will increase within 2 hours of the first dose. 1
The apparent half-life in premature infants is 9 hours. 1
==Special Considerations/Preparation== Hydrocortisone sodium succinate is available as powder for injection in 2-mL vials containing 100 mg.
 Reconstitute using preservative-free sterile water for injection to 50 mg/mL. 0
Also available in 2-, 4-, and 8-mL vials with a concentration of 125 mg/mL after reconstitution. 0
Reconstituted solution stable for 3 days refrigerated. 0
For intravenous infusion, may dilute to 1 mg/mL in D5W or NS for infusion. 0
Dilutions stable for at least 4 hours . 1
. 0
Ground hydrocortisone tablets were triturated with polysorbate 80 and the vehicle was added; water was added to 100 mL . 0
Acyclovir, amikacin, aminophylline, amphotericin B, ampicillin, atropine, aztreonam, calcium chloride, calcium gluconate, cefepime, chloramphenicol, clindamycin, dexamethasone, digoxin, dopamine, enalaprilat, epinephrine, erythromycin lactobionate, esmolol, famotidine, fentanyl, furosemide, heparin, hydralazine, insulin, isoproterenol, lidocaine, linezolid, lorazepam, magnesium, metoclopramide, metronidazole, morphine, neostigmine, netilmicin, nicardipine, oxacillin, pancuronium, penicillin G, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, propofol, propranolol, remifentanil, sodium bicarbonate, vecuronium and vitamin K1. 0
==Terminal Injection Site Incompatibility== Midazolam, nafcillin, pentobarbital, phenobarbital, and phenytoin. 0
Title Hydrocortisone 
===Dose===  Physiologic replacement: 7 to 9 mg/m2 per day IV or orally, in 2 or 3 doses. 0
. 0
. 0
==Special Considerations/Preparation== Hydrocortisone sodium succinate is available as powder for injection in 2-mL vials containing 100 mg.. 0
Title INFUVITEÂ® Pediatric 
===Dose===  Intravenous: Infuvite® Pediatric is a sterile product consisting of two vials: a 4 mL vial labeled Vial 1 and a 1 mL vial labeled Vial 2. 0
The daily dose is a function of infant weight as indicated in the following table . 1
to prevent tissue depletion of nutrients . 0
Inactive ingredients: 50 mg polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment and water for injection. 0
** Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E, and K. Inactive ingredients: 75 mg mannitol, citric acid and/or sodium citrate for pH adjustment and water for injection. 0
Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg per day accumulate aluminum at levels associated with central nervous system and bone toxicity. 1
. 0
. 0
, ampicillin, tetracycline. 0
Title INFUVITEÂ® Pediatric 
===Dose===  Intravenous: Infuvite® Pediatric is a sterile product consisting of two vials: a 4 mL vial labeled Vial 1 and a 1 mL vial labeled Vial 2. 0
The daily dose is a function of infant weight as indicated in the following table . 1
to prevent tissue depletion of nutrients . 0
Inactive ingredients: 50 mg polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment and water for injection. 0
. 0
Title Ibuprofen Lysine 
===Dose===  First dose: 10 mg/kg IV . 1
Second and third doses: 5 mg/kg IV . 0
Administer at 24 hour intervals . 1
==Administration== Dilute prior to administration in an appropriate volume of dextrose or saline and give over 15 minutes . 0
According to a review of 20 studies, ibuprofen was found to be as effective as indomethacin for closure of PDA. 0
and less evidence for transient renal impairment when compared with indomethacin . 0
In a clinical trial including preterm neonates less than 30 weeks GA with an asymptomatic PDA, treatment with ibuprofen within the first 72 hours of life was associated with a decreased need for rescue therapy when compared with placebo . 1
In another randomized, controlled, single-center study, the use of early ibuprofen therapy for PDA closure in patients who were mildly symptomatic was not associated with a reduction in supplemental oxygen needs in the first 28 days of life or oxygen requirements at 36 weeks PMA when compared with ibuprofen therapy provided once a PDA became symptomatic and required treatment. 1
This study was terminated early due to a recall of the intravenous ibuprofen lysine product; 105 of the needed 168 infants were enrolled by study termination . 0
congenital heart disease with ductal-dependent systemic blood flow . 0
and metabolites. 0
The mean half-life in premature neonates is approximately 43 hours, with large interpatient variability. 1
, a more significant increase in unbound bilirubin can be expected in those infants with a high unconjugated bilirubin/albumin ratio and those in whom high ibuprofen concentrations are achieved . 0
in babies receiving ibuprofen. 0
The cohorts were from 2 separate decades which could introduce historical bias . 0
for treatment of PDA . 0
Several studies have demonstrated an increased risk of oxygen dependency at 28 days postnatal age, but not 36 weeks PMA. 1
. 0
. 0
Monitor urine output and delay further doses if urine output falls below 0.6 mL/kg/hour . 0
==Special Considerations/Preparation== Supplied as a 10-mg/mL sterile solution for injection in 2-mL single use vials. 0
Administer within 30 minutes of preparation. 1
The pH is adjusted to 7. 0
Store at room temperature. 1
Title Ibuprofen Lysine 
===Dose===  First dose: 10 mg/kg IV . 1
This study was terminated early due to a recall of the intravenous ibuprofen lysine product; 105 of the needed 168 infants were enrolled by study termination . 0
==Special Considerations/Preparation== Supplied as a 10-mg/mL sterile solution for injection in 2-mL single use vials. 0
Title Imipenem/Cilastatin 
===Dose===  20 to 25 mg/kg/dose IV every 12 hours. 1
==Administration== Administer by IV infusion over 15 to 30 minutes at a concentration of 5 mg/mL or less . 1
==Pharmacology== Imipenem is a broad-spectrum carbapenem antibiotic combined in a 1:1 ratio with cilastatin, a renal dipeptidase inhibitor with no intrinsic antibacterial activity. 0
Serum half-life of imipenem in neonates is 2.5 hours; the half- life of cilastatin is 9 hours. 1
Other reactions, including eosinophilia, elevated hepatic transaminases, and diarrhea, also occur in more than 5% of patients. 0
==Special Considerations/Preparation== Available as powder for injection in 250-mg, and 500-mg vials. 0
Reconstitute with 10 mL of compatible diluent. 0
When reconstituted with compatible diluent, solution is stable for 4 hours at room temperature, 24 hours refrigerated. 1
Maximum concentration for infusion is 5 mg/mL. 0
Title Imipenem/Cilastatin 
===Dose===  20 to 25 mg/kg/dose IV every 12 hours. 1
==Solution Compatibility== D5W, D10W, and NS. 0
Give at 12- to 24-hour intervals with close monitoring of urine output. 1
Longer treatment courses may be used: 0.2 mg/kg every 24 hours for a total of 5 to 7 days. 1
PDA Closure : 0.1 mg/kg every 24 hours for 3 doses, beginning at 6 to 12 hours of age. 1
==Administration== IV infusion by syringe pump over at least 30 minutes to minimize adverse effects on cerebral, gastrointestinal, and renal blood flow velocities. 1
Serum half-life is approximately 30 hours, with a range of 15 to 50 hours, partially dependent on postnatal age. 1
==Adverse Effects== Hypoglycemia is common, usually preventable by increasing the glucose infusion rate by 2 mg/kg per minute. 0
infusions are associated with reductions in organ blood flow. 0
==Special Considerations/Preparation== Supplied as a lyophilized powder in 1-mg single-dose vials . 0
Indomethacin sodium trihydrate salt is not buffered, and is insoluble in solutions with pH less than 6; the manufacturer therefore recommends against continuous infusion in typical IV solutions. 0
Reconstitute using 1 to 2 mL of preservative-free NS or sterile water for injection. 0
Reconstituted indomethacin is stable in polypropylene syringes and glass vials for 12 days when stored at room temperature or refrigerated. 0
: D2.5W, D5W, and NS. 0
Solution Incompatibility D7.5W, D10W, and Dex/AA Solutions. 0
: 0.1 mg/kg every 24 hours for 3 doses, beginning at 6 to 12 hours of age. 1
==Administration== IV infusion by syringe pump over at least 30 minutes to minimize adverse effects on cerebral, gastrointestinal, and renal blood flow velocities. 1
==Special Considerations/Preparation== Supplied as a lyophilized powder in 1-mg single-dose vials . 0
Title Insulin 
===Dose===  Hyperglycemia: Continuous IV infusion: 0.01 to 0.1 unit/kg/hour. 1
Intermittent dose: 0.1 to 0.2 unit/kg subQ every 6 to 12 hours. 1
Hyperkalemia: Initial: Regular insulin 0.1 to 0.2 units/kg/hour in combination with 0.5 g/kg/hour of dextrose given as continuous IV infusion. 1
For continuous infusion, dilute regular insulin in compatible solution to a concentration of 0.05 to 1 unit/mL. 0
. 0
A recent study found that 20 mL of priming volume was sufficient to minimize adsorption losses for a 1 unit/mL insulin infusion. 0
Plasma half-life in adults is 9 minutes. 1
after starting insulin infusion and after changes in infusion rate. 1
==Special Considerations/Preparation== Regular human insulin [rDNA origin] is available as a 100-unit/mL concentration in 10-mL vials. 0
For subcutaneous administration, dilute with sterile water or NS to a concentration of 0.5 or 1 unit/mL. 0
For IV administration, make a 10 units/mL dilution with sterile water, then further dilute in compatible solution to a concentration of 0.05 to 1 unit/mL. 0
==Solution Compatibility== D5W, and D10W, and NS. 0
Title Insulin 
===Dose===  Hyperglycemia: Continuous IV infusion: 0.01 to 0.1 unit/kg/hour. 1
Hyperkalemia: Initial: Regular insulin 0.1 to 0.2 units/kg/hour in combination with 0.5 g/kg/hour of dextrose given as continuous IV infusion. 1
==Special Considerations/Preparation== Regular human insulin [rDNA origin] is available as a 100-unit/mL concentration in 10-mL vials. 0
===Dose===  Usual Dosage: 500 to 750 mg/kg per dose over 2 to 6 hours. 1
For neonatal alloimmune thrombocytopenia, doses have ranged from 400 mg/kg to 1 g/kg. 0
Most studies have used a single dose, although additional doses have been given at 24 hour intervals. 0
All preparations are reported to contain more than 92% IgG monomers and a normal distribution of IgG subclasses. 0
Total IgG titers in treated, septic neonates remain elevated for approximately 10 days. 1
have been used. 0
Shelf life varies, but is at least 2 years, when stored properly. 1
* IVIG PreparationsSolution Compatibility D5W, D15W, and Dex/AA. 0
===Dose===  Usual Dosage: 500 to 750 mg/kg per dose over 2 to 6 hours. 1
Shelf life varies, but is at least 2 years, when stored properly. 1
Title Ipratropium  or nebulized solution. 0
via MDI with spacer device placed in the inspiratory limb of the ventilator circuit, and 75 to 175 mcg via jet nebulizer. 0
Peak effect occurs 1 to 2 hours after administration. 1
Duration of effect is 4 to 6 hours in children. 1
providing 200 actuations per each 12.9-g canister. 0
Each actuation delivers 21 mcg of ipratropium from the valve and 17 mcg from the mouthpiece. 0
in a sterile, preservative-free, isotonic saline solution that is pH- adjusted to 3.4 with hydrochloric acid. 0
It may be mixed with albuterol or metaproterenol if used within 1 hour. 0
Title Ipratropium  or nebulized solution. 0
via MDI with spacer device placed in the inspiratory limb of the ventilator circuit, and 75 to 175 mcg via jet nebulizer. 0
Title Iron Dextran  per day IV continuous infusion in Dex/AA solutions containing at least 2% amino acids. 1
Complete clearance occurred by 3 days. 0
Approximately 40% of the labeled iron was bound to transferrin within 11 hours. 1
intramuscular doses administered to infants were associated with increased risk of infection. 0
Retrospective reviews of adult patients who received larger doses injected over a few minutes report a 0.7% risk of immediate serious allergic reactions, and a 5% risk of delayed such as myalgia, arthralgia, phlebitis, and lymphadenopathy. 0
==Special Considerations/Preparation== Available as a 50 mg/mL concentration in 2-mL single-dose vials. 0
Title Iron Dextran  per day IV continuous infusion in Dex/AA solutions containing at least 2% amino acids. 1
Title Isoproterenol 
===Dose===  0.05 to 0.5 mcg/kg per minute continuous IV infusion. 1
Maximum dose 2 mcg/kg per minute. 1
:Mix 50 mL of 10-mcg/mL solution using isoproterenol concentration of 0.2 mg/mL. 0
to yield 50 mL of infusion solution with a concentration of 10 mcg/mL. 0
Maximum concentration 20 mcg/mL. 0
. 0
Afterload reduction via β2 effects on arterioles. 0
solution in 1-mL and 5-mL ampuls. 0
Title Isoproterenol 
===Dose===  0.05 to 0.5 mcg/kg per minute continuous IV infusion. 1
solution in 1-mL and 5-mL ampuls. 0
Title LORazepam 
===Dose===  0.05 to 0.1 mg/kg per dose IV slow push. 1
Onset of action within 5 minutes; peak serum concentration within 45 minutes. 1
Duration of action is 3 to 24 hours. 1
Mean half-life in term neonates is 40 hours. 1
. 0
benzyl alcohol and 18% polyethylene glycol 400 in propylene glycol. 0
A dilution of 0.4 mg/mL may be prepared by adding 1 mL of 4 mg/mL concentration in 9 mL of preservative-free sterile water for injection. 0
This will make it easier to measure the dose and decrease the benzyl alcohol content to 0.5 mg/kg per dose. 0
==Solution Compatibility== D5W, NS, and sterile water for injection. 0
Title LORazepam 
===Dose===  0.05 to 0.1 mg/kg per dose IV slow push. 1
Title LamiVUDine 
===Dose===  HIV Infection; Prevention of Transmission or Treatment: 2 mg/kg orally every 12 hours . 1
==Uses== HIV-1 infection; Prevention of transmission or Treatment: If an infant is definitively diagnosed with HIV infection while receiving prophylactic treatment for prevention of mother-to-child transmission of HIV, prophylactic antiretrovirals should be discontinued immediately and treatment initiated with a 3-drug combination regimen. 0
Pediatric FDA Approved Indications Epivir® Treatment of HIV-1 infection in combination with other antiretroviral agents in children 3 months of age and older . 0
Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus and HIV-1 and have discontinued lamivudine. 0
. 0
is a synthetic nucleoside analog that inhibits HIV and HBV replication by interfering with viral reverse transcriptase. 0
Poor CNS penetration with a percent CSF to serum drug concentration of approximately 12%. 1
The oral solution is well-absorbed, with 66% bioavailability in children. 0
Peak reached in 0.5 to 1.5 hours. 1
The serum half-life in children is approximately 2.2 +/- 2 hours. 1
. 0
In 36 infants up to 1 week of age administered lamivudine and zidovudine, lamivudine clearance was substantially reduced in 1-week-old neonates compared with children older than 3 months of age . 1
were reported in 3 neonates. 0
. 0
. 0
strengths. 0
==Uses== HIV-1 infection; Prevention of transmission or Treatment: If an infant is definitively diagnosed with HIV infection while receiving prophylactic treatment for prevention of mother-to-child transmission of HIV, prophylactic antiretrovirals should be discontinued immediately and treatment initiated with a 3-drug combination regimen. 0
were reported in 3 neonates. 0
==Monitoring== KEY: AST = aspartate aminotransferase; ALT = alanine aminotransferase; BUN = blood urea nitrogen CBC = complete blood count * Baseline may not be necessary if pre-therapy monitoring was performed within 30 to 45 days. 1
. 0
Title Lansoprazole 
===Dose===  0.73 to 1.66 mg/kg/dose orally once daily. 0
==Administration== The contents of a capsule can be mixed in 40 mL of apple juice and administered by NG tube. 0
and completely clogged a 5 French pediatric feeding tube. 0
of proton pump inhibitors. 0
having protracted diarrhea and stool analysis for C.
 difficile, 68 cases of CDAD were identified and then randomly matched to 68 control subjects who testedC. 0
. 0
Extensively metabolized in the liver by CYP 2C19 and 3A4. 0
Onset of action is within one hour of administration, maximal effect is at approximately 1.5 hours. 1
Average elimination half-life is 1.5 hours. 1
Inhibition of acid secretion is about 50% of maximum at 24 hours and the duration of action is approximately 72 hours. 1
==Monitoring== Observe for symptomatic improvement within 3 days. 1
. 0
Measure AST and ALT if duration of therapy is greater than 8 weeks. 1
. 0
containing either 15 mg or 30 mg lansoprazole for oral administration . 0
Title Lansoprazole 
===Dose===  0.73 to 1.66 mg/kg/dose orally once daily. 0
of proton pump inhibitors. 0
containing either 15 mg or 30 mg lansoprazole for oral administration . 0
Title LevETIRAcetam 
===Dose===  Initial dose: 10 mg/kg/dose IV or orally every 24 hours in the neonatal period, every 12 hours later in infancy. 1
Adjust dosage upward as needed every 1 to 2 weeks to a maximum of 30 mg/kg/dose. 1
==Administration== Intravenous: Dilute to a concentration of 5 to 15 mg/mL and infuse over 15 minutes . 0
==Pharmacology== Rapidly and completely absorbed after oral administration, with the onset of action by 30 minutes and peak concentration within 2 hours. 1
Half-life in the immediate neonatal period is approximately 18 hours, decreasing to 6 hours by 6 months of age. 1
. 0
Therapeutic concentrations are approximately 10 to 40 mcg/mL. 0
. 0
Must be further diluted to a concentration of 5 to 15 mg/mL in compatible diluent prior to administration. 0
Diluted solution is stable for 24 hours at room temperature . 1
. 0
==Solution Compatibility== NS, LR, and D5W. 0
Title LevETIRAcetam 
===Dose===  Initial dose: 10 mg/kg/dose IV or orally every 24 hours in the neonatal period, every 12 hours later in infancy. 1
==Administration== Intravenous: Dilute to a concentration of 5 to 15 mg/mL and infuse over 15 minutes . 0
==Pharmacology== Rapidly and completely absorbed after oral administration, with the onset of action by 30 minutes and peak concentration within 2 hours. 1
==Solution Compatibility== NS, LR, and D5W. 0
Title Levothyroxine 
===Dose===  Initial oral dose: 10 to 14 mcg/kg/dose orally every 24 hours. 1
. 0
Dosage is adjusted in 12.5-mcg increments. 0
Initial IV dose: 5 to 8 mcg/kg/dose every 24 hours. 1
==Pharmacology== Tissue deiodination converts T4 to T3, the active metabolite. 0
Elimination of both T4 and T3 is equal in the urine and feces. 0
Clinical effects will persist for 1 week after discontinuation of the drug. 0
Levothyroxine prepared as an oral suspension is 50% to 80% bioavailable. 0
Oral dosing produces effects within 3 to 5 days, while IV dosing produces effects in 6 to 8 hours. 1
and should be maintained in this range for the first year of life. 0
, and TSH should have declined from initial value. 0
After 12 weeks of treatment, serum TSH concentration should be in the normal range, less than 15 milliunits/L. 1
Serum T4 and TSH concentrations should be measured at two weeks of age, then every 1 to 2 months, or 2 weeks after any change in dosage. 1
Available as scored tablets ranging from 25 to 300 mcg per tablet. 0
Also available in capsules that contain a viscous liquid ranging from 13 to 150 mcg per capsule. 0
To prepare a 15-mcg/mL levothyroxine oral suspension: Crush levothyroxine 100-mcg tablets in glycerol and add sterile water up to desired volume. 0
Product stability is 10 days when refrigerated between 2 and 8 degrees C.
 Stability tests demonstrated a 12% decline in levothyroxine concentration in the prepared suspension over 11 days. 1
An oral liquid formulation of levothyroxine sodium 25 mcg/mL in 40% glycerol compounded from crushed tablets and distilled water with no preservatives added was stable for 8 days when stored in amber bottles at 4 degrees C.
 Injectable form is available as lyophilized powder in vials containing 100 or 500 mcg. 0
Following reconstitution with 5 mL of NS, final concentrations are approximately 20 mcg/mL and 100 mcg/mL Use immediately. 0
Do not add to any other IV solution Reconstituted solution is preservative free and stable for 4 hours . 0
Title Levothyroxine 
===Dose===  Initial oral dose: 10 to 14 mcg/kg/dose orally every 24 hours. 1
and should be maintained in this range for the first year of life. 0
Title Lidocaine - Antiarrhythmic 
===Dose===  Initial bolus dose: 0.5 to 1 mg/kg IV push over 5 minutes. 1
Repeat every 10 minutes as necessary to control arrhythmia. 1
Maximum total bolus dose should not exceed 5 mg/kg. 0
Maintenance IV infusion: 10 to 50 mcg/kg per minute. 0
:Mix 50 mL of 2400 mcg/mL solution using lidocaine concentration of 20 mg/mL. 0
to yield 50 mL of infusion solution with a concentration of 2400 mcg/mL. 0
Maximum concentration is 8000 mcg/mL. 0
==Pharmacology== Lidocaine is a type 1b antiarrhythmic agent used intravenously. 0
Onset of action is 1 to 2 minutes after bolus administration. 1
Plasma half-life in neonates is 3 hours. 1
Free drug fraction in both term and premature neonates is approximately twice that found in older children because of significantly reduced protein binding by Î±1-acid glycoprotein. 0
Transformed in the liver to metabolites with antiarrhythmic activity; approximately 30% is excreted unchanged in neonates. 1
Therapeutic drug concentration is 1.5 to 6 mg/L, with toxicity associated with concentrations greater than 9 mg/L . 0
Available in multiple concentrations ranging from 1% to 20%. 0
in 9.5 mL NS or D5W, yielding a 1-mg/mL final concentration. 0
Title Lidocaine - Antiarrhythmic 
===Dose===  Initial bolus dose: 0.5 to 1 mg/kg IV push over 5 minutes. 1
Maintenance IV infusion: 10 to 50 mcg/kg per minute. 0
Therapeutic drug concentration is 1.5 to 6 mg/L, with toxicity associated with concentrations greater than 9 mg/L . 0
Title Lidocaine - CNS 
===Dose===  Term, normothermic newborns: Loading dose: 2 mg/kg IV over 10 minutes, followed immediately by a Maintenance infusion: 6 mg/kg per hour for 6 hours, then 4 mg/kg per hour for 12 hours, then 2 mg/kg per hour for 12 hours. 1
. 0
Approximately 30% is excreted unchanged in the urine. 1
The half-life in neonates is at least 3 hours, and clearance is dose-dependent. 1
The clinically effective dose of 6 mg/kg/hr will lead to accumulation of both lidocaine and metabolites within several hours. 0
Free drug fraction in both term and premature neonates is approximately twice that found in older children because of significantly reduced protein binding by alpha 1-acid glycoprotein. 0
Arrhythmias and significant bradycardia have occurred in 5% of reported cases. 0
in 9.5 mL NS or D5W, yielding a 1 mg/mL final concentration. 0
==Solution Compatibility== D5W, D10W, and NS. 0
Title Lidocaine - CNS 
===Dose===  Term, normothermic newborns: Loading dose: 2 mg/kg IV over 10 minutes, followed immediately by a Maintenance infusion: 6 mg/kg per hour for 6 hours, then 4 mg/kg per hour for 12 hours, then 2 mg/kg per hour for 12 hours. 1
Title Linezolid 
===Dose===  10 mg/kg/dose IV or orally every 8 hours . 1
Preterm newborns less than 1 week of age: 10 mg/kg/dose IV or orally every 12 hours . 1
==Administration== IV: Give as an intermittent IV infusion over 30 to 120 minutes. 1
; no further dilution is necessary . 1
Before administering oral suspension, gently mix by inverting bottle 3 to 5 times. 0
Peripheral and optic neuropathy have been reported in pediatric patients, mainly in patients treated for longer than 28 days. 0
Lactic acidosis has been reported in a case series of 3 children aged 6 months, 6 months, and 16 years receiving linezolid for 53, 31 and 7 days of treatment, respectively. 1
All 3 children had liver dysfunction and complicated medical courses while receiving linezolid therapy. 0
Safety and efficacy of linezolid therapy for greater than 28 days has not been evaluated in controlled clinical trials . 1
on March 16, 2007. 1
Patients in an open-label, randomized trial comparing linezolid with vancomycin, oxacillin, or dicloxacillin in the treatment of seriously ill patients with intravascular catheter-related bloodstream infections had a higher chance of death than did patients treated with any comparator antibiotic, and the chance of death was related to the type of organism causing the infection. 0
gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsan dProviders/ucm101503.htm. 0
CSF concentrations were 70% of plasma concentrations in older patients with non-inflamed meninges. 0
and two inactive metabolites. 0
Serum half-life in most neonates is 2 to 3 hours, with the exception of preterm neonates less than one week of age, who have a serum half-life of 5 to 6 hours . 1
==Adverse Effects== Elevated transaminases and diarrhea occur in approximately 5% of treated patients; thrombocytopenia and anemia occur in 2% to 5% . 0
==Monitoring== Monitor CBC weekly, especially in patients receiving linezolid for longer than 2 weeks, those with myelosuppression, those receiving concurrent myelosuppressive drugs, or those with a chronic infection who have received previous or concomitant antibiotic therapy . 1
should be monitored for signs and symptoms of neuropathy . 0
and in all patients experiencing visual impairment. 0
==Special Considerations/Preparation== Linezolid IV injection is supplied as a 2-mg/mL solution in single-use, ready-to-use 100-mL, 200-mL, and 300-mL plastic infusion bags in a foil laminate overwrap. 0
provides 20 mg/mL. 0
Use within 21 days after reconstitution. 1
==Solution Compatibility== D5W, NS, Lactated Ringers. 0
==Administration== IV: Give as an intermittent IV infusion over 30 to 120 minutes. 1
Title Lopinavir/Ritonavir 
===Dose===  HIV Infection 14 days and older: lopinavir 16 mg/ritonavir 4 mg/kg orally twice daily OR lopinavir 300 mg/ritonavir 75 mg/m2 orally twice daily . 0
Do not use until a postmenstrual age of 42 weeks and a postnatal age of at least 14 days. 1
which may lead to serious adverse events in neonates, particularly preterm neonates . 0
Co-administration with efavirenz, nevirapine, fosamprenavir, or nelfinavir is NOT recommended in patients less than 6 months of age . 1
When used in infants and young children, especially those 14 days to 6 months of age, it is critical to ensure that dose calculation, transcription of the medication order, and dosing instructions are accurate, and that total amounts of alcohol and propylene glycol from all concomitant medications are accounted for . 0
If coadministered with didanosine, give didanosine 1 hour before or 2 hours after lopinavir/ritonavir dose . 1
component, is the preferred protease inhibitor-based regimen for treatment-naive, HIV-infected neonates with postmenstrual age of 42 weeks and postnatal age of 14 days and older. 1
Pediatric FDA Approved Indications Lopinavir/ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients 14 days of age or older . 1
==Contraindications/Precautions== Due to cardiovascular toxicity observed in preterm infants, lopinavir/ritonavir should NOT be administered to neonates before a postmenstrual age of 42 weeks and a postnatal age of at least 14 days. 1
present in the oral solution . 0
. 0
, oral solution should be used within 2 months . 1
Co-administration with efavirenz, nevirapine, fosamprenavir, or nelfinavir is NOT recommended in patients less than 6 months of age . 1
If coadministered with didanosine, give didanosine 1 hour before or 2 hours after lopinavir/ritonavir dose . 1
Title Lucinactant . 0
Up to 4 doses may be given in the first 48 hours of life; give no more frequently than every 6 hours . 1
In clinical trials, lucinactant was administered within 20 to 30 minutes after birth . 1
. 0
. 0
Warmed vials should not be refrigerated after warming but may be stored in the carton at room temperature for no more than 2 hours . 1
Using a 16- or 18-gauge needle, slowly draw up the dose of warmed and vigorously shaken lucinactant intratracheal suspension into an appropriately sized syringe . 0
The infant should be positioned in the right lateral decubitus position with head and thorax at a 30 degree upward inclined position. 0
to allow maintenance of positive end-expiratory pressure. 0
. 0
Administer the first aliquot while continuing positive pressure mechanical ventilation and maintaining a positive end-expiratory pressure of 4 to 5 cm H2O. 1
. 0
Keep the head of the infant's bed elevated at least 10 degrees for at least 1 to 2 hours. 0
. 0
. 0
was 37.8% vs 33.1%, respectively . 0
, lucinactant had similar efficacy to the animal-derived and synthetic exogenous surfactant products for decreasing mortality and morbidity rates in premature neonates at risk for RDS. 0
. 0
In clinical trials, rates of bradycardia and oxygen desaturation have ranged from 3% to 23% and 8% to 58%, respectively. 0
Endotracheal tube reflux occurred at an incidence of 18% to 27% . 0
, and periventricular leukomalacia was not significantly different between lucinactant and the comparators in clinical trials . 0
==Special Considerations/Preparation== Available as an intratracheal suspension containing 8.5 mL in a glass vial. 0
, 4.05 mg palmitic acid, and 0.862 mg sinapultide. 0
. 0
Title Lucinactant . 0
. 0
. 0
, lucinactant had similar efficacy to the animal-derived and synthetic exogenous surfactant products for decreasing mortality and morbidity rates in premature neonates at risk for RDS. 0
==Special Considerations/Preparation== Available as an intratracheal suspension containing 8.5 mL in a glass vial. 0
. 0
Use within 60 to 90 days after a bottle is opened. 1
Title MCT Oil 
===Dose===  Medium Chain Triglyceride Oil Medium chain triglyceridesSpecial Considerations/Preparation Supplied as 50% concentration in 2-, 10-, and 50-mL single dose vials containing 500 mg/mL of magnesium sulfate which provides 4.06 mEq each of magnesium and sulfate. 0
Osmolarity is 4.06 mOsm/mL; pH range of 5.5 to 7 . 0
==Solution Compatibility== D5W, NS, LR, and Dex/AA solutions. 0
Title Magnesium sulfate  . 0
Hypomagnesemia 25 to 50 mg/kg IV infusion over 30 to 60 minutes; repeat dose as necessary . 1
For hypomagnesemia/torsades with pulses, an infusion time of 10 to 20 minutes is recommended . 1
0.25 to 0.5 mEq/kg/day IV . 0
. 0
for pulseless torsades, over 10 to 20 minutes for hypomagnesemia/torsades with pulses, and over 30 to 60 minutes for hypomagnesemia . 1
and only 1% is present in the extracellular fluid. 0
is reabsorbed by the kidney. 0
of magnesium sulfate for stopping pre-term labor in pregnant mothers . 0
==Special Considerations/Preparation== Supplied as 50% concentration in 2-, 10-, and 50-mL single dose vials containing 500 mg/mL of magnesium sulfate which provides 4.06 mEq each of magnesium and sulfate. 0
Title Meropenem 
===Dose===  Intra-abdominal and non-CNS infections Less than 32 weeks GA and less than 14 days PNA: 20 mg/kg IV every 12 hours . 1
Less than 32 weeks GA and 14 days PNA and older: 20 mg/kg IV every 8 hours . 1
32 weeks GA and older, and less than 14 days PNA: 20 mg/kg IV every 8 hours . 1
32 weeks GA and older, and 14 days PNA and older: 30 mg/kg IV every 8 hours . 1
Consider 40 mg/kg/dose at the recommended age-specific dosing interval Less than 32 weeks GA and less than 14 days PNA: every 12 hours . 1
Less than 32 weeks GA and 14 days PNA and older: every 8 hours . 1
32 weeks GA and older: every 8 hours . 1
==Administration== Administer as an IV infusion over 30 minutes at a concentration of 1 to 20 mg/mL . 1
, Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species in pediatric patients 3 months and older . 0
coli, Klebsiella pneumoniae, P aeruginosa, B fragilis, B thetaiotaomicron, and Peptostreptococcus species in pediatric patients 3 months and older . 0
Meropenem is considered an appropriate single agent for pediatric patients with a complicated extra-biliary intra-abdominal infection Treatment of bacterial meningitis caused by S pneumoniae, Haemophilus influenzae , and Neisseria meningitidis in pediatric patients 3 months and older . 0
It exhibits time-dependent killing of Gram-negative and Gram-positive pathogens, and the goal of therapy is to keep free drug concentrations above the MIC for at least 40% of the dosing interval. 0
Clearance is directly related to renal function, and 70% of a dose is recovered intact in the urine. 0
Serum half-life of meropenem is 3 hours in preterm and 2 hours in full term neonates. 1
. 0
as powder for injection in 500-mg, and 1000-mg vials. 0
. 0
When reconstituted with sterile water for injection, stable for up to 2 hours at room temperature or up to 12 hours when refrigerated. 0
When reconstituted with NS to a final concentration between 2.5 to 50 mg/mL, the solution is stable for up to 2 hours at room temperature or 18 hours when refrigerated. 0
When reconstituted with D5W to final concentration between 2.5 to 50 mg/mL, the solution is stable for up to 1 hour at room temperature or 8 hours when refrigerated. 0
Solutions prepared in sterile water for injection or NS at concentrations of 1 to 20 mg/mL are stable in plastic syringes for up to 48 hours when refrigerated. 0
Solutions prepared in D5W at concentrations of 1 to 20 mg/mL are stable in plastic syringes for up to 6 hours when refrigerated. 0
Solutions prepared for infusion in NS at concentrations of 1 to 20 mg/mL are stable in plastic IV bags for 4 hours at room temperature or 24 hours when refrigerated. 1
Solutions prepared for infusion in D5W at concentrations of 1 to 20 mg/mL are stable in plastic IV bags for 1 hour at room temperature or 4 hours when refrigerated. 0
Title Meropenem 
===Dose===  Intra-abdominal and non-CNS infections Less than 32 weeks GA and less than 14 days PNA: 20 mg/kg IV every 12 hours . 1
32 weeks GA and older, and less than 14 days PNA: 20 mg/kg IV every 8 hours . 1
==Administration== Administer as an IV infusion over 30 minutes at a concentration of 1 to 20 mg/mL . 1
. 0
Title Methadone 
===Dose===  Neonatal Abstinence Syndrome Initial dose: 0.05 to 0.1 mg/kg per dose orally every 6 to 24 hours . 1
and weaning schedule based on signs and symptoms of withdrawal . 0
Oral bioavailability is 50%, with peak plasma levels obtained in 2 to 4 hours. 0
. 0
Serum half-life ranges from 16 to 25 hours in neonates and is prolonged in patients with renal failure. 1
. 0
After birth, the infant's resting HR was 80 to 90 beats per minute and ECG showed a QTc of 510 msec. 0
This resolved spontaneously over 5 days . 1
A 12-lead ECG should be obtained on methadone-exposed infants experiencing bradycardia or tachycardia . 1
==Special Considerations/Preparation== Available as oral solutions in 1- and 2-mg/mL concentrations containing 8% alcohol, and a 10-mg/mL alcohol-free solution. 0
May dilute 1 mL of the 10-mg/mL concentrated solution with 19 mL of sterile water to provide an oral dilution with a final concentration of 0.5 mg/mL. 0
Also available as 5- and 10-mg tablets. 0
Title Metoclopramide 
===Dose===  0.033 to 0.1 mg/kg/dose orally or IV slow push every 8 hours. 1
(Also used to enhance lactation--10 mg every 8 hours. 1
Treatment with metoclopramide for longer than 12 weeks should be avoided except in rare cases where therapeutic benefit outweighs the risk of developing tardive dyskinesia. 0
Serum half-life in adults is 4 hours; prolonged in patients with renal failure. 1
. 0
A 0.1 mg/mL dilution may be made by adding 0.4 mL of the 5-mg/mL concentration to 19.6 mL of preservative-free NS. 0
Dilution is stable for 24 hours at room temperature. 1
Oral preparation available in 1-mg/mL concentration. 0
A 0.1 mg/mL oral dilution may be made by adding 1 mL of the 1-mg/mL concentration to 9 mL simple syrup. 0
Stable for 4 weeks at room temperature. 1
Acyclovir, aminophylline, atropine, aztreonam, caffeine citrate, cimetidine, ciprofloxacin, clindamycin, dexamethasone, famotidine, fentanyl, fluconazole, heparin, hydrocortisone, lidocaine, linezolid, meropenem, methadone, midazolam, morphine, multivitamins, piperacillin/tazobactam, potassium chloride, potassium phosphate, prostaglandin E1, quinupristin-dalfopristin, ranitidine, remifentanil, and zidovudine. 0
Title Metoclopramide 
===Dose===  0.033 to 0.1 mg/kg/dose orally or IV slow push every 8 hours. 1
Treatment with metoclopramide for longer than 12 weeks should be avoided except in rare cases where therapeutic benefit outweighs the risk of developing tardive dyskinesia. 0
Title MetroNIDAZOLE 
===Dose===  Loading dose: 15 mg/kg orally or IV infusion by syringe pump over 60 minutes. 1
Maintenance dose: 7.5 mg/kg/dose orally or IV infusion over 60 minutes. 1
The drug exhibits concentration-dependent bactericidal activity with a post-antibiotic effect of greater than 3 hours. 0
It is well absorbed after oral administration, with peak serum concentrations attained in 1 to 3 hours. 1
It is less than 20% protein bound. 0
Elimination half-life is strongly related to gestational age, ranging from 22 to 109 hours. 1
==Special Considerations/Preparation== Available in 5 mg/mL concentration in 100 mL single-dose plastic ready-to-use solution containers. 0
Osmolarity is 297 mOsm/L, pH is 4.5 to 7. 0
Each container contains 13.5 mEq of sodium. 0
Supplied as 250-mg and 500-mg tablets for oral administration. 0
, dissolving powder in 10 mL purified water, then adding cherry syrup to make a total volume of 83 mL. 0
Final concentration is 15 mg/mL. 0
==Solution Compatibility== D5W, and NS. 0
Acyclovir, amikacin, amiodarone, ampicillin, caspofungin, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, chloramphenicol, clindamycin, dopamine, enalaprilat, esmolol, fluconazole, gentamicin, heparin, hydrocortisone succinate, linezolid, lorazepam, magnesium sulfate, midazolam, milrinone, morphine, netilmicin, nicardipine, penicillin G, piperacillin-tazobactam, prostaglandin E1, remifentanil, and tobramycin. 0
Title MetroNIDAZOLE 
===Dose===  Loading dose: 15 mg/kg orally or IV infusion by syringe pump over 60 minutes. 1
Title Micafungin 
===Dose===  7 to 10 mg/kg/dose IV every 24 hours. 1
and those with meningitis. 0
==Administration== Administer by intermittent IV infusion over 1 hour at a concentration between 0.5 to 1.5 mg/mL. 1
It inhibits the synthesis of 1, 3-beta-D-glucan, an integral component of the fungal cell wall. 0
Metabolism occurs primarily in the liver through both noncytochrome and cytochrome P450 pathways to 2 biologically inactive metabolites that are eliminated in the feces. 0
. 0
was discontinued after 16 days of treatment and laboratory values gradually declined. 1
==Special Considerations/Preparation== Available in single-use lyophilized powder for injection in vials containing 50 and 100 mg. to each 50 mg or 100 mg vial yielding approximately 10 mg or 20 mg per mL, respectively. 0
Reconstituted vials may be stored at room temperature for up to 24 hours before use. 1
Reconstituted drug should be further diluted in NS or D5W to a final concentration between 0.5 to 1.5 mg/mL prior to administration. 0
Diluted infusion should be protected from light and may be stored at room temperature for up to 24 hours before use. 1
Title Micafungin 
===Dose===  7 to 10 mg/kg/dose IV every 24 hours. 1
Title MicrolipidÂ® 
===Dose===  Microlipid is a 50% safflower oil fat emulsion with 4.5 calories/mL. 0
: Not available Supplied: 48 three ounce bottles per case. 0
Opened product should be recapped, refrigerated, and discarded after 5 days. 1
1.117 Midazolam 
Title Midazolam 
===Dose===  Sedation: IV: 0.05 to 0.15 mg/kg over at least 5 minutes. 1
Repeat as required, usually every 2 to 4 hours. 1
. 0
Intranasal: 0.2 to 0.3 mg/kg per dose using 5-mg/mL injectable form. 0
Sublingual: 0.2 mg/kg per dose using 5-mg/mL injectable form mixed with a small amount of flavored syrup. 0
Oral: 0.25 mg/kg per dose using Versed® oral syrup. 0
. 0
Metabolized by hepatic CYP 3A4 to a less active hydroxylated metabolite, then glucuronidated before excretion in urine. 0
Duration of action is 2 to 6 hours. 1
Elimination half-life is approximately 4 to 6 hours in term neonates, and quite variable, up to 22 hours, in premature babies and those with impaired hepatic function. 1
Bioavailability is approximately 36% with oral administration and 50% with sublingual and intranasal administration. 0
Seizure-like myoclonus has been reported in 8% of premature infants receiving continuous infusions - this also may occur following rapid bolus administration and in patients with underlying CNS disorders. 0
==Special Considerations/Preparation== A preservative-free preparation is available as 1- and 5-mg/mL concentrations in 1-, 2-, and 5-mL vials. 0
benzyl alcohol as a preservative. 0
Stable for 24 hours when diluted with NS or D5W to a concentration of 0.5 mg/mL; stable for 4 hours in LR . 1
Oral syrup is available in a 2 mg/mL concentration. 0
. 0
Title Midazolam 
===Dose===  Sedation: IV: 0.05 to 0.15 mg/kg over at least 5 minutes. 1
. 0
Title Milrinone 
===Dose===  Loading dose: 75 mcg/kg IV infused over 60 minutes, immediately followed by Maintenance infusion: 0.5 to 0.75 mcg/kg per minute. 1
Premature infants less than 30 weeks GA: Loading dose: 135 mcg/kg IV infused over 3 hours, immediately followed by Maintenance infusion: 0.2 mcg/kg per minute. 1
treatment of acute low cardiac output after cardiac surgery or due to septic shock. 0
Based on results from a randomized, placebo-controlled clinical trial, milrinone was no more effective than placebo in preventing low systemic blood flow in preterm neonates less than 30 weeks GA. 0.75 mcg/kg/minute for the first 3 hours followed by 0.20 mcg/kg/minute until 18 hours of age. 1
. 0
Half-life is quite variable, ranging from approximately 10 hours in ELBW neonates to approximately 3 hours in older and more mature infants. 1
Blood pressure will likely fall 5% to 9% after the loading dose, but should gradually return to baseline by 24 hours. 1
Heart rate increases of 5% to 10% are also common. 0
==Special Considerations/Preparation== Available in 1-mg/mL solution for injection in 10-, 20-, and 50-mL single-dose vials. 0
Maximum concentration for infusion is 200 mcg/mL. 0
. 0
==Solution Compatibility== D5W, NS, and LR. 0
Title Milrinone 
===Dose===  Loading dose: 75 mcg/kg IV infused over 60 minutes, immediately followed by Maintenance infusion: 0.5 to 0.75 mcg/kg per minute. 1
Half-life is quite variable, ranging from approximately 10 hours in ELBW neonates to approximately 3 hours in older and more mature infants. 1
Title Morphine 
===Dose===  0.05 to 0.2 mg/kg per dose IV over at least 5 minutes, IM, or subQ. 1
. 0
Continuous infusion: Give a loading dose of 100 to 150 mcg/kg over 1 hour followed by 10 to 20 mcg/kg per hour. 1
Taper 10% to 20% per day as tolerated. 0
Oral dose is approximately 3 to 5 times IV dose. 1
Neonatal Abstinence Syndrome: Initial dose: 0.03 to 0.1 mg/kg per dose orally every 3 to 4 hours. 1
Maximum dose 0.2 mg/kg . 0
Wean dose by 10% to 20% every 2 to 3 days based on abstinence scoring. 1
Use a 0.4-mg/mL dilution made from a concentrated oral morphine sulfate solution . 0
that are renally excreted. 0
is a potent respiratory-depressant and analgesic. 0
is an antagonist to the effects of morphine and morphine-6- glucuronide. 0
Morphine is 20% to 40% bioavailable when administered orally. 0
Elimination half-life is approximately 9 hours for morphine and 18 hours for morphine-6-glucuronide. 1
Steady state concentrations of morphine are reached by 24 to 48 hours. 0
. 0
==Special Considerations/Preparation== Injectable solutions are available in dosage strengths ranging from 0.5 to 50 mg/mL. 0
Oral morphine sulfate solutions are available in concentrations of 2 and 4 mg/mL. 0
A 0.4-mg/mL oral morphine dilution may be made by adding 1 mL of the 4-mg/mL injectable solution to 9 mL preservative-free normal saline. 0
For continuous infusions of morphine containing heparin: Use only NS; maximum morphine concentration 5 mg/mL. 0
Title Morphine 
===Dose===  0.05 to 0.2 mg/kg per dose IV over at least 5 minutes, IM, or subQ. 1
Title Mupirocin 
===Dose===  Cutaneous infections: Apply small amounts topically to affected areas 3 times daily. 0
Decolonization: Apply small amounts to anterior nares twice daily for 5 to 7 days. 1
. 0
Title Mupirocin 
===Dose===  Cutaneous infections: Apply small amounts topically to affected areas 3 times daily. 0
Title Nafcillin 
===Dose===  Usual dosage: 25 mg/kg/dose IV over 15 minutes. 1
Meningitis: 50 mg/kg/dose IV over 15 minutes. 1
==Special Considerations/Preparation== Available in 1 and 2-g vials. 0
Reconstitute 1-g vial with 3.4 mL of sterile water for injection to provide a final volume of 4 mL and a concentration of 250 mg/mL. 0
Also available in 1-g in 50-mL and 2-g in 100-mL frozen single-dose bags. 0
pH of resulting solution 6 to 8.5. 0
Thawed solution stable for 3 days at room temperature, 21 days refrigerator. 1
Reconstituted solution stable for 3 days at room temperature, 7 days refrigerated. 1
Osmolality was determined to be 709 mOsm/kg of water. 0
For direct intravenous injection, dilute in 15 to 30 mL of NS. 0
Title Nafcillin 
===Dose===  Usual dosage: 25 mg/kg/dose IV over 15 minutes. 1
==Special Considerations/Preparation== Available in 1 and 2-g vials. 0
Reconstituted solution stable for 3 days at room temperature, 7 days refrigerated. 1
Title Naloxone 
===Dose===  Suggested dose: 0.1 mg/kg IV push. 0
===Dose===  needed to reverse narcotic-induced depression may be as low as 0.01 mg/kg. 0
Onset of action is variable, but usually within minutes after IV administration, and approximately 1 hour after IM administration. 1
Half-life in neonates is approximately 70 minutes. 1
and 1-mg/mL concentrations. 0
==Solution Compatibility== NS and D5W No data are currently available on Dex/AA. 0
Title Naloxone 
===Dose===  Suggested dose: 0.1 mg/kg IV push. 0
Title Neostigmine . 0
. 0
Reversal of neuromuscular blockade: 0.04 to 0.08 mg/kg IV, in addition to atropine 0.02 mg/kg. 0
was 13.1 mcg/kg in infants and 15.5 mcg/kg in children. 0
of 15% to 25%. 0
Volume of distribution of approximately 0.5 L/kg in infants and children. 0
Undergoes hydrolysis by cholinesterase and also metabolized by microsomal enzymes in the liver to 3-hydroxy-phenyl- trimethyl ammonium. 0
Renal excretion accounts for 50% of drug elimination. 0
. 0
. 0
. 0
. 0
Title Neostigmine . 0
Trough: 0.5 to 1 mcg/mL Suggested Dosing IntervalsSpecial Considerations/Preparation Available in a concentration of 100 mg/mL in 1.5 mL vials. 0
A 10 mg/mL dilution may be made by adding 1 mL of this solution to 9 mL of sterile water for injection. 0
Dilution is stable for 72 hours refrigerated. 1
, mezlocillin, nafcillin, oxacillin, penicillin G, propofol, and ticarcillin/clavulanate. 0
Trough: 0.5 to 1 mcg/mL Suggested Dosing IntervalsSpecial Considerations/Preparation Available in a concentration of 100 mg/mL in 1.5 mL vials. 0
, mezlocillin, nafcillin, oxacillin, penicillin G, propofol, and ticarcillin/clavulanate. 0
Title Nevirapine 
===Dose===  Prevention of Perinatal HIV Transmission: Birth weight 1.5 to 2 kg: 8 mg/dose orally for 3 doses in the first week of life; give first dose within 48 hours of birth, second dose 48 hours after first dose, and third dose 96 hours after second dose . 1
Birth weight greater than 2 kg: 12 mg/dose orally for 3 doses in the first week of life; give first dose within 48 hours of birth, second dose 48 hours after first dose, and third dose 96 hours after second dose . 1
All neonates born to HIV-infected women should receive 6 weeks of zidovudine prophylaxis beginning as soon as possible after birth. 1
for infants born to women who received antepartum/intrapartum antiretroviral therapy but have suboptimal viral suppression near delivery. 1
Zidovudine plus 3 doses of nevirapine is recommended for infants born to women who received only intrapartum antiretroviral therapy and for infants born to mothers who received no antepartum or intrapartum antiretroviral therapy . 1
. 0
==Pharmacology== Nevirapine is a non-nucleoside antiretroviral agent that inhibits HIV-1 replication by selectively interfering with viral reverse transcriptase without requiring intracellular metabolism. 0
Serum half-life in neonates is approximately 30 to 44 hours . 1
The 3- dose nevirapine regimen in neonates for prevention of perinatal HIV transmission provided serum concentrations above 100 ng/mL in all newborns through 10 days of life . 0
Nevirapine is extensively metabolized by, and an inducer of, hepatic CYP3A4 and CYP2B6 isoenzymes. 0
may affect plasma concentrations . 0
==Special Considerations/Preparation== Available as an oral suspension in a concentration of 10 mg/mL. 0
Title Nevirapine 
===Dose===  Prevention of Perinatal HIV Transmission: Birth weight 1.5 to 2 kg: 8 mg/dose orally for 3 doses in the first week of life; give first dose within 48 hours of birth, second dose 48 hours after first dose, and third dose 96 hours after second dose . 1
for infants born to women who received antepartum/intrapartum antiretroviral therapy but have suboptimal viral suppression near delivery. 1
==Special Considerations/Preparation== Available as an oral suspension in a concentration of 10 mg/mL. 0
Title NiCARdipine 
===Dose===  Initial dose: 0.5 mcg/kg per minute continuous IV infusion. 1
Blood pressure will begin to decrease within minutes of starting the infusion, reaching half of its ultimate decrease in approximately 45 minutes. 1
. 0
Maintenance doses are usually 0.5 to 2 mcg/kg per minute. 0
. 0
in children without significant problems, except for superficial phlebitis . 0
that can only be detected after long-term infusions. 1
==Special Considerations/Preparation== Available as 2.5-mg/mL solution for injection in 10-mL ampules. 0
Dilute prior to administration to a concentration of 0.1 mg/mL. 0
Dilution is stable at room temperature for 24 hours. 1
in dextrose or sodium chloride. 0
==Solution Compatibility== D5W, NS, and D5NS. 0
, hydrocortisone, lidocaine, linezolid, lorazepam, magnesium sulfate, metronidazole, midazolam, milrinone, morphine, nafcillin, nitroglycerin, norepinephrine, penicillin G potassium, piperacillin, potassium chloride, potassium phosphate, ranitidine, sodium acetate, sodium nitroprusside, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, and vecuronium. 0
, micafungin, sodium bicarbonate and thiopental. 0
Title NiCARdipine 
===Dose===  Initial dose: 0.5 mcg/kg per minute continuous IV infusion. 1
. 0
in children without significant problems, except for superficial phlebitis . 0
Begin at 20 ppm. 0
If within 4 hours PaO2 increases to at least 60 torr, decrease to 5 ppm. 1
Continue at 5 ppm and wean fiO2 as tolerated. 0
When fiO2 is less than 0.6 and ventilatory support has been decreased, wean iNO in 1 ppm increments at approximately 4 hour intervals as tolerated. 1
Discontinue when stable on 1 ppm for 4 hours. 1
The usual length of treatment is less than 4 days. 1
Infants who cannot be weaned off after 4 days should undergo further diagnostic testing for other diseases. 1
. 0
associated with clinical or echocardiographic evidence of pulmonary hypertension. 0
Available evidence does not support the use in preterm infants less than 34 weeks GA . 1
The risks of methemoglobinemia and elevated NO2 levels increase significantly at doses greater than 20 ppm. 0
Normal methemoglobin levels are less than 1%. 0
In most neonatal studies, methemoglobinemia was defined as levels of 5% to 7%. 0
Cyanosis develops at levels of 10%, although the patients generally remain asymptomatic. 0
At methemoglobin levels approaching 30%, patients begin to experience respiratory distress, and cardiac, gastrointestinal, and neurologic symptoms. 0
A methemoglobin level greater than 50% is usually lethal. 0
is a selective pulmonary vasodilator that decreases extrapulmonary right-to-left shunting. 1
Measure blood methemoglobin concentration 4 hours after initiation of therapy and at 24 hour intervals thereafter. 1
Monitoring of inspired gas must provide for continuous measurement of both NO and NO2 concentrations, with a feedback mechanism that cuts off delivery if NO or NO2 exceed acceptable limits. 0
and 800 ppm concentrations. 0
When fiO2 is less than 0.6 and ventilatory support has been decreased, wean iNO in 1 ppm increments at approximately 4 hour intervals as tolerated. 1
Title Nizatidine 
===Dose===  Oral: 2 to 5 mg/kg/dose orally every 12 hours. 1
==Pharmacology== Inhibits gastric acid secretion by histamine H2 -receptor antagonism. 0
Peak serum concentration occurs 0.5 to 3 hours after oral administration and is not influenced by food. 1
Greater than 90% eliminated in the urine within 12 hours with 60% excreted unchanged. 1
Elimination half-life in neonates is 3 to 7 hours, and is prolonged in preterm infants and patients with renal insufficiency. 1
is supplied in 480 mL bottles. 0
Title Nizatidine 
===Dose===  Oral: 2 to 5 mg/kg/dose orally every 12 hours. 1
is supplied in 480 mL bottles. 0
Title Norepinephrine 
===Dose===  Septic Shock Gestational age greater than 35 weeks: Initial dose, 0.2 to 0.5 mcg/kg/min by IV infusion; titrate every 30 minutes to target blood pressure. 1
Usual Infusion rate 0.2 to 2 mcg/kg/min; higher rates may be required . 0
==Administration== Must be diluted before infusion and administered via central venous route at a concentration of 16 to 100 mcg/mL . 0
that has not responded to fluid therapy and dopamine/dobutamine. 0
Norepinephrine was started via central venous catheter at 0.2 to 0.5 mcg/kg/min and titrated every 30 minutes to target mean blood pressure; maximum individual infusion rate was 7.1 mcg/kg/min. 1
The mortality rate was 18% . 0
demonstrated that norepinephrine improved lung function in neonates with PPHN having low systemic blood pressure and reduced cardiac output despite fluid resuscitation. 0
; the maximum infusion rate was 1 mcg/kg/min. 0
==Monitoring== Monitor blood pressure every 2 minutes from start of administration until target blood pressure is obtained and every 5 minutes thereafter until infusion is discontinued. 1
For a full- term newborn, the target heart rate and perfusion pressure are 120 to 180 beats/min and 55 mmHg, respectively . 0
==Special Considerations/Preparation== Available for IV infusion in 4-mL ampules containing 1 mg/mL. 0
since dextrose-containing solutions protect against excessive oxidation and subsequent potency loss Administration in saline alone is not recommended . 0
Final concentration of 100 mcg/mL ==Solution Compatibility== D5W, D5NS, NS, LR Terminal Injection Site Compatibility Norepinephrine 0.004 mg/mL: Famotidine 0.2 mg/mL, vasopressin 0.2 units/mL, 20 units/10 mL, and 40 units/10 mL. 0
Norepinephrine 0.016 mg/mL: Propofol 10 mg/mL, vasopressin 0.2 units/mL. 0
Norepinephrine 0.02 mg/mL: Clonidine 0.018 mg/mL. 0
Norepinephrine 0.032 mg/mL: Dobutamine 2 mg/mL, dopamine 3.2 mg/mL, epinephrine 0.008 mg/mL. 0
Norepinephrine 0.064 mg/mL: Dopamine 3.2 mg/mL, esmolol 40 mg/mL, labetalol 5 mg/mL, midazolam 1 mg/mL, milrinone 0.4 mg/mL, morphine 1 mg/mL. 0
Norepinephrine 0.1 mg/mL: Dobutamine 10 mg/mL. 0
Norepinephrine 0.12 mg/mL: Bivalirudin 5 mg/mL, cisatracurium 0.1, 2, and 5 mg/mL, dexmedetomidine 4 mcg/mL, diltiazem 1 mg/mL. 0
Norepinephrine 0.128 mg/mL: Argatroban 1 mg/mL, caspofungin 0.5 and 0.7 mg/mL, daptomycin 10 mg/mL, diltiazem 1 mg/mL, dobutamine 4 mg/mL, dopamine 3.2 mg/mL, epinephrine 0.02 mg/mL, ertapenem 20 mg/mL, fentanyl citrate 50 mcg/mL, granisetron 50 mcg/mL, heparin 100 units/mL, hydromorphone 1 mg/mL, labetalol 2 mg/mL, linezolid 2 mg/mL, lorazepam 0.5 mg/mL, methotrexate 15 mg/mL, metronidazole 5 mg/mL, micafungin 1.5 mg/mL, midazolam 2 mg/mL, milrinone 0.2 mg/mL, morphine 2 mg/mL, mycophenolate mofetil 6 mg/mL, nicardipine 1 mg/mL, nitroglycerin 0.4 mg/mL, octreotide acetate 5 mcg/mL, ondansetron 1 mg/mL, palonosetron 50 mcg/mL, pancuronium 0.1 mg/mL, piperacillin/tazobactam 40 and 5 mg/mL, ranitidine 1 mg/mL, tacrolimus 20 mcg/mL, vecuronium 1 mg/mL, voriconazole 4 mg/mL. 0
, methyldopate 25 mg/mL, methylprednisolone 125 mg/mL, metoclopramide 2.5 mg/mL, metoprolol 0.5 mg/mL, midazolam 2.5 mg/mL, morphine 4 mg/mL, nafcillin 250 mg/mL, nalbuphine 10 mg/mL, naloxone 16 mcg/mL, netilmicin 50 mg/mL, nitroglycerin 1.6 mg/mL, ondansetron 1 mg/mL, oxacillin 160 mg/mL, papaverine 15 mg/mL, penicillin G potassium 500,000 units/mL, penicillin G sodium 500,000 units/mL, phentolamine 5 mg/mL, phenylephrine 4 mg/mL, piperacillin 320 mg/mL, potassium chloride 1 mEq/mL, procainamide 250 mg/mL, prochlorperazine 2.5 mg/mL, propranolol 0.5 mg/mL, protamine 5 mg/mL, pyridoxine 50 mg/mL, ranitidine 2 mg/mL, succinylcholine 8 mg/mL, ticarcillin/clavulanate 195 mg/mL, tobramycin 6.4 mg/mL, vancomycin 20 mg/mL, vasopressin 4 units/mL, verapamil 1.25 mg/mL. 0
Norepinephrine 1 mg/mL: Argatroban 1 mg/mL, dobutamine 10 mg/mL, epinephrine 0.5 and 1 mg/mL, heparin 1 unit/mL, hydrocortisone 0.01 mg/mL, meropenem 1 and 50 mg/mL, mycophenolate mofetil 5.9 mg/mL, potassium chloride 0.04 mEq/mL, propofol 10 mg/mL. 0
Trissel’s™ 2 Clinical Pharmaceutics Database, version updated on 12/15/2012. 0
Title Norepinephrine 
===Dose===  Septic Shock Gestational age greater than 35 weeks: Initial dose, 0.2 to 0.5 mcg/kg/min by IV infusion; titrate every 30 minutes to target blood pressure. 1
==Administration== Must be diluted before infusion and administered via central venous route at a concentration of 16 to 100 mcg/mL . 0
Norepinephrine 0.032 mg/mL: Dobutamine 2 mg/mL, dopamine 3.2 mg/mL, epinephrine 0.008 mg/mL. 0
Norepinephrine 0.064 mg/mL: Dopamine 3.2 mg/mL, esmolol 40 mg/mL, labetalol 5 mg/mL, midazolam 1 mg/mL, milrinone 0.4 mg/mL, morphine 1 mg/mL. 0
, methyldopate 25 mg/mL, methylprednisolone 125 mg/mL, metoclopramide 2.5 mg/mL, metoprolol 0.5 mg/mL, midazolam 2.5 mg/mL, morphine 4 mg/mL, nafcillin 250 mg/mL, nalbuphine 10 mg/mL, naloxone 16 mcg/mL, netilmicin 50 mg/mL, nitroglycerin 1.6 mg/mL, ondansetron 1 mg/mL, oxacillin 160 mg/mL, papaverine 15 mg/mL, penicillin G potassium 500,000 units/mL, penicillin G sodium 500,000 units/mL, phentolamine 5 mg/mL, phenylephrine 4 mg/mL, piperacillin 320 mg/mL, potassium chloride 1 mEq/mL, procainamide 250 mg/mL, prochlorperazine 2.5 mg/mL, propranolol 0.5 mg/mL, protamine 5 mg/mL, pyridoxine 50 mg/mL, ranitidine 2 mg/mL, succinylcholine 8 mg/mL, ticarcillin/clavulanate 195 mg/mL, tobramycin 6.4 mg/mL, vancomycin 20 mg/mL, vasopressin 4 units/mL, verapamil 1.25 mg/mL. 0
Norepinephrine 1 mg/mL: Argatroban 1 mg/mL, dobutamine 10 mg/mL, epinephrine 0.5 and 1 mg/mL, heparin 1 unit/mL, hydrocortisone 0.01 mg/mL, meropenem 1 and 50 mg/mL, mycophenolate mofetil 5.9 mg/mL, potassium chloride 0.04 mEq/mL, propofol 10 mg/mL. 0
Trissel’s™ 2 Clinical Pharmaceutics Database, version updated on 12/15/2012. 0
Title Nystatin 
===Dose===  Topical: Apply ointment or cream to affected area every 6 hours. 1
Continue treatment for 3 days after symptoms have subsided. 1
of 100,000-units/mL suspension divided and applied with swab to each side of mouth every 6 hours. 0
Prophylaxis: 1 mL of 100,000 units/mL suspension orally or instilled into stomach via oro/nasogastric tube 3 times per day. 0
==Special Considerations/Preparation== Topical ointment/cream: 100,000 units/g in 15- and 30-g tubes. 0
Topical powder: 100,000 units/g in 15- and 30-g plastic squeeze bottles. 0
Oral suspension: 100,000 units/mL in 5-, 60-, and 480-mL bottles. 0
Contains less than 1% alcohol, saccharin, and 50% sucrose. 0
Title Nystatin 
===Dose===  Topical: Apply ointment or cream to affected area every 6 hours. 1
Oral suspension: 100,000 units/mL in 5-, 60-, and 480-mL bottles. 0
Title Octreotide 
===Dose===  Treatment of hyperinsulinemic hypoglycemia: Initial dose: 1 mcg/kg/dose every 6 hours subQ or IV. 1
Initial response should occur within 8 hours; tachyphylaxis may occur within several days. 1
Maximum dose: 10 mcg/kg/dose every 6 hours. 1
Treatment of chylothorax: Begin at 1 mcg/kg/hour IV continuous infusion. 1
Titrate upward as necessary based on reduction in chyle production; dosage increases of 1 mcg/kg/hour every 24 hours have been used. 1
Infusion is decreased gradually over 2 to 7 days. 1
Maximum dose: 10 mcg/kg/hour. 0
The elimination half-life of octreotide from plasma is approximately 1.7 hours in adults compared with 1 to 3 minutes for the natural hormone. 1
. 0
==Special Considerations/Preparation== Available in 1-mL single-dose ampules for injection containing 50-, 100-, or 500-mcg, and in 5-mL multiple-dose vials in concentrations of 200 and 1000 mcg/mL. 0
pH 3.9 to 4.5. 0
Osmolarity is 279 mOsm/kg. 1
After initial use, multiple dose vials should be discarded within 14 days. 1
For continuous IV administration, consider making a dilution of 10 to 25 mcg/mL using D5W or NS. 0
Title Octreotide 
===Dose===  Treatment of hyperinsulinemic hypoglycemia: Initial dose: 1 mcg/kg/dose every 6 hours subQ or IV. 1
The elimination half-life of octreotide from plasma is approximately 1.7 hours in adults compared with 1 to 3 minutes for the natural hormone. 1
Title Omeprazole 
===Dose===  0.5 to 1.5 mg/kg/dose orally once daily. 0
treatment of documented reflux esophagitis or duodenal ulcer refractory to conventional therapy. 1
Onset of action is within one hour of administration, maximal effect is at approximately 2 hours. 1
is supplied as a 20-mg powder for suspension packet. 0
A 2-mg/mL concentration can be prepared by reconstituting up to a total volume of 10 mL with water. 0
was stable under refrigeration for at least 45 days. 0
In another study, suspensions of 0.6 to 4 mg/mL were stable under refrigeration for up to 28 days; suspensions of 1 to 4 mg/mL were stable at room temperature for 7 days, with a yellow color change. 0
and as delayed-release capsules containing 10, 20, or 40-mg omeprazole as enteric-coated granules. 0
. 0
Stir and leave 2 to 3 minutes to thicken. 1
Stir and administer appropriate patient- specific dose within 30 minutes. 1
. 0
Shake syringe immediately and leave 2 to 3 minutes to thicken. 1
Shake syringe and inject patient-specific dose through the tube within 30 minutes. 1
Title Omeprazole 
===Dose===  0.5 to 1.5 mg/kg/dose orally once daily. 0
and as delayed-release capsules containing 10, 20, or 40-mg omeprazole as enteric-coated granules. 0
Title Oseltamivir 
===Dose===  Influenza, Treatment: Postmenstrual age less than 38 weeks: 1 mg/kg/dose orally twice daily for 5 days . 1
Longer treatment may be necessary for patients who remain severely ill after 5 days of treatment . 1
Postmenstrual age 38 to 40 weeks: 1.5 mg/kg/dose orally twice daily for 5 days . 1
Postmenstrual age greater than 40 weeks: 3 mg/kg/dose orally twice daily for 5 days . 1
Treatment should not wait for laboratory confirmation of influenza, but instead be initiated as soon as possible after the onset of symptoms , including patients seeking medical attention more than 48 hours after onset of symptoms. 1
The duration of therapy is 5 days , but a longer treatment duration may be considered in patients who remain severely ill after 5 days of treatment. 1
with no reported safety concerns . 0
Bioavailability is approximately 75%. 1
. 0
. 0
Elimination half-life ranges from 1 to 3 hours . 1
. 0
Oral Suspension In July 2011, the manufacturer changed the commercially available suspension concentration from 12 mg/mL to 6 mg/mL. 0
There were no quality issues with the 12 mg/mL product; therefore, the 12 mg/mL suspension may remain in the marketplace and in state or national stockpiles until such supplies expire. 0
The 12 mg/mL concentration will no longer be marketed after current supplies run out . 0
To reconstitute oral suspension, add 55 mL of water to bottle and shake well for 15 seconds. 0
The oral suspension has a concentration of 6 mg/mL after reconstitution. 0
Stable for 17 days refrigerated or 10 days if stored at room temperature . 1
Oseltamivir oral suspension contains 2 g of sorbitol per 75 mg dose, which exceeds the maximum daily sorbitol limit in patients with hereditary fructose intolerance, and may cause dyspepsia and diarrhea in these patients . 0
oral suspension, the suspension can be compounded using oseltamivir 75 mg capsules. 0
and total volume adequate for 1 patient for a 5-day course of treatment or a 10-day course of prophylaxis. 0
For a dose of 15 mg or less, total volume is 37.5 mL; for 30 mg, total volume is 75 mL; for 45 mg, total volume is 100 mL; for 60 mg, total volume is 125 mL; for 75 mg, total volume is 150 mL. 0
. 0
. 0
or for 5 days at room temperature. 1
with no reported safety concerns . 0
Oseltamivir oral suspension contains 2 g of sorbitol per 75 mg dose, which exceeds the maximum daily sorbitol limit in patients with hereditary fructose intolerance, and may cause dyspepsia and diarrhea in these patients . 0
and total volume adequate for 1 patient for a 5-day course of treatment or a 10-day course of prophylaxis. 0
Title Oxacillin 
===Dose===  Usual dosage: 25 mg/kg/dose IV over at least 10 minutes. 1
Meningitis: 50 mg/kg/dose IV over at least 10 minutes. 1
==Special Considerations/Preparation== Available as powder injection in 250-mg, 500-mg, 1-g, 2-g, and 10-g vials. 0
Reconstitute 250 mg vial with 5 mL of sterile water for injection to make a concentration of 50 mg/mL. 0
Reconstituted solution is stable for 4 days at room temperature, 7 days refrigerated. 1
Dilute further using sterile water or NS to a concentration less than or equal to 40 mg/mL. 0
Dilution stable for 4 days refrigerated. 1
Title Oxacillin 
===Dose===  Usual dosage: 25 mg/kg/dose IV over at least 10 minutes. 1
Title PENTobarbital 
===Dose===  2 to 6 mg/kg IV slow push. 1
and unknown in neonates. 0
Serum concentration for sedation: 0.5 to 3 mcg/mL. 0
==Special Considerations/Preparation== Available as a 50-mg/mL solution in 20 mL and 50 mL multidose vials. 0
Solution contains propylene glycol 40%, and alcohol 10%. 0
Irritating to veins; pH is 9.5. 0
A 5-mg/mL dilution may be made by adding 1 mL of the 50-mg/mL solution to 9 mL of preservative-free normal saline. 0
Title PENTobarbital 
===Dose===  2 to 6 mg/kg IV slow push. 1
Title PHENobarbital 
===Dose===  Anticonvulsant: Loading dose: 20 mg/kg IV, given slowly over 10 to 15 minutes. 1
Refractory seizures: Additional 5-mg/kg doses, up to a total of 40 mg/kg. 0
Maintenance: 3 to 4 mg/kg per day beginning 12 to 24 hours after the load. 1
. 0
Neonatal Abstinence Syndrome: Loading dose: 16 mg/kg orally on day 1. 1
Maintenance: 1 to 4 mg/kg/dose orally every 12 hours. 1
Based on abstinence scoring, weaning can be achieved by decreasing dose 20% every other day. 1
. 0
Phenobarbital sodium can be diluted to 10 mg/mL in normal saline prior to administration . 0
Oral:The intravenous formulation of phenobarbital, diluted to 10 mg/mL, has been used orally. 0
. 0
May enhance bile excretion in patients with cholestasis before 99Tc-IDA scanning. 0
Approximately 30% protein bound. 1
Serum half-life in neonates is 40 to 200 hours. 1
==Adverse Effects== Sedation at serum concentrations above 40 mcg/mL. 0
Respiratory depression at concentrations above 60 mcg/mL. 0
Irritating to veins - pH is approximately 10 and osmolality is approximately 15,000 mOsm/kg H2O. 1
is often needed. 1
Therapeutic serum concentration is 15 to 40 mcg/mL. 0
In infants with neonatal abstinence syndrome, serum concentrations of 20 to 30 mcg/mL are associated with adequate symptom control. 0
alcohol and 67.8% propylene glycol. 0
Phenobarbital sodium, diluted to 10 mg/mL in normal saline, was stable for 4 weeks under refrigeration . 0
Oral solution is available in 20 mg/5 mL concentration; contains 13.5 % alcohol. 0
into a fine powder. 0
Mix 30 mL of Ora-Plus with 30 mL of either Ora-Sweet or Ora-Sweet SF. 0
Add 15 mL to phenobarbital powder and triturate. 0
Transfer suspension to 2-ounce amber plastic bottle and fill to final volume of 60 mL with Ora-Plus/Ora-Sweet mixture. 0
Label "shake well before use"; suspension stable for 115 days at room temperature . 1
Title PHENobarbital 
===Dose===  Anticonvulsant: Loading dose: 20 mg/kg IV, given slowly over 10 to 15 minutes. 1
Phenobarbital sodium can be diluted to 10 mg/mL in normal saline prior to administration . 0
Phenobarbital sodium, diluted to 10 mg/mL in normal saline, was stable for 4 weeks under refrigeration . 0
Title Palivizumab 
===Dose===  15 mg/kg per dose IM, preferably in the anterolateral aspect of the thigh. 0
. 0
Risk factors include child care attendance or a sibling less than 5 years of age. 1
Once an infant qualifies for initiation of prophylaxis, it should continue throughout the RSV season, with the exception of infants 32 to less than 35 weeks gestation. 1
antibody sequences inhibits RSV replication. 0
The mean half-life of Synagis ®is approximately 20 days. 1
Adequate antibody titers are maintained in most infants for one month following a 15- mg/kg dose. 1
may not maintain optimal RSV titers for the entire initial month until after the second dose. 0
. 0
==Special Considerations/Preparation== Synagis® is supplied as 50-mg and 100-mg single-dose vials in ready-to-use, NO RECONSTITUTION required, liquid solution. 0
. 0
Title Palivizumab 
===Dose===  15 mg/kg per dose IM, preferably in the anterolateral aspect of the thigh. 0
Adequate antibody titers are maintained in most infants for one month following a 15- mg/kg dose. 1
. 0
Title Pancuronium  IV push, as needed for paralysis. 1
Usual dosing interval is 1 to 2 hours. 1
Partially hydroxylated by the liver, 40% excreted unchanged in urine. 0
Onset of action is 1 to 2 minutes; duration varies with dose and age. 1
. 0
benzyl alcohol. 0
Product maintains full clinical potency for 6 months if kept at room temperature or 36 months when refrigerated. 1
Stable for 48 hours when further diluted in compatible solution. 0
==Solution Compatibility== D5W, NS, and Lactated Ringer's. 0
Title Pancuronium  IV push, as needed for paralysis. 1
Title Papaverine 
===Dose===  30 mg per 250 mL of arterial catheter infusion solution. 0
. 0
==Special Considerations/Preparation== Supplied as 30-mg/mL solution for injection in 2-mL preservative-free vials and 10-mL multiple dose vials containing 0.5% chlorobutanol as a preservative. 0
Vials also contain edetate disodium 0.005%. 0
==Solution Compatibility== NS, 0.45 NS, both with 1 unit/mL heparin. 0
Title Papaverine 
===Dose===  30 mg per 250 mL of arterial catheter infusion solution. 0
. 0
==Solution Compatibility== NS, 0.45 NS, both with 1 unit/mL heparin. 0
Title Penicillin G 
===Dose===  »Use only aqueous crystalline penicillin G for IV administration« Bacteremia: 25,000 to 50,000 units/kg/dose IV infusion over 15 minutes, or IM. 0
Meningitis: 75,000 to 100,000 units/kg/dose IV infusion over 30 minutes, or IM. 1
Also recommended in infants who have a normal physical examination and a serum quantitative nontreponemal titer the same or less than fourfold the maternal titer and the:  mother was not treated, inadequately treated, or has no documentation of having received treatment;  mother was treated with erythromycin or another non-penicillin regimen; OR  mother received treatment less than 4 weeks before delivery ==Pharmacology== Inhibits synthesis of bacterial cell wall. 1
Significant CNS toxicity has been reported in adults with renal failure who developed CSF concentrations greater than 10 mcg/mL. 0
sodium per 1 million units. 0
sodium per 1 million units. 0
Reconstitute the 5-million unit vial with 8 mL sterile water for injection to make a final concentration of 500,000 units/mL. 0
Reconstituted solution good for 7 days refrigerated. 0
A 100,000 unit/mL dilution may be made by adding 10 mL of reconstituted solution to 40 mL sterile water for injection. 0
Dilution stable for 7 days refrigerated. 1
Penicillin G sodium reconstituted solution stable for 3 days in refrigerator. 0
Penicillin G potassium is also available as a premixed frozen iso-osmotic solution containing 1, 2 or 3 million units in 50 mL. 0
1 million units is the equivalent of 600 mg.
 Acyclovir, amikacin, amiodarone, caffeine citrate, calcium chloride, calcium gluconate, cefotaxime, cefoxitin, chloramphenicol, cimetidine, clindamycin, dopamine, enalaprilat, erythromycin lactobionate, esmolol, fluconazole, furosemide, gentamicin, heparin, hydrocortisone succinate, lidocaine, magnesium sulfate, metronidazole, morphine, nicardipine, potassium chloride, prostaglandin E1, ranitidine and sodium bicarbonate. 0
Title Penicillin G 
===Dose===  »Use only aqueous crystalline penicillin G for IV administration« Bacteremia: 25,000 to 50,000 units/kg/dose IV infusion over 15 minutes, or IM. 0
Significant CNS toxicity has been reported in adults with renal failure who developed CSF concentrations greater than 10 mcg/mL. 0
Title Penicillin G benzathine 
===Dose===  Congenital Syphilis: 50,000 units/kg/dose IM as a single dose. 0
Recommended as an alternative to aqueous crystalline penicillin G or procaine penicillin G in infants who have a normal physical examination and a serum quantitative nontreponemal titer the same or less than fourfold the maternal titer and the:  mother was not treated, inadequately treated, or has no documentation of having received treatment;  mother was treated with erythromycin or another non-penicillin regimen; OR  mother received treatment less than 4 weeks before delivery. 1
and mother has no evidence of reinfection or relapse. 0
, no treatment is required; however, it may be considered if follow-up is not assured. 0
Approximately 60% bound to serum protein. 1
==Special Considerations/Preparation== Available in a concentration of 600,000 units/mL in 1-, 2-, and 4-mL syringes. 0
Title Penicillin G benzathine 
===Dose===  Congenital Syphilis: 50,000 units/kg/dose IM as a single dose. 0
Recommended as an alternative to aqueous crystalline penicillin G or procaine penicillin G in infants who have a normal physical examination and a serum quantitative nontreponemal titer the same or less than fourfold the maternal titer and the:  mother was not treated, inadequately treated, or has no documentation of having received treatment;  mother was treated with erythromycin or another non-penicillin regimen; OR  mother received treatment less than 4 weeks before delivery. 1
Title Penicillin G procaine 
===Dose===  Congenital Syphilis: 50,000 units/kg/dose IM once daily for 10 days. 0
Also recommended as an alternative to aqueous crystalline penicillin G in infants who have a normal physical examination and a serum quantitative nontreponemal titer the same or less than fourfold the maternal titer and the:  mother was not treated, inadequately treated, or has no documentation of having received treatment;  mother was treated with erythromycin or another non-penicillin regimen; OR  mother received treatment less than 4 weeks before delivery. 1
Dissolves slowly at site of injection, with maximum blood level at approximately 4 hours, declining slowly over a period of 15 to 20 hours. 1
Approximately 60% to 90% of a dose is excreted in the urine within 24 to 36 hours. 1
Title Penicillin G procaine 
===Dose===  Congenital Syphilis: 50,000 units/kg/dose IM once daily for 10 days. 0
Also recommended as an alternative to aqueous crystalline penicillin G in infants who have a normal physical examination and a serum quantitative nontreponemal titer the same or less than fourfold the maternal titer and the:  mother was not treated, inadequately treated, or has no documentation of having received treatment;  mother was treated with erythromycin or another non-penicillin regimen; OR  mother received treatment less than 4 weeks before delivery. 1
Title Phentolamine 
===Dose===  Inject a 0.5-mg/mL solution of phentolamine subcutaneously into the affected area. 0
Usual amount needed is 1 to 5 mL, depending on the size of the infiltrate. 0
Biological half-life when injected subcutaneously is less than 20 minutes. 1
Consider using topical 2% nitroglycerin ointment if affected extremity is significantly swollen. 0
==Special Considerations/Preparation== Available in 5-mg vial as a lyophilized powder. 0
Reconstitute one vial with 1 mL of normal saline. 0
Dilute to a concentration of 0.5 mg/mL with 9 mL normal saline. 0
Title Phentolamine 
===Dose===  Inject a 0.5-mg/mL solution of phentolamine subcutaneously into the affected area. 0
==Special Considerations/Preparation== Available in 5-mg vial as a lyophilized powder. 0
===Dose===  1 drop instilled in the eye at least 10 minutes prior to funduscopic procedures. 0
Use only the 2.5% ophthalmic solution in neonates. 0
Mydriasis begins within 5 minutes of instillation and lasts for 60 minutes. 1
The use of 10% solutions has caused systemic hypertension and tachycardia in infants. 0
==Special Considerations/Preparation== Supplied as ophthalmic solution in 0.12%, 2.5%, and 10% concentrations in 2 to 15 mL quantities. 0
is commercially available in 2- and 8-mL Drop-tainers. 0
Use within 24 hours, as the solution contains no preservatives. 1
===Dose===  1 drop instilled in the eye at least 10 minutes prior to funduscopic procedures. 0
Title Phenytoin 
===Dose===  Loading dose: 15 to 20 mg/kg IV infusion over at least 30 minutes. 1
Maintenance dose: 4 to 8 mg/kg every 24 hours IV slow push, or orally. 1
. 0
Maximum rate of infusion 0.5 mg/kg per minute. 1
in pediatric patients because of the risk of severe hypotension and cardiac arrhythmias. 0
Serum half-life is 18 to 60 hours. 1
85% to 90% protein bound. 0
. 0
==Monitoring== Monitor electrocardiogram, blood pressure, and respiratory function continuously during infusion, and for 15 minutes to 1 hour after infusion . 1
Follow serum concentration closely: therapeutic range is 6 to 15 mcg/mL in the first weeks, then 10 to 20 mcg/mL due to changes in protein binding. 0
Obtain initial trough level 48 hours after IV loading dose. 1
==Special Considerations/Preparation== Injectable solution available in a concentration of 50 mg/mL. 0
. 0
Oral suspension available in a concentration of 25 mg/mL . 0
Solution Incompatibility D5W and D10W. 0
Amikacin, cefepime, ceftazidime, chloramphenicol, clindamycin, dobutamine, enalaprilat, fentanyl, heparin, hyaluronidase, hydrocortisone succinate, insulin, lidocaine, linezolid, methadone, micafungin, morphine, nitroglycerin, pentobarbital, potassium chloride, procainamide, propofol, sodium bicarbonate, and vitamin K1. 0
Title Phenytoin 
===Dose===  Loading dose: 15 to 20 mg/kg IV infusion over at least 30 minutes. 1
==Special Considerations/Preparation== Injectable solution available in a concentration of 50 mg/mL. 0
Amikacin, cefepime, ceftazidime, chloramphenicol, clindamycin, dobutamine, enalaprilat, fentanyl, heparin, hyaluronidase, hydrocortisone succinate, insulin, lidocaine, linezolid, methadone, micafungin, morphine, nitroglycerin, pentobarbital, potassium chloride, procainamide, propofol, sodium bicarbonate, and vitamin K1. 0
Title Piperacillin 
===Dose===  50 to 100 mg/kg/dose IV infusion by syringe pump over 30 minutes, or IM. 1
==Monitoring== Desired peak serum concentration is approximately 150 mcg/mL. 0
. 0
==Special Considerations/Preparation== Available as powder for injection in 2-g, 3-g, 4-g, and 40-g vials. 0
Reconstitute 2-g vial with 10 mL of sterile water for injection to make a final concentration of 200 mg/mL. 0
Reconstituted solution stable for 24 hours at room temperature, 2 days refrigerated. 1
A 50 mg/mL dilution may be made by adding 2.5 mL of reconstituted solution to 7.5 mL sterile water for injection. 0
Dilution stable for 2 days refrigerated. 1
IM Administration : Use 400 mg/mL concentration. 0
Title Piperacillin 
===Dose===  50 to 100 mg/kg/dose IV infusion by syringe pump over 30 minutes, or IM. 1
Title Piperacillin/Tazobactam  IV infusion. 1
==Pharmacology== Zosyn® combines the extended-spectrum antibiotic piperacillin with the beta-lactamase inhibitor tazobactam in a 8:1 ratio. 0
The mean half-life of piperacillin and tazobactam in neonates is approximately 1.5 hours. 1
in 2.25-g, 3.375-g, and 4.5-g single-dose vials. 0
is not available. 0
The entire contents of the single-dose vial should be withdrawn and further diluted to 10 to 40 mg/mL with a compatible solution prior to withdrawing the desired patient-specific dose. 0
The 40.5 g pharmacy bulk vial, when reconstituted as directed by the manufacturer, has a known final concentration of 200 mg/mL. 0
The desired dose should be further diluted to 10 to 40 mg/mL with a compatible solution prior to administration. 0
Maximum concentration 80 mg/mL. 0
Reconstituted solution stable for 24 hours at room temperature, 48 hours refrigerated. 1
of sodium, respectively. 0
as 2.25 g/50 mL, 3.375 g/50 mL, and 4.5 g/100 mL. 0
==Solution Compatibility== D5W, D10W, NS and LR. 0
Title Piperacillin/Tazobactam  IV infusion. 1
in 2.25-g, 3.375-g, and 4.5-g single-dose vials. 0
, 4 months, 6 months, and 12 to 15 months of age . 1
The recommended dosing interval is 4 to 8 weeks . 1
in children 6 weeks to less than 59 months of age. 1
. 0
PCV13 is a sterile suspension of saccharides of the capsular antigens of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to diphtheria CRM197 protein. 0
The increased antigenic load of PCV13 did not interfere with immune responses against other vaccines given concurrently nor did it increase vaccine reactogenicity during clinical trials. 0
Each dose contains 0.125 mg aluminum as aluminum phosphate adjuvant. 0
after each injection. 0
. 0
==Special Considerations/Preparation== Prevnar 13™ is supplied in 0.5-mL single-dose, latex-free, pre-filled syringes. 0
, 4 months, 6 months, and 12 to 15 months of age . 1
. 0
Title Poliovirus Vaccine Enhanced-Inactivated 
===Dose===  0.5 mL IM or subQ x 4 doses at 2, 4, 6 to 18 months of age, and at 4 to 6 years of age. 1
First dose may be given at 6 weeks of age if needed . 1
==Uses== Immunoprophylaxis against poliomyelitis caused by poliovirus types 1, 2 and 3 in infants 6 weeks or older, children, and adults . 0
Contraindications/Precautions Contraindicated in patients with anaphylaxis or shock within 24 hours after dose, or to any component of the vaccine which includes neomycin, streptomycin, polymyxin B, formaldehyde, and 2-phenoxyethanol. 1
==Pharmacology== Sterile suspension of types 1, 2, and 3 poliovirus inactivated with formaldehyde. 0
, irritability, and tiredness were observed during clinical studies. 0
is a clear, colorless suspension, available in 0.5 mL single-dose syringes and multidose vial. 0
. 0
==Pharmacology== Sterile suspension of types 1, 2, and 3 poliovirus inactivated with formaldehyde. 0
Title Poly-Vi-SolÂ® MVI Drops  every 24 hours, or as directed by physician. 1
Poly-Vi-Sol® Multivitamin Drops1.151 Poractant alfa 
Title Poractant alfa 
===Dose===  Initial dose is 2.5 mL/kg per dose intratracheally, divided into 2 aliquots followed by up to two subsequent doses of 1.25 mL/kg per dose administered at 12-hour intervals if needed . 1
==Administration== For Endotracheal Tube Instillation Using a 5-French end-hole Catheter Clear the trachea of secretions. 0
Shorten a 5F end-hole catheter to 8 cm so the tip of the catheter will protrude just beyond end of ET tube above infant's carina. 0
needle. 0
Infant's ventilator settings should be changed to a rate of 40 to 60 breaths/min, inspiratory time 0.5 second, and supplemental oxygen sufficient to maintain oxygen saturation at greater than 92% immediately before administration. 1
. 0
After administration of the aliquot, the dosing catheter is removed from the ET tube and the infant is ventilated for at least 1 minute until stable. 0
needle. 0
Do not attach a 5 F end-hole catheter. 0
Administer dose over 1 minute without interrupting mechanical ventilation . 1
and 1 mg of protein including 0.3 mg of SP-B . 0
vials. 0
Unopened vials that have been warmed to room temperature one time may be refrigerated within 24 hours and stored for future use. 0
Title Poractant alfa 
===Dose===  Initial dose is 2.5 mL/kg per dose intratracheally, divided into 2 aliquots followed by up to two subsequent doses of 1.25 mL/kg per dose administered at 12-hour intervals if needed . 1
needle. 0
Title Potassium chloride . 0
1 g KCl = 13.4 mEq K+1 mEq K+= 74.6 mg KCl Acute treatment of symptomatic hypokalemia: Begin with 0.5 to 1 mEq/kg IV over 1 hour, then reassess. 0
Maximum concentration: 40 mEq/L for peripheral, 80 mEq/L for central venous infusions. 0
==Special Considerations/Preparation== Potassium chloride for injection is supplied as 2-mEq/mL solution. 0
Hyperosmolar - 4355 mOsm/kg determined by freezing-point depression. 0
pH ranges from 4 to 8 depending on buffering. 0
Various oral solutions are available, with concentrations ranging from 10 to 40 mEq per 15 mL. 0
Title Potassium chloride . 0
==Special Considerations/Preparation== Potassium chloride for injection is supplied as 2-mEq/mL solution. 0
Title Procainamide 
===Dose===  Initial bolus dose: 7 to 10 mg/kg IV. 0
Maintenance IV infusion: 20 to 80 mcg/kg per minute. 0
==Administration== Intravenous/Intraosseous: Administer loading dose over 30 to 60 minutes at a concentration of 20 mg/mL. 0
For continuous infusion, administer at a concentration of 2 to 4 mg/mL . 0
Half-life is approximately 5 hours in the term neonate, and longer in preterms. 1
, an active metabolite. 0
The drug should be discontinued if the QRS duration increases by more than 35 to 50 percent to avoid serious toxicity. 0
concentrations at 2, 12, and 24 hours after starting the loading dose infusion . 1
Therapeutic concentrations: Procainamide: 4 to 10 mcg/mL, NAPA 6 to 20 mcg/mL . 0
Sum of procainamide and NAPA: 10 to 30 mcg/mL . 0
Increasing frequency of toxicity associated with procainamide levels greater than 10 mcg/mL . 0
==Special Considerations/Preparation== Available in 10-mL vials providing 100 mg/mL or 2-mL vials providing 500 mg/mL. 0
Dilute initial bolus dose to a final concentration of 20 mg/mL prior to administration. 0
Maintenance infusion should be diluted to 2 to 4 mg/mL in compatible solution before administration . 0
, 0.45% NaCl, and NS. 0
. 0
Title Procainamide 
===Dose===  Initial bolus dose: 7 to 10 mg/kg IV. 0
==Special Considerations/Preparation== Available in 10-mL vials providing 100 mg/mL or 2-mL vials providing 500 mg/mL. 0
MF® formulated to meet target of 4 Cal/fl oz. 0
Fortifies breast milk up to 2.3 g of protein in 100 mL of nutrition. 0
MF® formulated to meet target of 6 Cal/fl oz. 0
Fortifies breast milk up to 2.8 g of protein in 100 mL of nutrition. 0
MF® formulated to meet target of 8 Cal/fl oz. 0
Fortifies breast milk up to 3.2 g of protein in 100 mL of nutrition. 0
MF® formulated to meet target of 10 Cal/fl oz. 0
Fortifies breast milk up to 3.7 g of protein in 100 mL of nutrition. 0
MF® formulated to meet target of 4 Cal/fl oz. 0
Fortifies breast milk up to 3.7 g of protein in 100 mL of nutrition. 0
1.155 Propranolol 
Title Propranolol 
===Dose===  Hypertension and Tachyarrhythmias Starting oral dose: 0.25 mg/kg per dose every 6 hours. 1
Increase as needed to maximum of 3.5 mg/kg per dose every 6 hours. 1
Starting IV dose: 0.01 mg/kg every 6 hours over 10 minutes. 1
Increase as needed to maximum of 0.15 mg/kg per dose every 6 hours. 1
Infantile Hemangiomas Usual maintenance doses have been 2 to 3 mg/kg/day orally in 3 divided doses. 0
Initial doses of 2 mg/kg/day orally in 3 divided doses have been used while some authors recommend starting at 0.3 to 1 mg/kg/day to assess tolerability and then increasing to 2 mg/kg/day incrementally over several days. 0
Therapy should continue until full involution of the lesion has occurred or until 1 year of age. 1
Tapering periods have ranged from 2 weeks to 1 month. 0
is an important consideration with regards to risks for hypoglycemia. 0
Peak serum concentration is reached approximately 2 hours after an oral dose. 1
Propranolol undergoes significant first-pass hepatic metabolism, resulting in 30% to 40% bioavailability. 0
Protein binding is 70% in neonates. 0
Infants less than 3 months of age are at increased risk. 1
. 0
Injectable form is available in 1-mL vials containing 1 mg.
 Make a 0.1 mg/mL dilution by adding 1 vial to 9 mL preservative-free normal saline. 0
Title Propranolol 
===Dose===  Hypertension and Tachyarrhythmias Starting oral dose: 0.25 mg/kg per dose every 6 hours. 1
is an important consideration with regards to risks for hypoglycemia. 0
. 0
Title Protamine 
===Dose===  ==Intravenous== Time since last heparin dose in minutes and protamine dose: Less than 30 min: 1 mg per 100 units heparin received . 1
30 to 60 min: 0.5 to 0.75 mg per 100 units heparin received . 1
60 to 120 min: 0.375 to 0.5 mg per 100 units heparin received . 0
Greater than 120 min: 0.25 to 0.375 mg per 100 units heparin received . 0
Maximum dose: 50 mg ==Administration== Administer intravenously. 0
Recommended to be given undiluted, but if necessary, may further dilute in D5W or NS. 0
should not exceed 5 mg/min . 0
. 0
in 5- and 25-mL vials. 0
Store at room temperature Can be diluted in D5W or NS if necessary . 0
Maximum dose: 50 mg ==Administration== Administer intravenously. 0
===Dose===  Prevention and Treatment of Venous Thrombosis and Purpura Fulminans associated with Protein C Deficiency: Acute Episode/Short-Term Prophylaxis: Initial dose: 100 to 120 international units/kg IV, followed by 60 to 80 international units/kg IV every 6 hours for next 3 doses . 1
Maintenance dose: 45 to 60 international units/kg IV every 6 or 12 hours . 1
===Dose===  regimen should be adjusted to maintain a target peak protein C activity of 100%. 0
After resolution of acute episode, maintain trough protein C activity level above 25% for duration of treatment. 1
Long-Term Prophylaxis: 45 to 60 international units/kg IV every 12 hours. 1
Maintain trough protein C activity level above 25% . 0
==Administration== Administer by IV infusion at a maximum rate of 0.2 mL/kg/minute . 0
One pharmacokinetic analysis determined a half-life of 4.2 to 8.3 hours and a recovery of about 44% after infusion in children. 1
. 0
. 0
. 0
. 0
international units human protein C.
 Vials should be brought to room temperature and reconstituted with 5 mL and 10 mL of sterile water for injection, respectively, to provide a concentration of 100 international units/mL. 0
Should be used within 3 hours of reconstitution. 1
When reconstituted, contains the following excipients: human albumin 8 mg/mL, trisodium citrate dihydrate 4.4 mg/mL, and sodium chloride 8.8 mg/mL. 0
Store unopened vials at 2 to 8 degrees C and protect from light. 0
Title Pyridoxine 
===Dose===  Pyridoxine-Dependent Seizures Initial diagnostic dose: 50 to 100 mg IV push, or IM . 0
Maintenance dose: 50 to 100 mg orally every 24 hours . 1
They typically present in the neonatal period or early infancy; however, seizures can occur for the first time at up to 3 years of age. 1
. 0
Title Quinupristin/Dalfopristin 
===Dose===  7.5 mg/kg/dose every 12 hours by IV infusion over 60 minutes. 1
that inhibit bacterial protein synthesis by binding to separate sites on the bacterial ribosome. 0
Serum half-life of quinupristin in adults ranges from 1 to 3 hours, and of dalfopristin ranges from 5 to 9 hours. 1
==Special Considerations/Preparation== Synercid® is supplied as a lyophilized powder in single-dose, 10-mL vials containing 500 mg or 600 mg.
 Reconstitute 500-mg and 600-mg vials by adding 5 mL or 6 mL of Sterile Water for Injection or D5W, respectively, resulting in a concentration of 100 mg/mL. 0
Reconstituted solution should be diluted within 30 minutes. 1
Before administration, dilute with D5W to a concentration of 2 mg/mL. 0
A concentration up to 5 mg/mL may be used for central lines. 0
Concentrations less than 1 mg/mL may be used if venous irritation occurs following peripheral administration. 0
Diluted solution is stable for 5 hours at room temperature, or 54 hours if stored under refrigeration. 1
==Solution Compatibility== D5W. 0
Title Quinupristin/Dalfopristin 
===Dose===  7.5 mg/kg/dose every 12 hours by IV infusion over 60 minutes. 1
Concentrations less than 1 mg/mL may be used if venous irritation occurs following peripheral administration. 0
Title Ranitidine 
===Dose===  Oral: 2 mg/kg/dose every 8 hours. 1
IV:Term: 1.5 mg/kg/dose every 8 hours slow push. 1
Preterm:0.5 mg/kg/dose every 12 hours slow push. 1
Continuous IV infusion: 0.0625 mg/kg/hour; dose range, 0.04 to 0.1 mg/kg/hour. 1
==Contraindications/Precautions== The use of H2-blockers in preterm infants has been associated with facilitating Candida species colonization , and an increased risk for late-onset bacterial and fungal sepsis . 0
. 0
. 0
Peak serum concentration occurs 1 to 3 hours after oral administration and is not influenced by food. 1
Hepatic biotransformation predominates after oral absorption, with 30% excreted unchanged in the urine. 0
In contrast, 70% of an IV dose is excreted unchanged in the urine. 0
Elimination half-life in neonates is 3 to 7 hours, and is prolonged in preterm infants and patients with renal or hepatic insufficiency. 1
==Special Considerations/Preparation== Available as a 1 mg/mL preservative-free solution for injection in 50 mL single-dose plastic containers, and a 25 mg/mL injectable solution in 2- and 6-mL vials. 0
A 2 mg/mL dilution may be made by adding 0.8 mL of the 25 mg/mL concentration to 9.2 mL preservative-free sterile water or normal saline for injection. 0
contains 7.5% alcohol. 0
Also available as 150- and 300-mg tablets. 0
May prepare oral solution by crushing a 150-mg tablet and dissolving in 30 mL of sterile water to yield a final concentration of 5 mg/mL. 0
Stable for 28 days refrigerated. 1
Acyclovir, acetazolamide, amikacin, aminophylline, ampicillin, atropine, aztreonam, cefazolin, cefepime, cefoxitin, ceftazidime, chloramphenicol, clindamycin, dexamethasone, digoxin, dobutamine, dopamine, enalaprilat, epinephrine, erythromycin lactobionate, fentanyl, fluconazole, flumazenil, furosemide, gentamicin, glycopyrrolate, heparin, insulin, isoproterenol, lidocaine, linezolid, lorazepam, meropenem, metoclopramide, midazolam, milrinone, morphine, nicardipine, nitroprusside, pancuronium bromide, penicillin G, piperacillin, piperacillin/tazobactam, potassium chloride, propofol, protamine, remifentanil, tobramycin, vancomycin, vecuronium, vitamin K1, and zidovudine. 0
Title Ranitidine 
===Dose===  Oral: 2 mg/kg/dose every 8 hours. 1
. 0
==Special Considerations/Preparation== Available as a 1 mg/mL preservative-free solution for injection in 50 mL single-dose plastic containers, and a 25 mg/mL injectable solution in 2- and 6-mL vials. 0
Acyclovir, acetazolamide, amikacin, aminophylline, ampicillin, atropine, aztreonam, cefazolin, cefepime, cefoxitin, ceftazidime, chloramphenicol, clindamycin, dexamethasone, digoxin, dobutamine, dopamine, enalaprilat, epinephrine, erythromycin lactobionate, fentanyl, fluconazole, flumazenil, furosemide, gentamicin, glycopyrrolate, heparin, insulin, isoproterenol, lidocaine, linezolid, lorazepam, meropenem, metoclopramide, midazolam, milrinone, morphine, nicardipine, nitroprusside, pancuronium bromide, penicillin G, piperacillin, piperacillin/tazobactam, potassium chloride, propofol, protamine, remifentanil, tobramycin, vancomycin, vecuronium, vitamin K1, and zidovudine. 0
Title Remifentanil 
===Dose===  Endotracheal Intubation Remifentanil alone Preterm, 29 to 32 weeks gestation: 2 mcg/kg IV bolus over 60 seconds; dose may be repeated . 1
Concomitant with midazolam Preterm, 28 to 34 weeks gestation: 1 mcg/kg IV bolus over 60 seconds . 1
doses by up to 75% may be necessary . 0
Full-term neonate weighing at least 2500 g: Maintenance rate: 0.4 mcg/kg/min IV, titrated up to 1 mcg/kg/min IV in increments of up to 50% or reduced by 25% to 50% decrements every 2 to 5 minutes for desired effect; plus nitrous oxide . 0
Supplemental bolus: 1 mcg/kg IV every 2 to 5 minutes if needed. 1
Mechanical Ventilation: Adjunct Full-term: initial rate, 0.15 mcg/kg/min IV, followed by incremental increases of 0.05 mcg/kg/min as needed up to a maximum 0.5 mcg/kg/min; use with midazolam . 0
Administer single doses over 30 to 60 seconds in non-intubated patients. 1
, during mechanical ventilation , or for a procedure in patients on mechanical ventilation . 0
. 0
. 0
The longest duration of remifentanil infusion was 5.9+/-5.7 days, with extubation time of 36+/-12 minutes after discontinuing the infusion, in 48 preterm infants with respiratory distress disease requiring mechanical ventilation . 1
were 0.075 to 0.5 mcg/kg/min and titrated up to 0.94 mcg/kg/min. 0
At the time of extubation, the rates were reduced by 50%, then discontinued after 30 minutes . 1
when undergoing laser therapy for retinopathy of prematurity. 1
in neonates administered remifentanil/midazolam and fentanyl/midazolam, respectively, in mechanically ventilated neonates and infants. 0
and a gestational age of at least 36 weeks. 1
The dose of midazolam was 0.83 mcg/kg/min, followed by incremental increases of 0.833 mcg/kg/min as needed up to a maximum of 6.67 mcg/kg/min. 0
The mean remifentanil dose was 0.23 +/- 0.08 mcg/kg/min . 0
Due to concomitant anesthetics, respiratory depression may occur up to 30 minutes after discontinuation of remifentanil . 0
in neonates due to their inability to respond to verbal commands to breathe deeply . 0
Pharmacokinetics fit a 3-compartment model, with a central Vd of 100 mL/kg and a steady-state Vd of 350 mL/kg. 0
Rapid and slow distribution half-life are 1 and 6 minutes, respectively. 1
Approximately 70% protein bound, the majority to alpha- 1-acid-glycoprotein. 0
Terminal elimination half-life is 10 to 20 minutes, however, the effective biological half-life is 3 to 10 minutes. 1
undergoing elective surgery or diagnostic procedures; however, infants up to the age of 2 years experienced higher clearance rates compared with older children. 0
Clearance rates were 90 mL/kg/min in 5 days to 8 weeks of age infants, 92 mL/kg/min in children older than 2 months to younger than 2 years, 76 mL/kg/min in children 2 to 6 years of age, and 46 to 59.7 mL/kg/min in 7 to younger than 18 years. 1
, 307.9 mL/kg, 240.1 mL/kg, and 223 to 248.9 mL/kg, respectively. 0
. 0
were required with remifentanil and morphine infusions, respectively, in 20 ventilated premature neonates with respiratory distress syndrome . 0
. 0
: Available in 3-mL, 5-mL, and 10-mL vials containing 1 mg, 2 mg, and 5 mg, respectively, of remifentanil lyophilized powder for solution. 0
. 0
Reconstitute with 1 mL of diluent per mg of remifentanil. 0
. 0
The reconstituted solution should then be diluted to a final concentration of 20, 25, 50, or 250 mcg/mL prior to administration. 0
Stable for 24 hours at room temperature after reconstitution and further dilution. 1
A final concentration of 20 or 25 mcg/mL for pediatric patients 1 year or older is recommended . 0
==Solution Compatibility== D5W, D5LR, D5NS, NS, 0.45% sodium chloride, sterile water for injection. 0
, sulfamethoxazole/trimethoprim 4/0. 0
8 mg/mL, ticarcillin/clavulanate 31 mg/mL, tobramycin 5 mg/mL, vancomycin 10 mg/mL, zidovudine 4 mg/mL. 0
Remifentanil 0.12 mg/mL: Heparin 417 units/mL, insulin 1 unit/mL, magnesium 8 mg/mL, midazolam 1 mg/mL, potassium chloride 0.1 mEq/mL. 0
Remifentanil 0.2 mg/mL: Cefepime 120 mg/mL, ceftazidime 120 mg/mL. 0
, sulfamethoxazole/trimethoprim 4/0. 0
8 mg/mL, tacrolimus 20 mcg/mL, ticarcillin/clavulanate 31 mg/mL, tobramycin 5 mg/mL, vancomycin 10 mg/mL, vasopressin 1 unit/mL, vecuronium 1 mg/mL, voriconazole 4 mg/mL, zidovudine 4 mg/mL. 0
Remifentanil 0.5 mg/mL: Linezolid 2 mg/mL. 0
Trissel’s™ 2 Clinical Pharmaceutics Database, version updated on 06/15/2012. 0
Title Remifentanil 
===Dose===  Endotracheal Intubation Remifentanil alone Preterm, 29 to 32 weeks gestation: 2 mcg/kg IV bolus over 60 seconds; dose may be repeated . 1
Full-term neonate weighing at least 2500 g: Maintenance rate: 0.4 mcg/kg/min IV, titrated up to 1 mcg/kg/min IV in increments of up to 50% or reduced by 25% to 50% decrements every 2 to 5 minutes for desired effect; plus nitrous oxide . 0
, during mechanical ventilation , or for a procedure in patients on mechanical ventilation . 0
in neonates administered remifentanil/midazolam and fentanyl/midazolam, respectively, in mechanically ventilated neonates and infants. 0
Terminal elimination half-life is 10 to 20 minutes, however, the effective biological half-life is 3 to 10 minutes. 1
, sulfamethoxazole/trimethoprim 4/0. 0
8 mg/mL, ticarcillin/clavulanate 31 mg/mL, tobramycin 5 mg/mL, vancomycin 10 mg/mL, zidovudine 4 mg/mL. 0
Remifentanil 0.2 mg/mL: Cefepime 120 mg/mL, ceftazidime 120 mg/mL. 0
, sulfamethoxazole/trimethoprim 4/0. 0
8 mg/mL, tacrolimus 20 mcg/mL, ticarcillin/clavulanate 31 mg/mL, tobramycin 5 mg/mL, vancomycin 10 mg/mL, vasopressin 1 unit/mL, vecuronium 1 mg/mL, voriconazole 4 mg/mL, zidovudine 4 mg/mL. 0
Trissel’s™ 2 Clinical Pharmaceutics Database, version updated on 06/15/2012. 0
Title Rifampin 
===Dose===  Oral: 10 to 20 mg/kg/dose every 24 hours. 1
IV:5 to 10 mg/kg/dose every 12 hours , given via syringe pump over 30 minutes. 1
Prophylaxis for high-risk contacts of invasive meningococcal disease: 5 mg/kg per dose orally every 12 hours, for 2 days. 1
Prophylaxis for high-risk contacts of invasive H influenzae type b disease: 10 mg/kg per dose orally every 24 hours, for 4 days. 1
Nearly all of the rifampin excreted into the bile is deacetylated within 6 hours. 1
Serum half-life ranges from 1 to 3 hours. 1
Rifampin in a potent inducer of several cytochrome P450 enzymes. 0
==Special Considerations/Preparation== Available as a lyophilized powder for injection in 600-mg vials. 0
Reconstitute with 10 mL of sterile water for injection to make a final concentration of 60 mg/mL. 0
Reconstituted solution is stable for 24 hours at room temperature. 1
Further dilution is required - maximum concentration for infusion is 6 mg/mL. 0
A 3 mg/mL dilution may be made by adding 0.5 mL of reconstituted solution to 9.5 mL of NS or D5W. 0
Dilution made with NS is stable for 24 hours at room temperature. 1
Dilution made with D5 W is stable for 4 hours at room temperature. 1
of the reconstituted IV solution with 25 mL of simple syrup to make a final concentration of 10 mg/mL. 0
Suspension is stable for 4 weeks at room temperature or refrigerated. 1
Also available in 150- and 300-mg capsules. 0
Title Rifampin 
===Dose===  Oral: 10 to 20 mg/kg/dose every 24 hours. 1
Rifampin in a potent inducer of several cytochrome P450 enzymes. 0
Title Rocuronium 
===Dose===  0.3 to 0.6 mg/kg per dose IV push over 5 to 10 seconds. 1
==Pharmacology== Rocuronium is an amino steroid nondepolarizing neuromuscular blocking agent that is an analog of vecuronium with 10% to 15% of its potency. 0
The rapid distribution half-life is 1 to 2 minutes and the slower distribution half-life is 14 to 18 minutes. 1
Onset of clinical effect usually occurs within 2 minutes and the duration ranges from 20 minutes to 2 hours. 1
lead to more rapid onset and longer duration of clinical effect. 0
Average half-life in newborns is 1.1 hours. 1
Rocuronium is approximately 30% protein bound, and is primarily excreted by the liver. 1
in heart rate after intubation, whereas only 1 of 19 infants anesthetized with halothane and fentanyl who received atropine for induction experienced this magnitude of change. 1
==Special Considerations/Preparation== Zemuron® for intravenous injection is available in 5 mL and 10 mL multiple-dose vials containing 10 mg/mL. 0
Each mL contains 10 mg rocuronium bromide and 2 mg sodium acetate. 0
The solution is clear, colorless to yellow/orange, and is adjusted to isotonicity with sodium chloride and to a pH of 4 with acetic acid and/or sodium hydroxide. 0
. 0
, use within 60 days. 1
Use opened vials within 30 days. 1
To prepare a 1 mg/mL solution, dilute 1 mL of the 10 mg/mL solution up to a final volume of 10 mL with NS. 0
Title Rocuronium 
===Dose===  0.3 to 0.6 mg/kg per dose IV push over 5 to 10 seconds. 1
==Special Considerations/Preparation== Zemuron® for intravenous injection is available in 5 mL and 10 mL multiple-dose vials containing 10 mg/mL. 0
===Dose===  2 mL per dose orally . 0
The RotaTeq® vaccine is a 3-dose series with at least 4 weeks between each dose. 1
. 0
Vaccination should not be initiated for infants 15 weeks, 0 days of age and older . 1
Tear open the pouch and remove the dosing tube. 0
Clear the fluid from the dispensing tip by holding tube vertically and tapping cap. 0
Puncture the dispensing tip by screwing cap clockwise until it becomes tight, then remove the cap by turning it counterclockwise. 0
Administer dose by gently squeezing liquid into infant's mouth toward the inner cheek until dosing tube is empty . 0
in utero, administration of live vaccines, such as rotavirus vaccine, is not recommended until 6 months after the mother's last injection in pregnancy . 0
==Uses== Pediatric FDA Approved Indications Immunoprophylaxis against rotavirus gastroenteritis caused by serotypes G1, G2, G3, and G4 in children 6 weeks to 24 weeks of age . 1
in utero, administration of live vaccines, such as rotavirus vaccine, is not recommended until 6 months after the mother's last injection in pregnancy . 0
==Pharmacology== RotaTeq® is a bovine-based pentavalent vaccine containing 5 live reassortant rotaviruses. 0
from the bovine rotavirus parent strain. 0
from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain. 0
Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell-culture media, and trace amounts of fetal bovine serum. 0
of 385 subjects after dose 3. 1
In phase III studies, shedding was observed as early as 1 day and as late as 15 days after a dose. 0
It has 98% efficacy for prevention of severe illness and 74% for prevention of rotavirus-induced diarrheal episodes . 0
. 0
Analysis of these events revealed a persistent clustering of events during days 3 to 6 after administration of the first dose. 0
The estimated excess risk of intussusception was 0.74, 0.21, and -0.16 events per 100,000 vaccinated infants during the 3 to 6 day window after doses 1, 2 and 3, respectively; the overall excess risk from all 3 doses was estimated at approximately 0.79. 0
Thirty-three excess events per year are expected in the US when the rotavirus vaccine program is fully mature . 0
of Kawasaki disease did not show an elevated risk with RotaTeq® or other US-licensed vaccines . 0
In clinical studies, vaccine virus shedding was noted from 1 day to 15 days after a dose. 0
Each dosage tube contains 2 mL. 0
in utero, administration of live vaccines, such as rotavirus vaccine, is not recommended until 6 months after the mother's last injection in pregnancy . 0
of 385 subjects after dose 3. 1
In phase III studies, shedding was observed as early as 1 day and as late as 15 days after a dose. 0
. 0
===Dose===  1 mL per dose. 0
The Rotarix® vaccine is a 2-dose series with at least 4 weeks between each dose. 1
. 0
Connect transfer adapter onto vial of lyophilized vaccine. 0
. 0
Connect the oral applicator to the transfer adapter. 0
. 0
Withdraw the entire mixture back into the oral applicator. 0
Twist and remove the oral applicator from the transfer adapter. 0
. 0
. 0
, no increased risk of intussusception was observed in infants receiving Rotarix® when compared with placebo. 0
There were 6 cases of intussusception reported in the Rotarix® infants versus 7 cases in the placebo infants within 31 days after any dose . 1
were reported, with a cluster of cases occurring in the first 7 days post- vaccination. 1
Shedding of rotavirus in the stool occurs after vaccination, with peak excretion approximately on day 7 after dose 1; transmission of vaccine virus to healthy seronegative contacts was demonstrated in 1 clinical trial; consider benefit to risk when deciding to vaccinate infants with immunodeficient close contacts; handwashing is recommended after diaper changes to help prevent spreading of vaccine virus . 0
in utero, administration of live vaccines, such as rotavirus vaccine, is not recommended until 6 months after the mother's last injection in pregnancy . 0
==Pharmacology== Rotarix® is a human-derived rotavirus vaccine from the 89-12 strain, which belongs to G1P type. 0
Fecal shedding after vaccination was reported in approximately 26% of vaccinated infants, in two studies. 0
Peak excretion occurred around day 7 after the first dose. 1
Approximately 80% of Rotarix® recipients will be seroconverted one to two months after a 2-dose series . 1
placebo recipients from 16 completed or ongoing clinical trials. 0
Of the 27 cases, 5 occurred following Rotarix® in clinical trials that were either not placebo-controlled or 1:1 randomized. 0
were reported within 30 days post-vaccination. 1
in placebo-controlled trials. 0
Among recipients of Rotarix®, the time of onset after study dose ranged from 3 days to 19 months . 1
with a plunger stopper, and a transfer adapter for reconstitution. 0
Reconstituted vaccine may be stored refrigerated or at room temperature, and vaccine should be administered within 24 hours of reconstitution. 1
Discard if not used within 24 hours. 1
. 0
placebo recipients from 16 completed or ongoing clinical trials. 0
with a plunger stopper, and a transfer adapter for reconstitution. 0
Title Sildenafil . 0
and not an efficacy trial . 0
Oral: 0.5 to 2 mg/kg/dose every 6 to 12 hours . 1
Some authors have successfully used doses of 3 mg/kg/dose orally every 6 hours in term and post-term neonates . 1
According to an intervention review of the use of sildenafil in neonates with PPHN, sildenafil was associated with a significant reduction in mortality with a number need to treat to benefit of 3. 0
All studies included in the review were in resource-limited settings . 0
, oral sildenafil was more effective than magnesium sulfate in a setting without iNO or high frequency ventilation based on time to adequate effect, duration of mechanical ventilation, and use of inotropic support . 0
with pulmonary hypertension refractory to inhaled nitric oxide . 0
despite limited evidence to support its use. 0
inhibitor. 0
Oral absorption is rapid in adults with approximately 40% bioavailability; peak concentrations are reached in 30 to 120 minutes. 0
Protein binding is 94%. 1
that also has PDE5 inhibitory activity . 0
The terminal half-life of sildenafil in neonates on Day 1 of life is estimated to be 56 hours, and that of the metabolite 10 hours. 1
This compares to adult data where both sildenafil and the metabolite have terminal half-lives of 4 hours. 0
Significant increases in sildenafil concentrations may occur when used concomitantly with drugs that are CYP3A4 inhibitors: eg, fluconazole, erythromycin, amlodipine, and cimetidine . 0
, positive ocular findings were reported in 4 patients, none of which were considered drug-related . 0
==Special Considerations/Preparation== Oral Revatio® is supplied as 20-mg tablets and an oral suspension . 0
Viagra® is supplied as 25-mg, 50-mg, and 100-mg tablets. 0
Remove the cap and add 60 mL of water. 0
Shake the closed bottle for a minimum of 30 seconds. 1
Open the bottle and add an additional 30 mL of water and shake the closed bottle for another 30 seconds. 0
The prepared solution contains sildenafil 10 mg per 1 mL. 0
or in the refrigerator for up to 30 days. 1
The Revatio® oral suspension is supplied as an off-white powder for constitution, forming a white to off-white grape flavored solution, which when constituted with water as directed contains 10 mg/mL of sildenafil. 0
Available in glass bottles containing approximately 112 mL of solution after constitution; a press-in bottle adaptor and oral syringe are supplied with each bottle. 0
of sildenafil, equivalent to 0.8 mg sildenafil per mL. 0
Each mL of solution also contains 50.5 mg dextrose and water for injection . 0
25- mg tablets into a fine powder and add a 1:1 mixture of Ora-Sweet® and Ora-Plus® or methylcellulose 1% and Simple Syrup, NF to make a final concentration of 2.5 mg/mL. 0
Suspension is stable for 91 days in plastic bottles at 4 and 25 degrees C . 1
Title Sildenafil . 0
1.168 Sodium Bicarbonate 
Title Sodium Bicarbonate  Administer half of calculated dose, then assess need for remainder. 1
Usual dosage: 1 to 2 mEq/kg IV over at least 30 minutes. 1
According to the manufacturer, for infants less than 2 years of age, the administration rate should not exceed 10 mL/minute. 0
. 0
==Adverse Effects== Bicarbonate administered during inadequate ventilation increases PCO2, thereby decreasing pH. 0
. 0
. 0
Terminal Injection Site Compatibility Acyclovir, amikacin, aminophylline, amphotericin B, atropine, aztreonam, cefepime, cefoxitin, ceftazidime, ceftriaxone, chloramphenicol, cimetidine, clindamycin, dexamethasone, erythromycin lactobionate, esmolol, famotidine, furosemide, heparin, hydrocortisone succinate, ibuprofen lysine, indomethacin, insulin, lidocaine, linezolid, milrinone, morphine, nafcillin, netilmicin, penicillin G, phenobarbital, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, vancomycin, and vitamin K1. 0
==Terminal Injection Site Incompatibility== Dex/AA. 0
Title Sodium Bicarbonate  Administer half of calculated dose, then assess need for remainder. 1
. 0
Terminal Injection Site Compatibility Acyclovir, amikacin, aminophylline, amphotericin B, atropine, aztreonam, cefepime, cefoxitin, ceftazidime, ceftriaxone, chloramphenicol, cimetidine, clindamycin, dexamethasone, erythromycin lactobionate, esmolol, famotidine, furosemide, heparin, hydrocortisone succinate, ibuprofen lysine, indomethacin, insulin, lidocaine, linezolid, milrinone, morphine, nafcillin, netilmicin, penicillin G, phenobarbital, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, vancomycin, and vitamin K1. 0
==Terminal Injection Site Incompatibility== Dex/AA. 0
:10 mL/kg IV over 5 to 10 minutes. 1
Consider a second dose of 10 mL/kg if there is no significant improvement after the first dose. 0
, give over 5 to 10 minutes. 1
Consider a longer duration of administration in preterm neonates less than 30 weeks GA . 1
is the preferred isotonic crystalloid solution, and Lactated Ringer's is an acceptable alternative. 0
Title Sodium Glycerophosphate 
===Dose===  Phosphate Supplement:1 to 1.5 mmol/kg/day, individualized to needs of patient . 0
Administer over no less than 8 hours . 1
. 0
The switch to sodium glycerophosphate as the sole phosphorus source not only increased the amount of phosphorus that could be administered each day, but also allowed an increase in the amount of calcium infused to 1.5 mmol/kg/day. 0
By 60 hours, all patients had achieved a plasma phosphorus concentration of 1.5 mmol/L or greater . 0
Product contains 2 mEq/mL of sodium. 0
, organic phosphate is less likely to precipitate . 0
Bioavailability is dependant on hydrolysis of the phosphate group from the glycerophosphate molecule, which occurs most efficiently at plasma concentrations of greater than 0.7 mmol/L. 0
Normal serum alkaline phosphatase is capable of hydrolyzing approximately 12 to 15 mmol of sodium glycerophosphate each day. 0
containing 2 mEq/mL of sodium and 1 mmol/mL of phosphate in a 20-mL single-dose plastic vial . 0
Do not store above 25 degrees C.
 Note: Glycophos™ contains 1 mmol/mL of organic phosphate. 0
Sodium and potassium phosphate products typically used in the US are 3 mmol/mL of inorganic phosphate . 0
may be added to 1000 mL of D5W . 0
may be added to 1000 mL of D20W . 0
may be added to 1000 mL of D50W . 0
More complete information on the composition of these products is available . 0
. 0
Bioavailability is dependant on hydrolysis of the phosphate group from the glycerophosphate molecule, which occurs most efficiently at plasma concentrations of greater than 0.7 mmol/L. 0
containing 2 mEq/mL of sodium and 1 mmol/mL of phosphate in a 20-mL single-dose plastic vial . 0
Title Sodium Nitroprusside 
===Dose===  Initial 
===Dose=== : 0.25 to 0.5 mcg/kg/minute continuous IV infusion. 0
Titrate dose upward every 20 minutes until desired response is attained. 1
Usual maintenance dose is less than 2 mcg/kg per minute. 1
For hypertensive crisis, may use up to 10 mcg/kg per minute, but for no longer than 10 minutes. 1
. 0
Black Box Warning According to the manufacturer's black box warning, nitroprusside is not suitable for direct injection; the reconstituted solution must be further diluted in sterile 5% dextrose injection before infusion. 0
should never last more than 10 minutes. 1
Rapid onset of action with a serum half-life of 3 to 4 minutes in adults. 1
Thiocyanate is renally eliminated with a half-life of 4 to 7 days. 1
doses. 0
concentrations. 0
==Special Considerations/Preparation== Available as powder for injection in 2 mL single-dose 50 mg vials. 0
Reconstitute contents of vial with 2 to 3 mL of D5W or NS. 0
in D5W or NS. 0
Use within 24 hours of preparation. 1
==Solution Compatibility== D5W, NS, and LR only. 0
Terminal Injection Site Compatibility Caffeine citrate, calcium chloride, cimetidine, dobutamine, dopamine, enalaprilat, epinephrine, esmolol, famotidine, furosemide, heparin, indomethacin, insulin, isoproterenol, lidocaine, magnesium, micafungin, midazolam, milrinone, morphine, nicardipine, nitroglycerin, pancuronium, potassium chloride, procainamide, propofol, prostaglandin E1, ranitidine, and vecuronium. 0
Title Sodium Nitroprusside 
===Dose===  Initial 
===Dose=== : 0.25 to 0.5 mcg/kg/minute continuous IV infusion. 0
Title Sodium phenylacetate/Sodium benzoate 
===Dose===  Pending Definitive Diagnosis of Urea Cycle Enzyme Deficiency: Loading dose: Sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg in combination with arginine hydrochloride 600 mg/kg as an IV infusion over 90 to 120 minutes . 0
Maintenance dose: Sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg in combination with arginine hydrochloride 600 mg/kg as an IV infusion over 24 hours . 0
Known CPS, OTC, or NAGS Deficiency: Loading dose: Sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg in combination with arginine hydrochloride 200 mg/kg as an IV infusion over 90 to 120 minutes . 0
Maintenance dose: Sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg in combination with arginine hydrochloride 200 mg/kg as an IV infusion over 24 hours . 0
Known ASS or ASL Deficiency: Loading dose:Sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg in combination with arginine hydrochloride 600 mg/kg as an IV infusion over 90 to 120 minutes . 0
For loading and maintenance doses, dilute sodium phenylacetate/sodium benzoate and arginine in 25 to 35 mL/kg of D10W prior to administration . 0
==Contraindications/Precautions== Caution advised for use in patients with congestive heart failure, severe renal impairment, or other clinical conditions involving sodium retention with edema; product contains 30.5 mg of sodium per mL. 0
Phenylacetylglutamine is excreted by the kidney and results in removal of 2 moles of waste nitrogen for each mole of phenylacetate administered. 0
Hippurate is excreted by the kidney and results in removal of 1 mole of waste nitrogen for each mole of benzoate administered . 0
. 0
Hypotension seen more frequently in patients 30 days of age and less. 1
Potentially life-threatening toxicity can occur with doses greater than 750 mg/kg per day . 1
==Monitoring== Measure plasma ammonia levels every hour during dialysis until levels stabilize to less than 200 to 300 micromoles/L. 1
. 0
An anion gap that is greater than 15 mEq/L or has increased by greater than 6 mEq/L from baseline may indicate drug accumulation. 0
is available as a 10%/10% solution in a single-use glass vial containing 50 mL. 0
Contains 30.5 mg of sodium per mL. 0
provided by the manufacturer must be used when injecting Ammunol® into the 10% dextrose IV bag . 0
==Solution Compatibility== D10W and arginine hydrochloride 10%. 0
Known ASS or ASL Deficiency: Loading dose:Sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg in combination with arginine hydrochloride 600 mg/kg as an IV infusion over 90 to 120 minutes . 0
. 0
is available as a 10%/10% solution in a single-use glass vial containing 50 mL. 0
Title Sotalol 
===Dose===  Initial dose: 1 mg/kg/dose orally every 12 hours. 1
Gradually increase as needed every 3 to 5 days until stable rhythm is maintained. 1
Maximum dose: 4 mg/kg/dose orally every 12 hours. 1
, creatinine clearance less than 40 mL/minute, and bronchial asthma . 0
Oral bioavailability is good, but absorption is decreased by 20% to 30% by food, especially milk. 0
Limited pharmacokinetic data in infants show a half-life of 8 hours, increasing significantly in elderly patients and those with renal dysfunction. 1
==Adverse Effects== Proarrhythmic effects occur in 10% of pediatric patients: sinoatrial block, A-V block, torsades de pointes and ventricular ectopic activity. 0
==Special Considerations/Preparation== Oral formulation supplied in 80-mg, 120-mg, 160-mg, and 240-mg tablets. 0
in a 6-ounce amber plastic bottle. 0
Stable for 90 days at room temperature or refrigerated . 1
Title Sotalol 
===Dose===  Initial dose: 1 mg/kg/dose orally every 12 hours. 1
==Special Considerations/Preparation== Oral formulation supplied in 80-mg, 120-mg, 160-mg, and 240-mg tablets. 0
Title Spironolactone 
===Dose===  1 to 3 mg/kg/dose orally every 24 hours. 1
Metabolized to canrenone and 7-a-thiomethylspironolactone, active metabolites with extended elimination half-lives. 1
Serum half-life with long term use is 13 to 24 hours. 1
==Special Considerations/Preparation== Available in 25-mg, 50-mg, and 100-mg tablets. 0
A 2.5- or 5-mg/mL oral suspension can be made by crushing five or ten 25-mg spironolactone tablets, respectively, and suspending the powder in 50 mL of simple syrup. 0
Suspensions are stable for 1 month refrigerated. 0
25-mg tablets to a fine powder in a mortar. 0
Add 40 mL of vehicle* and mix to a uniform paste. 0
Transfer contents of the mortar to the calibrated bottle and add enough vehicle to bring the total volume to 120 mL. 0
. 0
. 0
Title Spironolactone 
===Dose===  1 to 3 mg/kg/dose orally every 24 hours. 1
25-mg tablets to a fine powder in a mortar. 0
Title Succinylcholine 
===Dose===  Skeletal Muscle Relaxation/Paralysis ==Intravenous== 1 to 2 mg/kg IV immediately prior to intubation . 0
Repeat doses of 1 mg/kg up to a maximum total dose of 4 mg/kg have been used if muscle relaxation was not attained by 1 to 3 minutes after administration . 0
Intramuscular 2 to 4 mg/kg may be given via the IM route only if IV route not accessible . 0
==Administration== May administer undiluted as an IV bolus or further dilute in compatible solution to a concentration of 1 to 2 mg/mL . 0
after administration of succinylcholine chloride . 0
Onset of paralysis after IV administration is 30 to 60 seconds with a duration of action of 4 to 6 minutes . 1
Onset of action after IM administration is 2 to 4 minutes with a duration of action of 19 to 23 minutes . 1
Approximately 10% of the drug is eliminated in the urine as unchanged drug . 0
==Special Considerations/Preparation== Available in 100 mg/mL single-use vials and 20 mg/mL multi-dose vials. 0
Multidose vials are stable for up to 14 days if stored at room temperature. 1
May be further diluted in compatible solution to a concentration of 1 to 2 mg/mL. 0
Diluted solutions should be used within 24 hours of preparation . 1
==Solution Compatibility== D5W, D10W, D5LR, D5NS, D5 1/2 NS, NS, 1/2 NS, and LR. 0
. 0
. 0
. 0
==Administration== May administer undiluted as an IV bolus or further dilute in compatible solution to a concentration of 1 to 2 mg/mL . 0
after administration of succinylcholine chloride . 0
==Solution Compatibility== D5W, D10W, D5LR, D5NS, D5 1/2 NS, NS, 1/2 NS, and LR. 0
. 0
Title Sucrose 
===Dose===  Preterm infants: 0.5 to 1 mL of 12% to 24% sucrose solution. 1
Term infants: 2 mL of 12% to 24% sucrose solution. 1
Administer sucrose solution directly to the tongue 2 minutes prior to the painful procedure. 1
Alternatively, a pacifier dipped in sucrose solution can be offered 2 minutes prior to the procedure. 0
The time to maximal effect is approximately 2 minutes and the duration of effect is approximately 5 to 10 minutes. 1
==Adverse Effects== Sucrose 24% has an osmolarity of approximately 1000 mOsm/L. 0
==Special Considerations/Preparation== Sweet-Ease®, a 24% sucrose and water solution, is aseptically packaged in an 15 ml cup with a peel off lid that is suitable for dipping a pacifier or for administration via a dropper. 0
Title Sucrose 
===Dose===  Preterm infants: 0.5 to 1 mL of 12% to 24% sucrose solution. 1
==Special Considerations/Preparation== Sweet-Ease®, a 24% sucrose and water solution, is aseptically packaged in an 15 ml cup with a peel off lid that is suitable for dipping a pacifier or for administration via a dropper. 0
. 0
The lung-mince extracts Survanta® and Curosurf® contain less than 10% of the SP-B contained in the lung-wash extract Infasurf®. 0
If the infant becomes dusky or agitated, heart rate slows, oxygen saturation falls more than 15%, or surfactant backs up in the ET tube, dosing should be slowed or halted. 0
If necessary, ventilator settings and/or FiO2 should be turned up. 0
Pulmonary hemorrhage occurs in 2% to 4% of treated infants, primarily the smallest patients with untreated PDA. 0
If the infant becomes dusky or agitated, heart rate slows, oxygen saturation falls more than 15%, or surfactant backs up in the ET tube, dosing should be slowed or halted. 0
Title THAM acetate  per dose IV. 1
Infuse in a large vein over at least 30 minutes. 1
may be calculated from the following formula:  Maximum dose in neonates with normal renal function is approximately 5 to 7 mmol/kg per 24 hours. 1
. 0
is a proton acceptor that generates NH3+ and HCO3- without generating CO2. 0
The protonated R-NH3+ is eliminated by the kidneys. 0
Unlike bicarbonate, THAM does not require an open system for CO2 elimination in order to exert its buffering effect. 0
in a 500-mL single-dose container with no bacteriostatic agent. 0
Title THAM acetate  per dose IV. 1
Title Ticarcillin/Clavulanate 
===Dose===  75 to 100 mg/kg/dose IV infusion by syringe pump over 30 minutes. 1
. 0
==Pharmacology== Timentin® combines the extended-spectrum antibiotic ticarcillin with the β-lactamase inhibitor clavulanic acid in a 30:1 ratio. 0
As a result the mean half-life of ticarcillin in neonates is 4.2 hours compared to a mean half-life of 2 hours for clavulanate. 1
==Special Considerations/Preparation== Available as powder for injection in 3.1-g vials. 0
Reconstitute vial by adding 13 mL of sterile water for injection. 0
Dilute further with a compatible solution to a concentration between 10 and 100 mg/mL. 0
. 0
Frozen dilutions stable for 7 days for D5W and 30 days for NS and LR. 1
of sodium per gram of ticarcillin/clavulanate. 0
==Solution Compatibility== D5W, LR, and NS. 0
Title Ticarcillin/Clavulanate 
===Dose===  75 to 100 mg/kg/dose IV infusion by syringe pump over 30 minutes. 1
==Pharmacology== Timentin® combines the extended-spectrum antibiotic ticarcillin with the β-lactamase inhibitor clavulanic acid in a 30:1 ratio. 0
Trough: 0.5 to 1 mcg/mL ==Special Considerations/Preparation== Pediatric injectable solution available in a concentration of 10 mg/mL. 0
, linezolid, magnesium sulfate, metronidazole, midazolam, milrinone, morphine, nafcillin, nicardipine, ranitidine, remifentanil, theophylline, and zidovudine. 0
, mezlocillin, oxacillin, penicillin G, propofol, and ticarcillin/clavulanate. 0
Obtain peak concentration 30 minutes after end of infusion, and trough concentration just prior to the next dose. 1
. 0
was started at initiation of hypothermia, followed by doses of either 5 mg/kg or 3 mg/kg given on days 2 and 3 . 0
. 0
The dose being used in this trial is 10 mg/kg/dose for 3 doses . 0
. 0
, 5 of 6 patients were seizure-free on topiramate monotherapy. 0
Of these 5 patients, 4 received topiramate 10 mg/kg/day; the remaining patient received 3 mg/kg/day . 0
. 0
Indicated for seizures associated with Lennox-Gastaut syndrome in patients 2 years or older . 0
. 0
. 0
activity at some subtypes of the GABA-A receptors, antagonism of AMPA/kainate subtype of the glutamate receptor, and inhibition of the carbonic anhydrase enzyme, particularly isozymes II and IV . 0
. 0
All patients received a topiramate dose of 5 mg/kg every 24 hours for 3 days, starting with the initiation of hypothermia. 1
, likely due to more irregular absorption and elimination. 0
. 0
. 0
Serum concentrations within the reference range of 5 to 20 mg/L were achieved in most patients . 0
. 0
When used for seizure disorders, 3 of 6 term infants had a weight of less than the 5th percentile, however, these patients also had poor oromotor control . 0
==Special Considerations/Preparation== Oral Sprinkle Capsules: Available as 15-mg and 25-mg sprinkle capsules. 0
; protect from moisture . 0
. 0
. 0
Title Tri-Vi-SolÂ® MVI Drops  every 24 hours, or as directed by physician. 1
Tri-Vi-Sol® Multivitamin DropsSpecial Considerations/Preparation Supplied as ophthalmic solution in 0.5%, and 1% concentrations in 2-, 3-, and 15-mL dropper bottles. 0
===Dose===  1 drop instilled in the eye at least 10 minutes prior to funduscopic procedures. 0
Use only the 0.5% ophthalmic solution in neonates. 0
Mydriasis begins within 5 minutes of instillation; cycloplegia occurs in 20 to 40 minutes. 1
Recovery of accommodation occurs in 6 hours. 1
==Special Considerations/Preparation== Supplied as ophthalmic solution in 0.5%, and 1% concentrations in 2-, 3-, and 15-mL dropper bottles. 0
Title Ursodiol 
===Dose===  10 to 15 mg/kg/dose orally every 12 hours. 1
Serum half-life is 3 to 4 days in adults. 1
==Special Considerations/Preparation== Available in 300-mg capsules. 0
300-mg capsules into a glass mortar. 0
Mix this powder with 10 mL of glycerin and stir until smooth. 0
Add 60 mL of Ora-Plus® to the mixture and stir. 0
Pour the remaining contents into the amber glass bottle, then add enough simple syrup to make the final volume 120 mL, with a final concentration of 25-mg/mL. 0
Mixture is stable for 60 days stored at room temperature or refrigerated. 1
Title Ursodiol 
===Dose===  10 to 15 mg/kg/dose orally every 12 hours. 1
Title ValGANciclovir 
===Dose===  16 mg/kg per dose orally every 12 hours. 1
Treat for a minimum of 6 weeks; longer-term treatment may be appropriate. 1
less than 500 cells/mm3, hold drug until ANC greater than 750 cells/mm3. 0
If the ANC falls again to less than 750 cells/mm3, reduce the dosage by 50%. 0
If ANC again falls to less than 500 cells/mm3, discontinue the drug. 0
is less than 500 cells/mcL, the platelet count is less than 25,000/mcL, or if the hemoglobin is less than 8 g/dL. 0
. 0
Bioavailability is 40% to 60%, and may be improved by administering with food. 0
Elimination half-life in infants is 3 hours. 1
==Monitoring== CBC, including differential, and platelet counts should be monitor frequently, especially in patients with a history of leukopenia resulting from ganciclovir or other nucleoside analogue use, and in those with neutrophil counts less than 1000 cells/mcL at the beginning of treatment. 0
==Special Considerations/Preparation== Valcyte® is supplied as a white to slightly yellow powder for constitution, forming a colorless to brownish yellow tutti-frutti flavored solution, which when constituted with water as directed contains 50 mg/mL valganciclovir free base. 0
Available in glass bottles containing approximately 100 mL of solution after constitution. 0
The inactive ingredients of Valcyte for oral solution are sodium benzoate, fumaric acid, povidone K- 30, sodium saccharin, mannitol and tutti-frutti flavoring. 0
To prepare the oral solution measure 91 mL of purified water in a graduated cylinder. 0
Remove the cap and add approximately half the total amount of water for constitution to the bottle and shake the closed bottle well for about 1 minute. 0
Add the remainder of water and shake the closed bottle well for about 1 minute. 0
This prepared solution contains 50 mg of valganciclovir free base per 1 mL. 0
for no longer than 49 days. 1
Title ValGANciclovir 
===Dose===  16 mg/kg per dose orally every 12 hours. 1
Title Vancomycin  and penicillin-resistant pneumococci. 0
MICs for sensitive organisms are less than or equal to 1 mcg/mL. 0
CSF concentrations in premature infants ranged from 26 to 68% of serum concentrations. 0
Protein binding is as high as 50% in adults. 0
. 0
Due to the variability in pharmacokinetic parameters, peak and trough concentrations have been recommended to provide more individualized dosing in neonates If peak concentrations are measured, draw 60 minutes after end of infusion. 0
is 10 to 15 mcg/mL . 0
Recommended trough concentration range for bacterial meningitis is 15 to 20 mcg/mL . 0
Many experts recommend a trough of 15 to 20 mcg/mL when treating MRSA bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, complicated skin and soft-tissue infections, or bone/joint infections . 0
A suggested AUC/MIC ratio greater than 400 provides near maximal bactericidal activity and may be an alternative monitoring parameter for efficacy when treating MRSA . 0
Recommended trough concentration range for less severe infections is 10 to 15 mcg/mL . 0
For treatment of MRSA, vancomycin doses necessary to achieve trough concentrations of 15 to 20 mcg/mL or an AUC/MIC ratio greater than 400, particularly when treating infections with an MIC greater than 1 mcg/mL, may increase the risk for nephrotoxicity . 0
Additionally, an MIC greater than 1 mcg/mL has been associated with an increased likelihood of treatment failure in adult patients with MRSA . 0
In a recent report from a US institution, the modal vancomycin MIC was 1.5 mcg/mL for invasive community-acquired MRSA isolates in pediatric patients . 0
. 0
There was no difference in the number of patients with MICs greater than 1 mcg/mL or in the time to troughs greater than 15 mcg/mL between treatment failures and non-failures. 0
Methicillin-resistant Staphylococcus aureus isolates with a vancomycin MIC greater than 2 mcg/mL (eg, vancomycin-intermediate or vancomycin-resistant S. and potential drug accumulation . 0
==Special Considerations/Preparation== Available as powder for injection in 500-mg and 1-g vials. 0
Reconstitute 500-mg and 1- g vial with 10 mL and 20 mL of sterile water for injection, respectively, to make a final concentration of 50 mg/mL. 0
Reconstituted solution stable for 4 days refrigerated. 0
. 0
, hydrocortisone succinate, insulin, linezolid, lorazepam, magnesium sulfate, meropenem, midazolam, milrinone, morphine, nicardipine, pancuronium bromide, potassium chloride, propofol, ranitidine, remifentanil, sodium bicarbonate, vecuronium, and zidovudine. 0
, mezlocillin, nafcillin, pentobarbital, phenobarbital, piperacillin, piperacillin/tazobactam, ticarcillin, and ticarcillin/clavulanate. 0
Title Vancomycin  and penicillin-resistant pneumococci. 0
is 10 to 15 mcg/mL . 0
. 0
, hydrocortisone succinate, insulin, linezolid, lorazepam, magnesium sulfate, meropenem, midazolam, milrinone, morphine, nicardipine, pancuronium bromide, potassium chloride, propofol, ranitidine, remifentanil, sodium bicarbonate, vecuronium, and zidovudine. 0
Title Varicella-zoster Immune Globulin 
===Dose===  Prevention or Attenuation of Varicella Infection Administer a single dose as soon as possible, ideally within 96 hours of exposure, for greatest effectiveness . 1
May be administered up to 10 days following exposure . 0
Administer a second full dose if additional exposures occur more than 3 weeks following initial dose . 1
IM . 0
IM . 0
whether the patient is at greater risk for complications than the general population. 0
The following neonatal patients should receive varicella zoster immune globulin following exposure :  Immunocompromised patients  Neonates whose mothers have signs and symptoms of varicella from 5 days before to 2 days after delivery  Premature infants, exposed anytime during entire period for which they require hospital care for their prematurity, born at 28 weeks of gestation or greater whose mothers do not have evidence of immunity  Premature infants, exposed anytime during entire period for which they require hospital care for their prematurity, born at less than 28 weeks of gestation or who weigh 1000 g or less at birth, regardless of maternal immunity Varicella zoster immune globulin is not recommended for healthy, full-term infants who are exposed postnatally, even if their mothers have no history of varicella infection . 1
High-risk groups include :  Premature infants  Newborns of mothers having varicella shortly before or after delivery  Infants less than 1 year old  Immunocompromised patients  Pregnant females ==Contraindications/Precautions== Contraindicated in IgA-deficient patients with antibodies against IgA and history of hypersensitivity to avoid a possible anaphylactoid reaction . 0
In volunteers, the mean peak concentration of varicella antibodies occurs within 5 days of administration. 0
. 0
==Special Considerations/Preparation== Available as a kit with a glass vial containing approximately 125 international units of freeze-dried varicella zoster virus antibodies and a single dose vial of sterile diluent. 0
May store reconstituted solution for up to 12 hours under refrigeration prior to use. 0
As this product is available only through investigational new drug application expanded access protocol, obtain through FFF Enterprises by calling 1-800- 843-7477 or by contacting online at http://www. 0
High-risk groups include :  Premature infants  Newborns of mothers having varicella shortly before or after delivery  Infants less than 1 year old  Immunocompromised patients  Pregnant females ==Contraindications/Precautions== Contraindicated in IgA-deficient patients with antibodies against IgA and history of hypersensitivity to avoid a possible anaphylactoid reaction . 0
Title Vecuronium  IV push, as needed for paralysis. 1
Vecuronium is metabolized rapidly in the liver to 3-desacetyl-vecuronium, which is 50% to 70% active, and is excreted renally. 0
Onset of action is 1 to 2 minutes; duration of effect is prolonged with higher doses and in premature infants. 1
==Special Considerations/Preparation== Available as powder for injection in 10-mg and 20-mg vials. 0
. 0
After reconstitution- 24 hrs stability in refrigerator. 1
After dilution, use within 24 hours after admixing. 1
A 0.4-mg/mL dilution may be made by diluting 1 mL of 1-mg/mL concentration with 1.5 mL of preservative-free normal saline. 0
Dilution is stable for 24 hours in refrigerator. 1
Title Vecuronium  IV push, as needed for paralysis. 1
Title Vi-DaylinÂ® MVI Drops 1.190 Vi-SolÂ® Multivitamin Products 
Title Vi-SolÂ® Multivitamin Products  every 24 hours, or as directed by physician. 1
Vi-Sol® Products  every 24 hours, or as directed by physician. 1
Vi-Sol® Products 1.191 Vitamin A 
Title Vitamin A 
===Dose===  Vitamin A Deficiency - VLBW and ELBW Neonates: 5000 units IM 3 times weekly for 4 weeks . 0
Administer IM using a 29-g needle and insulin syringe . 0
In the NICHD-sponsored trial, 14 infants needed to be treated to prevent 1 case of chronic lung disease . 1
In a follow-up study of this trial, there were no significant differences in neurodevelopmental outcomes or mortality at 18 to 22 months corrected age between infants receiving vitamin A and controls; however, the original trial was not adequately powered to confirm these follow-up endpoints . 1
Desired concentrations are approximately 30 to 60 mcg/dL . 0
Concentrations less than 20 mcg/dL indicate deficiency, while those greater than 100 mcg/dL are potentially toxic . 0
50,000 units per mL, equivalent to 15 mg retinol per mL, in 2-mL vials. 0
. 0
Title Vitamin A 
===Dose===  Vitamin A Deficiency - VLBW and ELBW Neonates: 5000 units IM 3 times weekly for 4 weeks . 0
Title Vitamin D 
===Dose===  Supplementation: 400 units per day orally . 1
Treatment of vitamin D deficiency: 1000 units per day orally. 0
Exclusively formula-fed infants receiving at least 1000 mL/day of formula receive adequate amounts of vitamin D without supplementation. 0
-D levels in the infant to levels similar to those seen with infant supplementation without causing hypervitaminosis D in the mother. 0
radiation. 0
. 0
, the active form of vitamin D.-D levels when compared with vitamin D2. 0
==Adverse Effects== Signs of vitamin D toxicity include hypercalcemia, azotemia, vomiting, and nephrocalcinosis. 0
-D concentration greater than 250 nmol/L may be associated with a risk for vitamin D intoxication. 0
concentration of less than 50 nmol/L is thought to be indicative of vitamin D deficiency in infants . 0
. 0
vitamin D2 per drop. 0
is supplied as 400 units vitamin D3 per drop. 0
is supplied as 400 units per drop. 0
is supplied as 400 units vitamin D3 per mL. 0
is supplied as 400 units vitamin D3 per mL. 0
Inactive ingredients include glycerin, water, polysorbate 80, citric acid, sodium citrate, sodium hydroxide, artificial flavor and artificial caramel color. 0
The vitamin D3 content of Vi-Daylin® and Vi-Sol® products is 400 units per mL. 0
The vitamin D3 content of AquADEKs™ drops is 400 units per mL. 0
Title Vitamin D 
===Dose===  Supplementation: 400 units per day orally . 1
-D levels when compared with vitamin D2. 0
==Adverse Effects== Signs of vitamin D toxicity include hypercalcemia, azotemia, vomiting, and nephrocalcinosis. 0
is supplied as 400 units vitamin D3 per drop. 0
Title Vitamin E 
===Dose===  5 to 25 units per day orally. 0
Infants receiving supplemental iron amounts above 2 mg/kg/day may also require additional vitamin E.
 Physiologic serum vitamin E concentrations are between 0.8 and 3.5 mg/dL. 0
per 0.3 mL. 0
Also contains polysorbate 80, propylene glycol, sorbitol, saccharin, and artificial flavor. 0
. 0
Title Vitamin E 
===Dose===  5 to 25 units per day orally. 0
Title Vitamin K1 
===Dose===  Recommended Prophylaxis: 0.5 to 1 mg IM at birth. 0
Preterm infants less than 32 weeks of gestation: Birthweight greater than 1000 grams: 0.5 mg IM. 1
Birthweight less than 1000 grams: 0.3 mg/kg IM. 0
Alternate strategy for healthy, term, exclusively breast-fed infants: 1 to 2 mg orally at birth, at 1 to 2 weeks of age, and at 4 weeks of age. 1
Also: Maternal daily intake of 5 mg/day of phylloquinone significantly increases Vitamin K concentrations in breast milk and infant plasma. 0
Treatment of severe hemorrhagic disease: 1 to 10 mg IV slow push. 0
==Administration== For IV administration, give very slowly, not exceeding 1 mg per minute, with physician present. 0
Treatment of hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K1. 0
Black Box Warning Fatalities have occurred during and immediately after IV and IM administration, even when precautions have been taken to dilute phytonadione and to avoid rapid infusion for the IV route. 0
. 0
Vitamin K1 does not counteract the anticoagulant action of heparin. 0
With IV administration, give very slowly, not exceeding 1 mg per minute, with physician present. 0
Efficacy of treatment with vitamin K1 is decreased in patients with liver disease. 0
The risk of childhood cancer is not increased by IM administration of vitamin K1. 0
==Monitoring== Check prothrombin time when treating clotting abnormalities. 0
A minimum of 2 to 4 hours is needed for measurable improvement. 1
==Special Considerations/Preparation== Available as a 2 mg/mL aqueous dispersion in 0.5-mL ampules and 10 mg/mL aqueous dispersion in 1-mL ampules and 2.5- and 5-mL vials. 0
benzyl alcohol as a preservative. 0
An extemporaneous oral suspension can be made by triturating six 5-mg tablets in a mortar. 0
While mixing, add 5 mL purified water, USP and 5 mL 1% methylcellulose. 0
Transfer to a graduate and qs to 30 mL with 70% sorbitol solution. 0
Final concentration is 1 mg/mL and suspension is stable for 3 days refrigerated. 0
*** ==Solution Compatibility== D5W, D10W, and NS. 0
Title Vitamin K1 
===Dose===  Recommended Prophylaxis: 0.5 to 1 mg IM at birth. 0
. 0
With IV administration, give very slowly, not exceeding 1 mg per minute, with physician present. 0
Title Zidovudine 
===Dose===  Prevention of Perinatal HIV Transmission: ==Oral== 35 weeks gestation and older: 4 mg/kg/dose orally every 12 hours . 1
30 weeks to less than 35 weeks gestation: 2 mg/kg/dose orally every 12 hours, then 3 mg/kg every 12 hours at 15 days postnatal age . 1
Less than 30 weeks gestation: 2 mg/kg/dose orally every 12 hours, then 3 mg/kg every 12 hours after 4 weeks postnatal age . 1
Start therapy as soon as possible after birth, preferably within 6 to 12 hours of birth; prophylaxis should be continued through 6 weeks of age. 1
Neonates born to HIV- infected women who have not received antepartum antiretroviral therapy should also receive 3 doses of nevirapine; at birth, 48 hours later, and 96 hours after the second dose . 1
==Intravenous== 35 weeks gestation and older:3 mg/kg/dose IV every 12 hours if unable to tolerate oral . 1
30 weeks to less than 35 weeks gestation: 1.5 mg/kg/dose IV every 12 hours, then 2.3 mg/kg every 12 hours at 15 days postnatal age . 1
Less than 30 weeks gestation: 1.5 mg/kg/dose IV every 12 hours, then 2.3 mg/kg every 12 hours after 4 weeks postnatal age . 1
Neonates born to HIV- infected women who have not received antepartum antiretroviral therapy should also receive 3 doses of nevirapine; at birth, 48 hours later, and 96 hours after the second dose . 1
Intravenous: Administer IV at a constant rate over 1 hour at a concentration not greater than 4 mg/mL. 1
HIV-infected women with HIV RNA of 400 copies/mL or greater should receive IV zidovudine during labor and delivery. 0
Intravenous zidovudine is not required in women with an HIV RNA of less than 400 copies/mL. 0
Protein binding is approximately 25%. 1
The CSF: plasma ratio is 0.24. 1
The relationship between serum concentration and clinical efficacy is unclear. 0
The oral syrup is well-absorbed, but only 65% bioavailable due to significant first-pass metabolism. 0
The serum half-life in term newborns is 3 hours, declining to 2 hours after 2 weeks of age. 1
In preterm infants less than 33 weeks gestation, half-life during the first two weeks of life ranges from 5 to 10 hours, decreasing to 2 to 6 hours afterward . 1
==Adverse Effects== Anemia and neutropenia occur frequently, and are associated with serum concentrations greater than 3 micromol/L . 0
==Special Considerations/Preparation== Available as a syrup for oral use in a concentration of 10 mg/mL . 0
The IV form is supplied in a concentration of 10 mg/mL in a 20 mL single-use vial. 0
Dilute in D5W before IV administration to a concentration not exceeding 4 mg/mL. 0
A dilution of 4 mg/mL may be prepared by adding 4 mL of the 10-mg/mL concentration to 6 mL D5W. 0
After dilution, the drug is stable for 24 hours at room temperature or 48 hours if refrigerated. 1
30 weeks to less than 35 weeks gestation: 2 mg/kg/dose orally every 12 hours, then 3 mg/kg every 12 hours at 15 days postnatal age . 1
. 0
The CSF: plasma ratio is 0.24. 1
The relationship between serum concentration and clinical efficacy is unclear. 0
The IV form is supplied in a concentration of 10 mg/mL in a 20 mL single-use vial. 0
